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A historical comparison to the life of a Ph.D. student:-
Lapsed into a state of almost mindless depression and s tu p o r ,  
Robert Bruce king of Scots perceived that, although his wits h a d  
sunk into a dull vacancy, his senses had not. He had, in fact, b e e n  
heavily watching a spider which was striving assiduously to
attach it’s slender thread to a point on the sheer rock wall of th e  
cave .
Four times it had gone through the difficult and involved p ro cess  
without success. The fifth attempt again ended in failure. T h e
sixth effort showed intelligence as well as de term ination  and i t  
looked as though this effort might succeed- but no.
“It is of no avail” the Bruce muttered, shaking his head. “Can y o u
not see it?”
But the spider would not admit defeat. U ndeterred it la u n c h e d  
itself downwards with unabated resolve, and this time it m a n a g e d  
to hold on to the cave wall.
“Now, by the saints,- here is a wonder!” Bruce exclaimed.
“Six efforts did not deter this spider. Shall I despair more easily?”
Adapted from The Path of the Hero King, by Nigel Tranter, 1970.
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Abstract
There is an ever increasing list of disease states which h a v e  
been shown to have an association with EBV latent infection. I n 
particular research has focused on the latent m em brane p ro te in  
(LMP-1). Study of this gene has largely been restricted to B-cells 
in vitro  due to the inability to infect epithelial cells with EBV in  
vitro. This has resulted in little information concerning the e ffec ts  
of LMP-1 in an epithelial environment. As a consequence, the ro le  
of LMP-1 in nasopharyngeal carcinoma (NPC), with which EBV is 
most closely associated, is poorly understood.
Creation of transgenic mice where LMP-1 is directed to t h e  
epithelial cell com partm ent has therefore achieved two im p o r ta n t  
goals. LMP-1 can now be studied in an epithelial cell in v iv o  
whilst the mice provide the first step in a model for the d ise a se  
state of NPC. In this study the m echanism  of action of LMP-1 in  
the PyLMP-1 line 53 of transgenic mice has been investigated. I n  
addition, a study on the progression of the transgenic LM P-1 
induced hyperplastic phenotype to carcinoma has been conducted.
Firstly, using im m unohistochem ical techniques, t h e  
hyperplastic  epidermal phenotype of the PyLMP-1 m ice  
previously reported is shown to result from a 2-3 fold increase in  
the rate of cellular proliferation whilst d ifferentiation c o n tin u es  
unimpeded in the transgenic skin.
Secondly, the mouse skin model of m u lt i - s ta g e  
carcinogenesis is utilised to show that LMP-1 does not act as an  
initiator of carcinogenesis nor does it affect the conversion to a 
more m alignant tumour. However, LMP-1 does function to  
increase both the rate and num ber of lesions forming d u r in g  
chemical tum our promotion, and more im portantly  LMP-1 acts as 
a weak or second stage promoter on it’s own. This finding h a s  
significant implications for NPC.
Thirdly, by cross-breeding PyLMP-1 line 53 with other l ines  
of transgenic or knockout mice it is shown that LMP-1 does n o t  
co-operate with activated H a -ras  or loss of p53 function in  
tumour progression. However, the combination of the PyLM P-1 
transgene and KlO-TGFpi transgene results in embryonic lethality.
Lastly, the EpLMP-1 line 39 transgenic mice which e x p re s s  
LMP-1 in the B-cell com partm ent at very low levels have b e e n  
studied for a 24 month period and shown to succumb to a long 
latency lymphoma.
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Commonly used abbreviations
oca- Amino acid
b p - Base pair
BL (e or s)- B urkitt’s lymphoma (endemic or sporadic)
B rdU - B ro m o -d eo x y u r id in e
C /N - te rm in u s - Carboxy or Amino terminus
CR2- Complement receptor type 2
CST- C om plem entary strand transcrip t
d 7  - Day 7
DMBA- D im e th y lb e n z a n th ra c e n e
DNA- Deoxy-ribonucleic acid
EBNA- Epstein-Barr virus nuclear antigen
EBV- Epstein-Barr virus
EGF/R- Epidermal growth factor/Receptor
E|i- IgH heavy chain intronic enhancer
FCS- Foetal calf serum
Ha-r«.y- H a rv e y -ra s
HD- H odgkin’s disease
K (6)- K eratin
LCL- Lymphoblastoid cell line
L M P- Latent membrane protein
LOH- Loss of heterozygosity
m RNA- Messenger RNA
N F-kB - Nuclear factor kB
NPC- N asopharyngeal carcinom a
ORF- Open reading frame
PKC- Protein kinase C
P y - P o lyom a
RAR- Retinoic acid receptor
RNA- Ribonucleic acid
RS- R e e d -S te rn b e rg
ST- S tro m ely s in
TANK- TRAF family member associated NF- kB activator
TGF- Transforming growth factor
TNF/R- Tumour necrosis factor/Receptor
T PA - 1 2 - 0 -  te t rad ecan o y lp h o rb o l-13-aceta te
TRAF- TNF receptor associated factor
ts - T em pera ture  sensitive
W T- W ild - ty p e
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CHAPTER 1:- GENERAL INTRODUCTION
1A . EPSTEIN-BARR VIRUS.
Epstein-Barr Virus (EBV) is a human herpes virus which is 
common in all human populations (for reviews see Kieff, 1996; 
Rickinson and Kieff, 1996). Primary infection with EBV u su a lly  
occurs at an early age, is clinically inapparent, and results in 
lifelong virus persistence in a latent state which the host im m u n e  
system keeps under surveillance. However, if infection with EBV is 
delayed, infectious mononucleosis, a lym phopro lifera tive  d iso rd e r ,  
often ensues. Malignant diseases have also been identified in  
latently infected humans, in which EBV is thought to play a k e y  
role. These include Burkitt’s Lymphoma (BL), imm unoblastic B cell 
lymphomas, certain T cell lymphomas, Hodgkin’s disease (HD), a n d  
Nasopharyngeal Carcinoma (NPC). The focus of this thesis conce rn s  
the oncogenic activity of one of the viral proteins e x p re s s e d  
during latency, the latent m em brane protein-1 (LMP-1), and its 
m echanism  of action with particular respect to N a so p h a ry n g ea l  
Carcinoma (NPC).
1 A . 1 Genome o r g a n i s a t i o n .
The genome of EBV within its virion is a linear d u p lex  
deoxyribonucleic acid (DNA) molecule of approximately 172,000bp 
(see figure 1.1). The ends of the linear virion DNA contain d i re c t  
repeats, described as the terminal repeats, which fuse to g e th e r  
allowing circularization of the molecule in the infected cell.
Figure 1.1;- Linear map o f  the EBV viral genome.
This linear map shows the relative positions of the coding exons of 
the latently transcribed genes. The genome circularizes in la te n t ly  
infected cells via fusion of the terminal repeats (TR), therefore th e  
LMP2 transcripts are transcribed across this fused TR region . 
(Adapted from Rickinson and Kieff, 1996).
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The size varies depending on the EBV strain, with the p r o t o ­
type B95-8 strain (derived from an infectious m o n o nuc leos is  
pa tien t and passaged in cotton top tam arins) being m o s t  
com m only quoted. Two major polym orphism s are known, b a s e d  
on a heterogeneous sequence of the Epstein-Barr virus n u c le a r  
antigen-2 (EBNA-2) gene and the restriction e n z y m e  
polym orphism s observed in several parts of the viral genom e. 
These have led to the term types 1 and 2 EBV (Abdel-Hamid et al.,
1992) where type 1 has a more efficient transform ing ability th a n  
type 2. One of the restriction enzyme polymorphism s is 
characterised  by an extra BAMH1 site within the BAMH1-F 
fragm ent of EBV, giving rise to a small fragm ent called B A M H l-f  
or simply the "f" variant.
The EBV linear map is organised according to the d i f f e re n t  
size o f fragments generated by Bam  HI digestion with most l a t e n t  
genes reading from left to right, and most lytic genes reading r ig h t  
to left. Initially many proteins were termed after the Bam H I 
fragm ent harbouring the coding exons and the direction of th e i r  
expression. For example, LMP-1 was originally referred to as 
BNLF-1 (Bam HI fragment N , Left Frame num ber l(Baichwal a n d  
Sugden, 1988)). LMP-1 has also been described as LYDMA 
(L y m p h o c y te -d e te rm in ed  m em brane antigen (Fennewald et al., 
1984)). It is now commonly referred to as LMP-1 and this is th e  
nomenclature I will use.
1 A .2  Infect ion and i m m o r t a l i z a t i o n .
Primary infection is thought to occur in the s t ra t i f ie d  
squam ous epithelium of the nasopharynx where the virus is 
thought to replicate during it’s “lytic phase” . The B95-8 v i ru s  
genome has been completely sequenced and dem onstrated  t h a t  
90% of the coding capacity of EBV is composed of genes e x p re s s e d  
during the lytic phase of the viral life cycle. These are classed as  
immediate-early, early or late genes depending on when they a r e
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expressed during productive infection, but are not the subject o f  
this thesis and will not be dealt with in any detail.
The method of entry into the target epithelial cell is 
unknown, but from here EBV is believed to gain access into t h e  
circulating B cell population where infection is largely n o n ­
productive and characterises the “latent state” . The interaction o f  
EBV with B cells is initiated through the virus binding to the B cell 
surface molecule, complement receptor type 2, CR2 (Fingeroth e t  
al ., 1984), also given the “cluster of differentiation” number CD21. 
This results in v itro  in virus induced growth transform ation a n d
subsequent immortalization of the B cell. Cells expressing any class 
of surface immunoglobulin (slg) are targets therefore EBV d o e s  
not distinguish between subsets of B cells. The external e n v e lo p e  
of EBV is dominated by the virus-encoded glycoprotein (gp) 
gp350/220  through which virus binding to the B ly m p h o c y te
receptor CR2 is mediated (Knox and Young, 1995). The lytic p h a s e  
of the viral life cycle ends with cell lysis and the release of n e w ly  
formed EBV virions.
Both the infection and immortalization of primary B
lym phocytes with EBV can be efficient. More than 50% of s lg + B 
cells isolated from the peripheral blood of an adult human can b e  
infected with EBV, and the efficiency with which the infected cells 
are imm ortalised is between 30-100% (Reviewed in Middleton e t  
al ., 1991). The proliferating immortal B lymphocytes produced a re  
called lym phoblastoid cell lines (LCLs) and harbour the v i ra l  
genome as an autonomously replicating episome in a latent s ta te .  
Only 10% of the coding capacity of EBV is represented  by genes o f  
the latent state of EBV.
1 A .3  Latent  gene e x p r e s s i o n .
There are 8 iproteins expressed during latency (Reviewed b y  
Kieff, 1996) and these include 6 nuclear antigens and 2 
membrane antigens. Again there are different systems to term th e  
proteins expressed during latency. The six nuclear proteins a r e  
termed Epstein-Barr Virus nuclear antigen (EBNA)-l, -2, -3a, -3 b ,  
-3c, and -LP in one system and EBNA-1, 2, 3, 4, 5 and 6 in th e  
other, where EBNA-3a, b, and c are EBNA-3, 4, and 6 re s p e c t iv e ly ,  
and EBNA-LP is EBNA-5. The two integral mem brane proteins a r e  
commonly referred to as LMP-1 and LMP-2, although d if fe re n t ia l  
splicing of LMP-2 gives rise to two proteins -2a, and -2b (w h e re  
2a has an additional 5 ’ exon). LMP-2a and -2b are also referred to  
as TP-1, and -2 (TP refers to Terminal Protein). In this thesis I
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will use the notation of EBNA-1, -2, -3a, -3b, -3c, -LP and LM P-1, 
LMP-2a, -2b (as shown in figure 1.1). There are also two sm a ll  
non-coding RNAs called EBER-1 and -2 which are expressed during 
latency and a family of intricately spliced mRNAs which a r e  
com plem entary  strand transcripts (CSTs) expressed from the B a m  
HI A region of the viral genome (Smith et a l., 1993). These w e r e  
originally identified in an NPC passaged tumour (Gilligan et al.,
1990) and now shown to contain open reading frames (ORFs). 
Functions have been identified for some of these proteins b r ie f ly  
described below (Raab-Traub,1996; Kieff, 1996).
EBNA-1 binds to the origin of replication of the plasmid form 
of the viral genome and allows replication of the viral episome b y  
the host DNA polymerase. EBNA-1 is the only viral protein w h ich  
is essential for transmission of the viral DNA to the progeny cells 
of a B cell.
EBNA-2 affects viral and cellular gene expression by b in d in g  
to the cellular transcription factor CBF1. Notch, a gene fam ily  
controlling cell fate determ ination in several tissues acts th ro u g h  
CBF1 also. Thus EBNA-2 may act like activated Notch fam ily  
m em bers (Hunter, 1997). EBNA-2 is essential for g ro w th  
transform ation  of lymphocytes (H am m erschm idt and Sugden , 
19 89).
The EBNA-3 proteins, -3a, -3b, and -3c, also bind to CBF1
and affect viral gene expression. Both EBNA-2 and EBNA-3
regulate the viral prom oters for LMP-1 and LMP-2. In ad d it io n , 
EBNA-2 and -3 are responsible for inducing expression of B-cell 
activation markers.
EBNA-LP, along with EBNA-2, is synthesised first fo llow ing 
lytic infection and they are required to transactivate  th e
expression of subsequent latent genes. EBNA-LP is not r e q u i r e d  
for immortalization of B cells (Hammerschmidt and Sugden, 1989).
LMP-1 is essential for growth transform ation  of B-
lym phocytes in vitro (Kaye et al., 1993). It is the only l a t e n t  
protein shown to be oncogenic in tissue culture assays (Wang e t  
al.,  1985). It induces or inhibits the expression of multiple c e l lu la r  
genes. As the focus of this thesis LMP-1 will be discussed in m o r e  
detail in later sections.
LMP-2 contains exons from both ends of the linear g e n o m e  
therefore can only be transcribed across the fused termini of th e  
episome (Sample et al., 1989). It has been shown to interact w i th  
the cellular tyrosine kinases fyn and lyn and thereby m a y  
interfere with signal transduction (Longnecker et al., 1991).
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The EBERs are the most abundant viral (ribonucleic acids) 
RNAs in EBV infected cells and are expressed in all of th e  
malignancies associated with EBV. Despite this they are n o t  
required for lymphocyte transformation.
The mRNAs originally found expressed from the B am  HI A 
fragment in passaged NPC cells (Gilligan et al. , 1990) have re c e n t ly  
been shown to encompass the BARFO open reading frame at the 3 ’ 
end of the transcripts. Rabbit antiserum  raised against BARFO 
revealed the presence of a m em brane associated protein (Fries e t  
al.,  1997) which may be one of a family of such proteins expressed 
during latency. Their function is poorly understood.
There are three types of latency described in LCLs with each  
corresponding to a characteristic disease state. Only EBNA-1 is 
expressed in Latency 1. In Latency 2 EBNA-1 and the LMPs a re  
expressed, and in Latency 3 all six nuclear antigens plus the LMPs 
are expressed. The EBERs are expressed in all types of latency.
IB .  EBV and Malignant Disease.
EBV is implicated in the pathogenesis of a num ber of h u m a n  
lymphoid and epithelial malignancies. The lymphoid tu m o u rs  
include the immunoblastic B lymphomas that arise in  
im m unocom prom ised  individuals, certain T cell ly m p h o m a s ,  
Burkitt's lymphomas and a subset of Hodgkin's disease cases. T he  
association is strongest in nasopharyngeal carcinoma where th e
virus is present in 100% of all poorly d ifferentiated  o r  
undifferen tia ted  cases and may also be present in all sq u a m o u s  
cell NPC’s (Reviewed in Karimi and Crawford, 1995; Rickinson a n d  
Kieff, 1996). EBV is also associated with other, but not all tu m o u rs ,  
of the sinonasal region (Leung et al., 1995). In particular there h a s  
recently been detected a specific association with nasal T cell 
lymphomas (Chiang et al., 1996; and Wu et al., 1996).
1 B . 1 I m m u n o b la s t i c  B cell l y m p h o m a s .
Im m unocom prom ised  patients such as recipients o f  
im m unosuppress ive  therapy, AIDS sufferers, or patients w i th  
prim ary im m unodeficiency diseases are at increased risk for th e  
developm ent of EBV-positive immunoblastic B cell ly m p h o m a s  
(Reviewed in Karimi and Crawford, 1995; Rickinson and Kieff,
1996). These lymphomas express all of the latent genes and the  
same cell surface markers as LCLs of latency 3 and g e n e ra l ly
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resem ble large-cell lymphomas. In around 50% of cases occurring  
in transplant patients there is evidence of a recent EBV infection. 
This strongly suggests that these tumours arise because the h o s t  
imm une system can no longer control EBV induced. B cell 
immortalization and proliferation. Extensive B cell im m o rta l iza tio n  
by EBV might greatly enhance the likelihood of accumulation of 
oncogenic mutations, thereby leading to these tumours.
I B . 2 T cell l y m p h o m a s .
EBV has been detected in various T cell lymphoproliferations 
and lymphomas such as nasal T cell lymphoma. A recent s tu d y  
showed that 100% of nasal lymphomas were EBV associated w ith  
expression of EBNA-1, LMP-1, LMP-2 and B am  HI A t r a n s c r ip t io n  
(Chiang et al. , 1996). This strong correlation between EBV and T 
cell lymphoma suggests a role for EBV in the pathogenesis of th e  
disease but as yet the precise events remain unexplored.
1 B .3 Burkitt 's l y m p h o m a .
The term "Burkitt's lymphoma" was originally coined to  
describe a tumour that accounts for about 50% of all ch ildhood  
neoplasms in equatorial Africa. The lymphom a is g e n e ra l ly  
discovered before the end of the teenage years and is 
d istinguishable by it’s geographical prevalence, although th e  
disease in both areas is identical by histology and characterised by 
a “starry sky” appearance. The endemic form (eBL) is found in 
equatorial Africa largely limited to a broad band covering 15° 
either side of the equator. The sporadic form (sBL) occurs 
e lsewhere in the world where the incidence is up to 50-fold less  
than for eBL. The two tumour forms can be distinguished via a 
variety of markers. For example, one of the characteristic  f e a tu re s  
of eBL is the presence of jaw tumours, whereas jaw in v o lv e m e n t  
in sBL is much less frequent. Also, EBV is associated with eBL in 
about 97% of cases, whereas the association of sBL with EBV is 
only of the order of 15-20% (Reviewed in Karimi and Craw ford, 
1995; Rickinson and Kieff, 1996). Presence of EBV can therefore be 
used to characterise or diagnose a BL but more im portantly  m a y  
also be involved in the pathogenesis of the endemic form of th e  
d isease .
One feature that all Burkitt's Lymphomas have in common is 
the presence of non-random  chromosomal translocations w h ich
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juxtapose the c -m yc  proto-oncogene to one of th e  
imm unoglobulin (Ig) genes. (Reviewed in Karimi and C raw ford , 
1995; Rickinson and Kieff, 1996). The type of breakpoints and th e  
position of the breakpoints on the involved chromosomes can also  
be used to define different types of BL. It is most likely t h a t  
altered expression of c -m yc  resulting from it's positioning next to  
immunoglobulin genes is central to the pathogenesis of BL. L eve ls  
of c -m yc  in BL are similar to levels of c -m y c  in LCLs su g ges tin g  
that it may be inappropriate  expression rather th a n  
overexpression which is important in BL.
The only EBV latent protein consistently expressed in eBL 
biopsies and eBL phenotype cell lines is EBNA-1, the virus g e n o m e  
m aintenance protein, although the EBERs are also c o n s is te n t ly  
detected (Reviewed in Karimi and Crawford, 1995; Rickinson a n d  
Kieff, 1996). Indeed EBNA-1 expression in transgenic mice, w h e re  
the transgene is directed to the lymphoid cell c o m p a r tm e n t ,  
predisposes the mice to monoclonal B cell lymphomas (Wilson a n d  
Levine, 1992; Wilson et al., 1996).
Two lines of EpEBNA-1 mice, lines 26 and 59 succumb to  
monoclonal B cell lymphoma, the indicator of which is a m a ss iv e  
enlargem ent of the spleen concurrent with massive e n la r g e m e n t  
of the liver and/or lymph nodes. 100% of line 26 mice a re  
overcome with an invasive lymphoma within the age range 4 - 1 2  
months. Line 59 mice demonstrate a much longer latency to o n se t  
of disease, with 50% of mice succumbing to lymphom a by 2 4  
m onths of age (Wilson and Levine, 1992; Wilson et al.y 1996). 
Expansion of the white pulp of the spleen and lymph n o d e s  
appears prior to the developm ent of neoplasia suggesting t h a t  
EBNA-1 is involved in the pre-neoplastic stage of tumorigenesis.
1 B . 4  Hodgk in ’s d i s e a s e .
EBV has also been implicated in Hodgkin's disease (HD) w ith  
reports of up to 50% association in the USA and Europe, and 9 0 -  
100% in Peru and Honduras (Reviewed in Karimi and C raw ford , 
1995; Rickinson and Kieff, 1996). EBV has been shown to b e  
present in all 4 types of HD but the closest association is with th e  
most aggressive types (>80%). The disease itself is c h a ra c te r i s e d  
by m ultinucleated Reed-Sternberg (RS) cells which are present in  
very small numbers (2%) in the tumour mass and are probably of 
B cell lineage (Rickinson and Kieff, 1996). However the disease and 
its pathogenesis are confusing and poorly understood.
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The association with EBV was noted when HD p a t ie n ts  
showed elevated antibody titres to EBV antigens (viral c aps id  
antigen-VCA, early, antigens of the lytic cycle and EBNA-1) at th e  
time of presentation as well as some years prior to d ise a se  
(Mueller et a l ,  1989). A threefold increased risk of HD has also  
been documented in people who have had in fec tious  
mononucleosis. The EBV latent genes expressed in HD give it a 
latency 2 phenotype with expression of EBNA-1, LMP-1, LM P-2a, 
and -2b, and the EBERs. Im m unohistochem ical analysis sh o w ed  
that LMP-1 is expressed at high levels in RS cells of EBV p o s i t iv e  
HD tumours. The observation that LMP-1 transfected into EBV 
negative HD cells gives rise to the formation of a m u lt in u c le a te d  
m orphology similar to that of RS cells raises the possibility t h a t  
LMP-1 acts to promote such a m ultinucleated cell p h e n o ty p e  
(Knecht et al., 1996). In 30% of HD cases, polym orphism s of th e  
LMP-1 gene have, been identified (Reviewed in Karimi a n d  
Crawford, 1995; Kieff, 1996). This may give rise to a m o re  
oncogenic LMP-1 as has been suggested for NPC (see section IE .2)
Although EBV is associated with HD, it is only a subset o f 
cases which dem onstrate  this. For example, among young a d u l t  
cases, the age group in which EBV serology is clearly p o s i t iv e  
generally has the lowest EBV-genome positive HD cases (Glaser e t  
al.y 1996). This paradox adds further complexity to the role of EBV 
in HD, a story which is clearly unfinished.
Whilst EBV is found associated with all of these d ise a se  
states, the strongest association of all the human malignancies is 
with Nasopharyngeal Carcinoma.
1C, EBV and Nasopharyngeal Carcinoma.
Nasopharyngeal carcinoma (NPC) is an epithelial t u m o u r  
showing world-wide incidence but a marked geographical a n d  
population bias. It develops with high incidence, particularly  in  
adult males, in Southeast Asia in the coastal provinces o f 
Guandong, Guangxi and Hunan where it may represent 20% of all 
cancer cases. Within China the incidence in variation is so dramatic 
that NPC was referred to as the "Canton Tumour". NPC also  
frequently  develops in Eskimo populations and occurs w ith  
elevated incidence in North Africa. Elsewhere in the world NPC is 
uncommon (Reviewed in Raab-Traub, 1996)
NPC develops at the back of the post-nasal space in a 
discrete area called the W aldeyer's ring. The World H ealth
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Organisation have classified NPC into 3 categories depending on 
the degree of differentiation shown by the tumour (Hording et al.,
1 9 9 3 ) :-
1) W HOl NPC are highly differentiated squamous cell c a rc in o m as  
with intercellular bridges and keratinization.
2) W H 02 NPC retain epithelial growth patterns and shape b u t  
show no evident squamous differentiation.
3) W H 03 NPC show no keratinization or distinctive growth p a t t e r n  
and have a syncytial appearance. They are c o m p le te ly  
u n d i f fe re n t ia te d .
The W H 02 and W H03 undifferentiated  NPCs are the type m o s t  
frequently  found and often contain numerous in f i l t ra t in g  
lym phocytes among the tumour cells giving rise to the t e r m  
"lymphoepithelioma." The tumour can m etastasise and in fact NPC 
is unique among the head and neck cancers in that it has th e  
highest rate of distant metastases. The various stages of d ise a se  
have also been classified according to the site and spread of th e  
tumour (Ho, 1978). Radiation therapy is the main treatm ent fo r  
NPC, but despite this a significant number of patients fail w i th  
d is tan t m etastases.
1 C . l  F a c to rs  in f lu e n c in g  NPC e p i d e m i o l o g y .
Studies of NPC are hampered by the relative rarity of in ta c t  
tumour material. M oreover it has not been possible to d ire c t ly  
passage tumour cells in culture. T ransplantation in nude m ice  
represents  a way of obtaining abundant, homogeneous tu m o u r  
material, but this is frequently unsuccessful with this p a r t ic u la r  
tumour. However one primary tumour (C15) and two m e ta s ta s i s e d  
tumours (C17 and C18) have been successfully t r a n s p la n te d  
(Busson et al., 1988). It was only possible to propagate th e s e  
tumours by passaging them through nude mice, and not po ss ib le  
to grow these tumours in v itro  . An EBV-positive NPC (CAO) h a s  
been successfully propagated as a xenograft in nude mice (Hu e t  
a l ., 1991), whilst 3 NPC tumour lines (designated Xeno-1, -2, and - 
3) were successfully established from fresh biopsy m a te r ia l  
injected sub-cutaneously  into athymic mice and then passaged in  
nude mice for many generations (Huang et al., 1989). This f u r t h e r  
highlights the difficulty in working with NPC material.
These solid tumour lines provide a valuable tool fo r  
investigating NPC. However, much of the information about NPC 
has come from the C15 tumour alone (Chen, F., et al, 1995; Brooks
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et a l ,  1992; Hu et al., 1991; Gilligan et a l ,  1990 - all d isc u sse d  
later) and so care should be taken when interpreting these re su l ts ,  
bearing in mind that these tumour lines represent h ig h ly  
manipulated cases which might not typify the in vivo situation.
1C.1.1 Genetic su scep tib il ity .
Various factors have been shown to play a role in th e  
pathogenesis of NPC. It is likely that the genetic background m a y  
be a factor since the area of highest incidence is Southeast Asia. 
However, a com prehensive epidemiological study has not b e e n  
conducted which might dem onstrate  heritable susceptibility. NPC 
afflicts both males and females although the incidence is higher in  
m ales .
1C. 1.2 D ie t  and l i f e s t y l e .
Diet and lifestyle are likely to be involved and studies h a v e  
shown that there is a higher incidence of NPC among people w h o  
live and work on boats and cook in the open. Similar studies h a v e  
shown that people who consume salted fish during weaning, in 
childhood and throughout their adult life, also have a high re la t iv e  
risk of NPC. Moreover, extracts of salted fish have been shown to  
enhance transforming activity in cell culture, and more tu m o u rs  
are observed in rats fed salted fish than in controls (Zou a n d  
Landolph, 1991; Yu et a l ., 1989). The salting process involves th e  
use of crude salt containing nitrite and nitrate contaminants, th e  
fish are not gutted, and are stored for 4-5 m onths b e fo re  
consumption. This combination allows nitrite red u c in g  
Staphylococci  to carry out nitrosation, producing volatile N- 
nitrosam ines which are mild tumour promoting agents. Indeed a 
correlation was found between the level of N-nitrosam ines in 
salted fish and risk of NPC (Zou et al., 1994). Thus the high leve ls  
of NPC may be attributed to the consumption of salted f ish  
containing high levels of N-nitrosamines. The lifestyle and d ie t  
might perhaps explain the average age for NPC in Southern China, 
which is 45-50 years demonstrating long latency.
It therefore appears that the incidence of NPC may be  
influenced by a heritable susceptibility and also an  
en v iro n m en ta l/d ie ta ry  factor. However, of all EB V -associa ted  
malignancies the tightest association is with NPC. Therefore it m a y  
be the combination of factors:- EBV, genetic susceptibility and d ie t  
that combine to fully dictate incidence.
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1C.1 .3 Viral in f lu en ce .
The most striking feature of NPC is the 100% association o f  
all poorly differentiated or undifferentiated  NPC's with EBV. E arly  
seroepidemiologic studies revealed that patients with NPC h a d  
unusually high antibody titles to the EBV viral capsid a n t ig e n  
(VCA) and to a complex of early replicative proteins termed e a r ly  
antigen (EA) (Henle et al., 1976). Detection of these antibodies is 
therefore an early indication of the onset of NPC. This w a s  
confirmed by polymerase chain reaction (PCR) and in s i tu  
hybrid isation (Chang et a l ., 1990; Niedobitek et al., 1991). EBV 
DNA was shown to be present in pre-invasive neoplastic les ions 
taken from biopsies (Pathm anathan et a l ., 1995). The viral DNA 
was clonal and in a latent state. Therefore EBV infection is critica l 
to the pathogenesis of NPC.
Not only is EBV consistently found in NPC cases, but t h e r e  
may be a prevalence of specific variants of EBV (see section 1A.1) 
in distinct geographic locations which contribute to the e n d em ic  
patterns of incidence. In a study of NPC biopsies from S o u th e rn  
China the vast majority were type 1 " f  variants (Lung et al.,
1991), whereas NPC cases from Caucasians in North America a n d  
in North Africa were predom inantly  the type 1 prototype "F" 
variant (Lung et al ., 1992; Bouzid et a l ., 1994). Alaskan NPCs 
surprisingly are type 2, but with the "F" variant (Abdel-Hamid e t  
a l ., 1992). Therefore no one subtype predominates in all NPCs, b u t  
in Chinese NPC the BAMH1- "f" variant may be the most co m m o n  
variant in the region.
1 C . 2  Genetic a l t e r a t i o n s .
W hilst heritability, diet and viral influence may p re -d is p o s e  
the nasopharynx to the developm ent of NPC, the progression m a y  
be a consequence of alterations in chromosomes such as loss o f  
tum our suppressor genes. Although alterations of the co m m o n  
tum our suppressor genes p53 and Rb are rare in NPC (Spruck e t  
a l ., 1992; Sun et al., 1993), cytogenetic studies have shown t h a t  
abnorm alities on chromosomes 1,3,11,12, and 17 were present in  
some NPC samples (Huang et al ., 1989). A region of ho m ozygo us  
deletion was then identified at position p21-p23 on chromosome 9 
(Huang et a l ., 1994). This frequent allelic loss on chromosome 9 in  
NPC may suggest the presence of a tumour suppressor gene(s) in  
this area, loss of which could contribute to NPC progression. T h e  
region identified on chromosome 9 includes the putative t u m o u r
20
suppressor gene p l6  (as well as p 15 and p l9 )  which binds to a n d  
inhibits the catalytic activity of the CDK4/Cyclin D com plexes  
(Serrano et cil., 1993). Loss of p i 6 function could th e re fo re  
contribute to uncontrolled cell growth. Indeed, ho m ozygous
deletion of p i 6 was shown to be common in primary NPC tu m o u rs
and NPC xenografts suggesting that inactivation of p l6  may b e  
involved in the pathogenesis of NPC (Lo et a l ., 1995). Loss of 
heterozygosity  on chromosome 11, which is a common genetic
aberration in many tumours, was also identified in NPC. Two 
distinct regions of deletions were found at 11 q 13.3-1 lq 2 2  a n d  
I l q 2 2 - l l q 2 4  suggesting the presence of multiple tu m o u r
suppressor genes on chromosome 11 (Hui et al ., 1996). T ak en  
together, these findings indicate multiple complex ch ro m o so m a l
alterations could be responsible in part for the progression of NPC.
1C .3  EBV a c t i o n .
1C.3.1 Lvtic p ro te in s .
Since elevated antibodies to EBV early antigens pre-date th e  
developm ent of N^C by several years, it is feasible that EBV lytic 
genes may be associated with the tumour. Many groups h a v e
looked at the viral state in NPC and could find no linear DNA, th e  
lytic form of the virus, nor expression of ZEBRA (BZLF-1), a p ro te in  
which switches EBV from latent to productive cycle (Gilligan et al., 
1990; Chao et a l ., 1996). There is however controversy about th e  
involvem ent of ZEBRA as one report cites 87% of NPC p a t ie n ts  
exhibiting antibodies to the ZEBRA protein, and in another, th e  
gene encoding ZEBRA was shown to be expressed in all NPC
specimens studied (Joab et al ., 1991; Cochet et a l ., 1993). In  
another report the immediate early genes were present in on ly
some of the NPC biopsies studied by a reverse transcribed PCR 
(RT-PCR) approach. A common feature however was th e  
expression of ZEBRA (M artel-Renoir et al ., 1995). Two poss ib ili ties  
therefore exist. The EBV lytic cycle may be partially r e - a c t iv a te d  
in NPC, or the lytic mRNAs may be present in only a few of th e  
cells within the tumour thus detectable by RT-PCR, but not re f le c t  
expression throughout the tumour. The role of ZEBRA is d e f in i te ly  
u n c lea r .
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1C .3.2 L atent p ro te in s .
It is most likely that one or more of the EBV latent genes a re  
responsible for the pathogenesis of NPC. Various methods h a v e  
been used to determine expression of the latent genes in NPC th e  
conclusion of which is that EBNA-1, LMP-1, LMP-2A and -2B, 
BARFO and the EBERs are all expressed to some extent.
EBNA-1 has been shown to be present in 100% of NPCs b y  
RT-PCR (Brooks et al., 1992; Chen, F., et al., 1995). Although EBNA- 
1 is expressed in all known forms of EBV latency due to i t 's  
requ irem ent for episomal maintenance, different EBNA-1 
prom oters are used in different situations giving rise to  
distinguishable EBNA-1 transcripts. It is interesting therefore t h a t  
the EBNA-1 mRNA species in NPC is of the Q/U/K spliced v a r ie ty  
driven from the Fp/Qp promoter (Brooks et al., 1992). This show s 
that EBNA-1 in NPC is associated with selective use of the Qp 
promoter as opposed to the Wp and Cp prom oters which are u se d  
in LCLs. EBNA-1 has been ascribed no in v itro  t r a n s fo rm in g  
ability and was not thought to play an oncogenic role in vivo in  
EBV associated disease. The recent dem onstra tion that EBNA-1 
predisposes transgenic mice to lymphoma (Wilson and Levine, 
1992; Wilson et al., 1996) revealed that EBNA-1 could act as an  
oncogene in B cells in v ivo .  In addition, EBNA-1 e x p re ss io n  
increases the tumorigenicity of EBV negative HONE-1 cells (of NPC 
origin) (Sheu et al., 1996). In conclusion, the biological effects o f 
EBNA-1 appear to be greater than just episomal maintenance, a n d  
it may be important to the development of NPC as well as B cell 
ly m p h o m a s .
The EBERs aije also found in 100% of primary and m e ta s ta t ic  
NPCs. In situ hybridisation using EBER specific probes can thus b e  
used to identify the presence of EBV in an NPC and to identify a 
metastasised tumour as being NPC in origin (Chao et al., 1996). The 
EBERs are therefore useful markers of NPC although their potential 
role in the disease is still unclear
In NPC there is consistent transcription of the B a m H l-A  
region of EBV, originally detected in the C15 xenograft (Busson e t  
al., 1988) but later shown to be present in tumour biopsies (Chen,
H.L., et al., 1992). Sequencing of cDNA clones from C15 revealed a 
num ber of rightward transcripts. The 3'-ends of all the c lones 
term inated  within a region containing two po ly-adenyla tion  sites. 
One thing that all the transcripts had in common was that th e y  
either partly or wholly encompassed the open reading frame (ORF) 
BARFO (Chen, H.L., et al., 1992), which is predicted to encode a
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basic protein of about 20 kilo-daltons (kDa). Since the function o f  
BARFO is as yet unknown, it’s relevance to NPC is not yet clear.
The LMP-2 gene contains exons located at both ends of th e  
linear EBV genome and therefore can only be transcribed across  
the fused termini of the episomal form. Northern blot and RT-PCR 
analysis have shown that the majority of NPC biopsies have LM P- 
2 message. Two studies (Busson et al., 1992; Brooks et a l., 1 9 9 2 )  
showed that LMP-2A was detected in almost 100% (10/11 a n d  
17/18 respectively) of the cases, whether primary NPC o r  
metastatic tumour, whereas LMP-2B was expressed at much lo w e r  
levels (3/11 and 7/18 respectively). The consistent expression of 
LMP-2 in all cases suggests that it may be involved in the onset o r  
progression of NPC.
The detection of LMP-1 in NPC biopsies has varied accord ing  
to the technique used. Total RNA from the nude mouse p a ssa g e d  
cell line C15 (Busson et al ., 1988) contained two messages w ith  
sequences specific for the 5'-end of LMP-1. Sequence analysis of a 
cDNA library made from the same cell line showed that two fo rm s  
of LMP-1, utilising the normal promoter and an internal p ro m o te r ,  
were indeed present (Gilligan et al ., 1990). W estern blot a n a ly s is  
of protein content from tumour biopsies showed that LMP-1 w a s  
present in 38-77% of NPC cases (Young et al., 1988 (24 cases); 
Zheng et al., 1994b (23 cases); Hu et al., 1995 (74 cases); and Fu e t  
al., 1991 (13 cases) in order of increasing LMP-1 levels d e te c ted ) .  
M onoclonal antibody immunohistochemistry staining allows sing le  
cell expression to be detected. In this way 78% of NPC tu m o u rs  
were shown to be LMP-1 positive (Stewart and Arrand, 1993; 
V era-Sem pere et al., 1996). RT-PCR amplification of the LM P-1 
gene, using nested primers and total RNA from two NPC d e r iv e d  
solid tumour lines, and from RNA extracted from 24 NPC b iopsies , 
showed the presence of LMP-1 message in >90% of cases (Chen, F., 
et al., 1995). Therefore it appears that LMP-1 message is p r e s e n t  
in the majority of NPC cases, but LMP-1 protein is only detected in  
about 65% of cases.
ID. The Latent Membrane Protein-1.
1 P .  1 LMP-1 protein structure.
LMP-1 was cloned and sequenced in 1984 by Fennewald e t  
al. The protein was shown to be 3 8 6 a a  long with a p re d ic te d
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molecular weight of 42kDa. Based on amino acid sequence, th e  
protein was shown to have:-
1) A short, 2 5 a a  ilong hydrophilic, cytoplasmic, amino te rm in a l  
do m ain . I
2) Six hydrophobic, 20ococ long, alpha-helical t r a n s m e m b r a n e  
segments, separated by five 8 to lOaoc long reverse turn loops.
3) A 2 0 0 a a  long carboxy terminal domain, rich in acidic, g lycine  
and proline residues that projects into the cytoplasm.
A polyclonal rabbit antiserum was raised against the p ro te in  
and this antiserum was used to identify a specific protein in e v e r y  
EBV infected B cell line tested (Hennessy et al ., 1984). This p ro te in  
separated with the m em brane/m icrosom al fraction and was n o t  
seen in the cytoplasmic supernatent. Furthermore, the a n t i s e r u m  
specifically reacted with the plasma m em brane of cells tested a n d  
stained in a characteristic patch/cap expression (Liebowitz et al., 
1986) where LMP-1 associated with vimentin in te r m e d ia te  
filaments (Liebowitz et al ., 1987). This association with th e  
cytoskeleton would explain why half or more of LMP-1 is resistant 
to non-ionic detergent extraction (Liebowitz et al ., 1987). LM P-1 
does not require vimentin to form these patches h o w e v e r  
suggesting that it may interact with itself or other cell m e m b r a n e  
proteins (Liebowitz et a l ., 1989). This was therefore the f i r s t  
characterisation of a membrane bound protein found in la te n t ly  
EBV infected B cells.
Being a m em brane protein it was initially assumed t h a t  
LMP-1 would function as a receptor and it was shown that LM P-1 
was structurally similar to members of the p adrenergic r e c e p to r  
family of signalling proteins. However, the amount of LM P-1 
projecting out of the cell as a potential binding site is very sm all  
and no ligand has yet been identified. With the discovery t h a t  
LMP-1 aggregates iin the plasma m em brane and associates w ith  
m em bers of the Tumour Necrosis Factor Receptor (TNFR) 
Associated Factor (TRAF) family of signalling proteins (d iscu ssed  
later in section ID.5.2) the current view is that LMP-1 is not a 
receptor in the classical sense, but rather the initiator of s ignalling  
events in the absence of ligand.
LMP-1 protein is characterised by s e r in e / th r e o n in e  
phosphoryla tion at a ratio of 6:1 of the C-terminal domain a n d  
rapid turnover (half-life of 2-3hrs) due to specific p ro teo ly tic  
cleavage, which causes the release of a phosphoryla ted  C -te rm in a l  
fragment (p25) into the cytoplasm (Moorthy and T h o r ley -L aw so n , 
1993b). Phosphorylation has long been recognised as a m e c h a n ism  
for regulating the function of proteins so may be important in th e
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function of LMP-1. Indeed two important sites at S-313 and T-324 
were identified therefore phosphorylation would seem to p ro v id e  
a mechanism for the regulation of LMP-1.
1 D .2  T ransform ing  ability of L M P - 1 .
ID .2.1 Rodent f ib rob las ts .
The first report that LMP-1 could act as an oncogene c am e  
via the transfection of LMP-1 into NIH3T3 and Rat-1 f ib ro b la s ts  
(Wang et al ., 1985). In NIH3T3 cells LMP-1 expression led to an  
altered morphology and reduced sensitivity to low s e r u m
inhibition of cell growth. The effect of LMP-1 expression in Rat-1 
cells was much more dramatic with LMP-1 expressing c lones 
forming foci of heaped up cells in 10%FCS medium. LM P-1 
expression also facilitated anchorage-independen t growth in so f t  
agar. Even more dramatically, LMP-1 expressing clones fo rm e d  
tumours when injected into nude mice. This was therefore th e  
first dem onstration that LMP-1 was indeed capable of
oncogenicity and strengthened the hypothesis that it has a role in 
EBV associated human malignancies. This initial finding w a s  
substantia ted  and expanded when it was shown that LMP-1 also
caused anchorage-independen t growth in Balb/c 3T3 cells a n d  
LMP-1 expressing clones were capable of inducing tumours in
athymic mice (Baichwal and Sugden, 1988). LMP-1 is th e re fo re  
capable of transforming rodent fibroblasts.
ID .2.2 Epithelial cells.
The first dem onstration that LMP-1 had an oncogenic e f fe c t  
in epithelial cells in vivo was demonstrated by Wilson et al., 1 9 9 0  
by expression in transgenic mice. Expression of LMP-1 in th e  
epidermis of transgenic mice resulted in mice which were r u n te d  
and had in common a distinct phenotype of dermatosis giving a 
gross appearance of wrinkled, scurfy skin soon after b ir th .
Histopathological examination revealed a thickening (h y p e rp la s ia )  
of the epidermis with a disorganisation of the d i f fe re n t ia t in g  
layers, and this was maintained throughout the animals l ife tim e.
This disruption of the epidermis by LMP-1 and the r e s u l ta n t  
hyperplasia  mimics the initial stages of tumorigenesis, a n d
provides clear evidence that LMP-1 is involved in e p ith e l ia l  
t ra n s fo rm a tio n .
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In support of the in vivo evidence that LMP-1 is oncogenic, 
LMP-1 was transfected into the SCC12F cell line which is an  
im m ortalised non-tumorigenic sub-clone of the human sq u a m o u s  
cell carcinoma line SCC12 (Dawson et al., 1990). SCC12F cells r e ta in  
certain features of normal keratinocyte behaviour in v i t ro , 
including responsiveness to differentiation signals. Because th e  
effects of LMP-1 in rodent cell transform ation assays r e s e m b le  
those produced by activated Ras proteins, SCC12F cells were also  
transfected with activated c-Ha-Ras  in parallel experiments.
The LMP-1 and Ras transfectants showed little evidence of 
normal cell stratification and were severely impaired in th e i r  
ability to form crosslinked envelopes in response to ca lc ium  
ionophore treatment. This suggests a reduced capacity fo r
terminal differentiation. Indeed, compared to con tro l 
transfectants, all LMP-1 expressing clones produced a m u c h  
thicker, but less well organised epithelium with poor in te rc e l lu la r  
contacts (desmosomal junctions) when grown on collagen rafts. I n 
the parallel Ras transfection studies, Ras produced an even th ic k e r  
m ultilayer structure than LMP-1 with a similar absence o f
terminal differentiation markers. This study indicates that LM P-1 
can induce changes in the surface phenotype and d if fe re n t ia t io n  
responsiveness of human epithelial cells and in certain aspects is 
functionally similar to activated Ras protein.
Similar studies using the immortalised non-tum origenic cell 
line Rhek-1 as the target cell for LMP-1 transfection p ro v id e d  
corroborative  evidence for the last study. In these cases LM P-1
expressing Rhek-1 clones had a more fibroblastic m orp h o lo g y , 
with altered architecture and growth pattern (Fahraeus et al., 
1990; Zheng et al ., 1994a). Cells grew in tight, d iso rg a n ise d
bundles that became m ultilayered and formed foci long b e fo re  
they reached confluence. This was different to control t r a n s fe c ta n t  
or parental Rhek-1 cells which grew as flat, polygonal colonies 
characterised by a, ’’cobble-stone" appearance.
ID .2.3 B -ce lls .
The first observation that LMP-1 was required for th e  
transformation of B cells came when the amino terminus of LM P-1 
was deleted from a recom binant virus abolishing B cell 
transforming activity (Wang et a l ., 1988). Subsequent studies have 
been done to analyse different regions of the LMP-1 protein us ing  
deletion m utants to attempt to discover the exact location of th e  
transforming portion of the protein (See section ID.6). All of th e s e
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studies confirmed that loss of LMP-1 function abolished the ability 
of EBV to transform  B cells (Liebowitz et a l ., 1992; Kaye et al., 
1993 and 1995). Although it is required in this function, it is n o t  
sufficient, since deletion of EBNA-2, EBNA-3a, -3c and EBNA-LP all 
result in loss of transform ing activity by the virus in B cells in 
culture (EBNA-1 being not possible to delete in this assay).
1 D .3  LMP-1 induced changes in gene e x p r e s s i o n .
1D.3.1 Epithelial cells.
The initial interest in the effects of LMP-1 in e p i th e l iu m  
stems from the fact that the oral epithelium is thought to be th e  
primary site of in v ivo  infection by EBV, and that of all th e  
human malignancies associated with EBV, NPC has the s t ro n g e s t  
association. There is however a lack of a suitable culture s y s te m  
because it is not possible to infect epithelial cells in v itro  w i th  
EBV without the prior introduction of the CR2 gene (Li et al., 
1992). This has therefore hampered studies into the effects of
LMP-1 in epithelial cells and limited in v itro  experim ents la rg e ly
to transfecting LMP-1 into various immortalised cell lines. D espite  
these problems the transfection system does allow observation of 
the effects of introduced viral or cellular genes on epithelial cell 
growth and differentiation.
For example, when LMP-1 was transfected into the SCC12F 
cell line (Dawson et al., 1990) it was shown that CD40 and ICAM-1 
levels were both increased. The levels of CD23, LFA-1, and LFA-3, 
which are effected in B cells, could not be assessed because e i th e r  
they are not normally present in epithelial cells or because th e y  
are already at very high levels in these cells. Further t ra n s fe c t io n
studies have shown that the anti-apoptotic gene A20 is induced in
the human cervical carcinoma derived epithelial cell line C33A 
upon LMP-1 transfection (Miller et al., 1995). Furtherm ore th e  
Epidermal Growth Factor Receptor (EGFR) has been shown to b e  
overexpressed in NPC (Zheng et al., 1994b), and was seen to b e  
present at elevated levels in LMP-1 transfected C33A ep ith e l ia l  
cells (Miller et al., 1995). The EGFR induced was predicted to b e  
functional because it became phosphorylated on Tyrosine re s id u e s  
when EGF was added to the medium. This led to p h o sp h o ry la t io n  
of other proteins downstream in the EGFR signalling pathway, one  
of which may be p55Shc thus linking the EGFR pathway to the Ras 
pathway. LMP-1 expression also increased the p ro l i fe ra t iv e  
response to EGF, as LMP-1 expressing C33A cells continued to
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increase in number when plated in serum free m e d ia
supplem ented with EGF unlike controls. Therefore, LMP-1 m a y  
induce EGFR and thereby upregulate the EGFR signalling p a th w a y .  
This may in part explain the similarities between t r a n s fe c te d
LMP-1 and Ras in growth transforming assays (Dawson et al.,
1990). The presence of increased EGFR in LMP-1 expressing NPC 
specimens (Zheng et a l ., 1994b) indicates that LMP-1 may in du ce  
EGFR in vivo also and that upregulation of EGFR by LMP-1 m a y  
contribute to the developm ent of NPC. The mechanism s by w hich  
LMP-1 upregulates EGFR and other proteins will be reviewed in 
section 1D.5)
LMP-1 expression in v ivo  in the epidermis of tran sg en ic
mice also caused changes in gene expression (Wilson et al., 1990). 
Here, the cytokeratin K14 was shown to be induced in th e  
suprabasal layers of the epidermis and not restricted to the basa l 
layers as is normally the case. More dram atically  th e  
hyperpro lifera tive  keratin K6, normally found expressed only in 
hair follicles, was induced within the hyperplastic region of th e
epidermis. Thus LMP-1 induced changes in gene expression can be  
detected both in vitro and in vivo.
1D.3.2 B-cells.
Due to the severe problems limiting in v itro  analysis of th e  
effects of LMP-1 in epithelial cells, most of the information on 
LMP-1 induced gene expression alterations has come from in v i tro  
investigations using B cells. Infection and imm ortalization of 
prim ary human B cells with EBV leads to a panoply of changes in 
gene expression (Reviewed in Kieff, 1996). Such imm ortalised EBV 
positive cell lines and also immortalised EBV positive and n e g a tiv e  
human B lymphoma or Burkitt's Lymphoma (BL) cell lines h a v e  
been invaluable in determining the nature and cause of th e s e  
changes in gene expression.
EBV negative human B lymphoma cells c h a rac te r is t ic a lly  
grow as single cells in culture and express low levels of ac tiv a tion  
and adhesion markers. EBV positive latency 3 type human B 
lym phom a cells on the other hand grow in clumps and show  
upregulated expression of activation and adhesion markers. Single 
gene transfer experiments where LMP-1 was transfected into EBV 
negative B lymphoma cell lines showed that LMP-1 had p ro fo u n d  
effects and was responsible for the increase in adhesion m a r k e r s  
and subsequent growth in clumps. LMP-1 also caused in c re a se d
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cell size, acid production, plasma m em brane ruffling, and v illous 
projections (Wang et al., 1988).
Expression of LMP-1 in a variety of cell lines has b e e n  
examined including the EBV negative B lymphom a lines L ouckes 
and BJAB, the EBV negative BL line BL41, and Daudi, an EBV 
positive cell line lacking LMP-1, EBNA-2 and part of EBNA-LP 
(Wang et a l ., 1988; Wang et al., 1990). Each cell type has a u n iq u e  
profile but in every case studied the BL marker CD10 w a s  
uniformly downregulated by LMP-1.
A summary of results from these cell lines showed t h a t  
LMP-1 can induce the expression of the adhesion molecules ICAM- 
1 (CD54), LFA-1 (CD11 a/CD 18) and LFA-3 (CD58); CD21, the EBV 
receptor; CD23, the B cell activation marker; CD39, a lymphoid cell 
activation antigen recently shown to have ecto-apyrase activ ity ; 
CD40, activation of which is critical for B-cell function, leading to  
activation and expression of cell surface markers, p ro l ife ra t io n ,  
immunoglobulin class switching and inhibition of program m ed cell 
death; CD44, a molecule implicated in enhanced lymphoid tu m o u r  
growth and dissemination; and CD71, the transferrin receptor.
Further analysis of CD23 upregulation by LMP-1 sh o w e d  
that LMP-1 specifically targets the type b CD23 mRNA (FceRIIb) 
for upregulation (Wang et al., 1990). This is one of two CD23 
mRNAs which is normally induced in B lymphocytes by IL-4, a n d  
would explain why EBV-infected LCL's have more FceRIIb th a n  
FceRIIa.
Other single gene transfection experim ents involving LM P-1 
have been invaluable in discovering further cellular g e n e  
expression changes induced by LMP-1. For example, only LM P-1 
transfected EBV negative B lymphoma cells, and not cells 
transfected with any other latently expressed gene, sh o w e d  
elevated expression of the anti-apoptotic gene bcl- 2 (H e n d erso n  
et al., 1991; Rowe et al., 1994). Another Bcl-2 family member, Mcl- 
1, was also shown to be rapidly induced in LMP-1 transfected EBV 
negative BL cell lines (Wang et al., 1996). One further a n t i -  
apoptotic protein, A20, was also shown to be induced in  
lymphocytes by LMP-1 (Laherty et al., 1992). The relevance o f  
LMP-1 inducem ent of Bcl-2 family members, and other a n t i -  
apoptotic proteins is discussed in greater detail in section 1D.4.
LMP-1 may also induce interleukin 10 (IL-10) e x p re s s io n  
(Nakagomi et al., 1994) perhaps effecting the im m u n o g en ic  
response to latently EBV infected cells in vivo .
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LMP-1 appears to also induce functional CaM k in a se  
(Mosialos et a l., 1994) which might be responsible for aspects o f 
the growth and transformation associated with LMP-1.
EBV transform ed LCLs express high levels of h u m a n  
leukocyte antigen (HLA) which are efficient in an tig en  
presentation. Latent gene transfection studies, where each la t e n t  
gene was transfected alone into the EBV negative BL cell l ine  
Louckes, showed that LMP-1 was responsible for upregulating th e  
HLA class II molecules (Zhang et al., 1994). Quite why a viral g en e  
should upregulate a component of one of the host cell's m a in  
defence m echanism s remains unclear.
LMP-1 co-localizes with and induces higher levels o f 
vimentin in latently infected B-lymphocyte plasma m e m b r a n e s  
patches (Liebowitz et al., 1987). Vimentin is not ordinarily fo u n d  
in plasma m em brane patches therefore is presum ably d ra w n  
there by LMP-1.
These effects on cell growth and activation, whilst v a ry in g
from cell type to cell type, indicate that LMP-1 is an im p o r ta n t  
m ediator of EBVs effects on lymphocyte growth. Inducem ent b y  
LMP-1 of Bcl-2 family members and also CD40 is likely to b e  
important in cell survival and is discussed in the next section.
1 D .4  LMP-1 express ion  and enhanced cell s u r v i v a l .
1D.4.1 B-cells.
Serial passage of cells with a BL phenotype can result in a 
broadening of EBV latent gene expression to that characteristic o f 
LCLs (from type 1 to type 3). Comparing the two groups th e re fo re  
allows analysis of the latent genes involved in the p h e n o ty p ic  
changes that ensue. BL phenotype cells rapidly die by ap op tos is  
when conditions that inhibit cell proliferation, such as s e ru m  
starvation, prevail. On the other hand, LCLs retain their v iab il i ty  
(Gregory et al., 1991). This suggests that one or more of the l a te n t
genes other than EBNA-1 is responsible for this enhanced ab il i ty
to survive in suboptimal conditions. It was subsequently  show n
that of the latent genes, LMP-1 could promote this cell survival, in  
part through upregulation of Bcl-2 (Henderson et al., 1991; M a rt in  
et a l ,  1993; and Rowe et a l, 1994). The increased cell su rv iv a l  
induced by LMP-1 might allow a bypass of normal se lec tion  
processes in vivo and thus allow the cell to enter the long l iv ed  
memory B cell pool. Promoting cell survival also increases th e  
chance of neoplastic alterations occurring.
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If LMP-1 induced Bel -2 expression was observed to ta k e  
48-72hrs then the cells would be at risk from apoptosis in th e  
interim period. With this in mind it was thought that another Bcl- 
2 family member might play a role prior to Bel -2 itself. Mcl-1, a 
rapidly inducible protein with a short half-life, was examined in 
EBV negative BL cell lines transiently or stably expressing LM P-1 
(Wang et al., 1996). It was shown that LMP-1 rapidly induces th e  
expression Mcl-1 which can protect BL cells from apoptotic s t im u li  
until such times as Bcl-2 levels are elevated. Thereafter M cl-1 
may be redundant and i t ’s levels therefore decrease.
The A20 zinc finger protein is Tumour Necrosis Factor a  
(T N F a )  inducible, and confers resistance to the cytotoxic effects o f 
TNFa. Cells expressing A20 would therefore be protected f ro m  
apoptosis and have a growth and survival advantage. It w a s  
shown that LMP-1 significantly induced the A20 transcript a n d  
was the single gene responsible for this upregulation (Laherty e t  
al., 1992).
LMP-1 induction of CD40 could also protect B cells f ro m  
apoptosis, not only as CD40 induces B cell proliferation and re sc u e  
from programmed cell death, but because CD40 activation in d u ces  
the apoptosis inhibitor A20 (Sarma et al., 1995).
As LMP-1 can induce Bcl-2 family members in certain cells 
thereby protecting the cells from apoptosis it was logical to  
determ ine  if LMP-1 could also protect B cells from p 5 3 - t r ig g e r e d  
apoptosis. BL41 is an EBV-negative BL line carrying an  
endogenous mutant p53. These cells were transfected with LM P-1 
and a tem pera tu re -sensitive  (ts) p53 which would in d u ce  
apoptosis at 32°C where ts-p53 behaves as wild-type (WT) ( b u t  
not at 37°C). Both parental and LMP-1 transfectant cells grew a t  
the permissive tem perature  (37°C) and were actively cycling, b u t  
only LMP-1 expressing cells survived at 32°C. However the cells 
were arrested in G1 of the cell cycle (Okan et al ., 1995). This 
suggests that LMP-1 protects B cells from p53 triggered ap op to s is  
m ediated at the non-perm issive tem perature, but not from p5  3 
induced cell cycle arrest. The LMP-1 expressing cells also h a d  
increased levels of Bel  -2 compared to parental cells implying t h a t  
an LMP-1 induced increase in Bel -2 may be responsible for th e  
resistance to p53 triggered apoptosis. Thus LMP-1 induction of Bel 
-2 may protect B cells from two types of apoptotic stimuli, n a m e ly  
serum starvation and p53 induction, and so give these cells 
enhanced survival abilities and therefore increased neop las t ic  
poss ib ili ties .
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In v itro  infection of primary human B cells by EBV re s u l ts  
in activation of resting B cells and the synthesis of p53. The LCLs 
produced are very sensitive to chem otherapeutic  agents r e su l t in g  
in apoptotic death (Allday et a l., 1995). In this example LMP-1 d id  
not interfere with the activation of p53 in response to DNA 
damage, or it’s function as a mediator of apoptosis. It w o u ld  
appear then, that LMP-1 can induce survival under c e r ta in  
conditions, but not under conditions where DNA damage occurs.
ID .4.2 Epithelial cells.
Although Bel- 2 can protect B lymphocytes from p 5  3 
mediated apoptosis, Bel-  2 levels are not altered in epithelial cells 
or NPC therefore Bcl-2  levels do not appear to play a role in  
blocking apoptosis in epithelial cells. A20 can protect b r e a s t  
cancer cells and fibroblasts from TNF mediated apoptosis, a n d  
since A20 expression is induced in both lymphocytes a n d  
epithelial cells by LMP-1, it may be able to protect epithelial cells 
from apoptosis (Laherty et al., 1992).
Okan et al had shown that LMP-1 may protect B cells f ro m  
p53 mediated apoptosis triggered by a n o n -p e rm is s iv e  
tem perature , and similar findings were observed in the h u m a n  
lung carcinoma cell line H1299 (Fries et al., 1996). In an ep ith e l ia l  
cell line transfected with LMP-1, A20 levels were s ign if ican tly  
increased (Miller et al., 1995). When A20 was transfected into th e  
H 1299(ts)-p53 cells it protected the cells from apoptosis in d u ce d  
at 32°C by serum withdrawal (Fries et al., 1996). Therefore LM P-1 
induces A20 which then protects cells from p53 m e d ia te d  
apoptosis in conditions of reduced tem perature and re d u c e d  
se ru m .
Just as in the B cell situation, LMP-1 has different effects in 
different epithelial cell lines tested and different effects at low, 
normal and high expression levels. For example, gene t ra n s fe c t io n  
studies involving LMP-1 often lead to low yields of s ta b le  
transfectants from cultures in which transient transfection g av e  
high LMP-1 expression. This has been shown on n u m e ro u s  
occasions and was interpreted to mean that high level LM P-1
expression is actually toxic to cells. The possibility that the cell
death could be due to apoptosis was investigated in Rhek-1 cells 
transfected with LMP-1 (Lu et al., 1996). Under normal cond itions, 
there was always more cell death in the LMP-1 t r a n s fe c ta n ts  
compared to control transfectants or parental cells. U n d e r
conditions of serum starvation, the LMP-1 expressing cells sh o w ed
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a dramatic increase in death, with the highest expressing clones 
exhibiting the greatest degree of cell death. This study th e re fo re  
concludes that LMP-1 induces apoptosis in epithelial cells a n d  
obviously contradicts previous reports. The role of LMP-1 in 
protecting epithelial cells from apoptosis is therefore perhaps still 
open to question.
This section has described the different effects that LM P-1 
has in B lymphocytes and epithelial cells. That many of th e  
alterations in gene expression in v itro  in tissue culture a re  
mirrored in vivo in the various disease states suggests that th e s e  
changes are im portant in the developm ent and progression of 
malignancy. The mechanism s used by LMP-1 to introduce th e s e  
shifts in gene expression patterns will now be discussed.
1 D .5  M e c h a n ism s  of ac tion  of L M P - 1 .
1D.5.1 LMP-1 acts through NF-kB.
Nuclear Factor kB (NF-kB) is a heterodim eric m em ber of th e  
Rel-related family of transcription factors composed of a 50 -kD a 
DNA binding subunit and a 65-kDa subunit containing a 
transactivation domain. NF-kB is normally bound in an inac tiv e  
form by its cytoplasmic inhibitor I k B ,  but upon certain stimuli will 
dissociate, translocate to the nucleus and cause transcription of 
target genes by binding to kB sequences within their p ro m o te r s  
(Reviewed in Opipari, 1990).
The A20 gene upregulated by LMP-1 contains two kB 
sequences, and NF-kB binding induces transcriptional activation. 11 
has been shown that LMP-1 can upregulate the A20 p ro m o te r ,  
through the NF-kB binding sites. Furthermore, gene induction  
through the first binding site is an early consequence of LMP-1 
expression (Rowe et al., 1994). Here LMP-1 was stably t r a n s e fc te d  
into an EBV negative BL cell line under the control of an in ducib le  
promoter, providing expression of LMP-1 at will. Induction o f  
LMP-1 in these cells led to the induction of a co-transfected kB 
luciferase reporter construct. LMP-1 expression results in  
phosphorylation and proteolysis of IkB allowing the n u c le a r  
translocation of NF-kB in the form of p65 in conjunction with p5  0 
and p52 (Herrero et al., 1995). LMP-1 may therefore mediate its  
various effects on protein expression, including upregulation of 
adhesion molecules and enhancem ent of cell survival, through an  
NF-kB pathway. Indeed, various members of the ad h es io n
molecule family, including ICAM-1, have NF-kB r e s p o n s iv e  
elements in their gene promoter region.
p53 has an NF-kB site in it's promoter region and as with th e  
previous studies it was shown that LMP-1 induced NF-kB 
activation and subsequent upregulation of the p53 gene (Chen a n d  
Cooper, 1996). This is then another example of LMP-1 induced NF- 
kB activity and poses a very intriguing question which m e r i ts  
further investigation. Namely, why do the increased levels o f 
functional p53 induced by LMP-1 fail to block cell division a n d /o r  
induce apoptosis?
The various studies described so far have all in v o lv ed  
transfection of LMP-1 into EBV negative B cell lines. Since LMP-1 
has different effects in different cell types it may be predicted to  
have different effects on NF-kB activity in epithelial o r  
fibroblastoid cells. Indeed, LMP-1 induced high levels of NF-kB 
activity in 293 cells, a transform ed fibroblastoid cell line. I n 
addition, a small but significant increase in NF-kB activity in HEp2 
cells, an epithelial carcinoma cell line, was observed. However, no 
effect on NF-kB activity was noted in Balb/c 3T3 cells, a m u r in e  
fibroblast cell line (Mitchell and Sugden, 1995). Thus, LMP-1 
affects NF-kB in a cell type dependent manner.
LMP-1 expression alone is reported to induce many of th e  
cell surface phenotype changes that are rem iniscent of th e  
activation process initiated by infection with EBV. To assess if  
these changes are a direct result of LM P-l's  ability to activate NF- 
kB, the induction of two cell surface activation markers, CD54 a n d  
CD40, were compared to levels of activation of NF-kB. It w as  
shown that high levels of NF-kB activity did not always e ff ic ien tly  
translate into surface phenotype changes. This implies that o th e r  
m echanisms must also be activated in concert with NF-kB to  
achieve the full extent of surface phenotype change. W hat th e s e  
other mechanisms might be became clearer with the d isc o v e ry  
that LMP-1 specifically interacts with members of the TNFR 
Associated Factor (TRAF) family of signalling molecules.
ID .5.2 LMP-1 interacts with members of the TRAF family of 
signalling m olecules.
LMP-1 forms discrete patch/cap structures in the p la sm a  
m em brane where it associates with the cytoskeletal p ro te in  
vimentin (Liebowitz et a l ., 1986) and is co-localized with LM P-2A  
(Longnecker et a l ,  1991). Although LMP-2A has been shown to
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be a substrate for src family tyrosine kinases (Longnecker et al., 
1991) a direct association with LMP-1 (for example using th e  
yeast two-hybrid system) has not been shown.
LMP-1 is capable of forming patches in the p la s m a  
m em brane  in the absence of vimentin or any other EBV p ro te in  
(Liebowitz and Kieff, 1989; Liebowitz et al ., 1992) suggesting t h a t  
it may interact with itself, or with other cell membrane proteins to 
form  large, noncovalently linked membrane complexes.
This hypothesis was substantiated when the yeast tw o -  
hybrid  screening system was used to identify proteins w h ich  
interact with the cytoplasmic C-terminal tail of LMP-1. A n 
interaction was shown with a human protein with a ring f in g e r  
and extended coiled-coil domain [LMP-associated protein (LAP1)], 
and with an EBV-induced protein EBI6 (Mosialos et al., 1995). 
These proteins were found to be homologous to members of th e  
recently  discovered family of tumour necrosis factor r e c e p to r  
(TNFR)-associated factors (TRAFs) (Rothe et al., 1994) which sh a re  
a c-terminal homology region called the TRAF domain.
LAP1 was identical to the third member of the TRAF fam ily , 
TRAF3, which was initially identified by several groups as b in d in g  
to the C-terminus of the CD40 molecule and th e re fo re  
a lternative ly  called CD40 binding protein (CD40bp), CD40 
Associated Factor (CRAF1) and (CAP-1), for CD40 A ssoc ia ted  
P ro te in -1, respectively (Hu et al., 1994; Cheng et al., 1995; a n d  
Sato et al., 1995). EBI6 was shown to be the human homologue of 
the murine TRAF1.
This initial discovery was the first direct evidence that LM P- 
1 may be acting as a signalling molecule as it was the first r e p o r t  
of LMP-1 directly interacting with signalling pathway fac tors, 
namely the TNF/CD40 pathway.
In transiently transfected cells, 30% of LMP-1 was shown to  
be associated with TRAF3, another 30% was associated with TRAF1 
or TRAF1-TRAF2 complexes (Devergne et a l ,  1996). In co n tra s t ,  
virtually all of the TRAF1 or TRAF3 observed was associated w ith  
LMP-1, and only 5% of TRAF2 likewise bound. Thus, the LM P-1 
cytoplasmic domain interacts with and associates with cell 
proteins that are mediators of cytoplasmic signalling from th e  
TNFR family.
In another study TRAF3 was used as the 'bait' in a y e a s t  
tw o-hybrid  screen and a protein called TANK (TRAF fam ily
m em ber associated NF-kB activator) was discovered (Cheng et al., 
1996). TANK is ubiquitously expressed, has no s ign if ican t 
homologies and could interact with all three TRAFs. TANK, in
35
conjunction with TRAF2, activates NF-kB. However, in c o m p le te  
contrast, TANK inhibits NF-kB activation from the LM P-1 
cytoplasmic tail. TANK competes with LMP-1 (and p r e s u m a b ly  
TRAF1) for the binding of TRAF2, and so may inhibit NF-kB 
activity under these conditions by preventing TRAF2 assoc ia tion  
with aggregated LMP-1.
A model would therefore be that LMP-1 aggregates in th e  
plasma membrane in association with TRAFs 1, 2, and 3. TRAF1 is 
constitutively bound to LMP-1 and requires TRAF2 to bind a n d  
form a heterodim er for NF-kB activation. TANK is a n e g a t iv e  
regulator of LMP-1 mediated NF-kB activation. TRAF3 binds to  
LMP-1 with the greatest affinity, but its role is not clear, with no  
involvement in NF-kB activation.
This interaction of LMP-1 and TRAFs might lead to
activation of the TNFR/CD40 pathways thereby causing
constitutive cell growth and inhibiting apoptosis. One of the d o w n  
stream effects of signalling through the TRAF molecules is also NF- 
k B  activation (section 1D.5.1).
The focus of discussion so far has been the effects of LM P-1 
on B-cells and epithelial cells both in vitro and in vivo. I n te n s iv e  
m utational analysis of all three domains of LMP-1, and in
particular the carboxy terminus, has been carried out in an e f fo r t  
to characterise the regions required for the transforming ability o f 
LMP-1 and the inducement of the numerous cellular g e n e
expression changes occurring apon LMP-1 expression. A discussion 
of the im portant structural findings will form the basis for th e  
next section.
1 D .6  Mutational analysis of L M P - 1 .
ID .6.1 Functional analysis of the domain structure of LM P-1.
Once it was discovered that LMP-1 was oncogenic in r o d e n t  
fibroblasts it became important to know which domains of th e  
protein were responsible for the transforming events and w h ich  
were responsible for the upregulation of cellular genes. T he  
principal approach used involved construction of deletion m u ta n ts  
of the LMP-1 gene and then testing them for their t ra n s fo rm in g  
activity in rodent fibroblasts or effects on gene expression a n d  
transformation in B cells.
Mutants lacking sequences in the N-terminus o r  
transm em brane (tm) domain had in term ediate  and no  
transform ing ability respectively when transfected into Balb 3T3
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cells (Hammerschmidt et a l ., 1989). This suggested that the am in o  
term inus and the transm em brane domain are necessary for th e  
transform ing effect of LMP-1 on rodent fibroblasts. In co n tra s t ,  
certain mutations in the C-terminus of LMP-1 were still able to  
transform Balb 3T3 fibroblasts.
The panel of mutants assessed was then extended. Both N- 
term inal mutants and transm em brane mutants a re  
phosphorylated  normally but are inefficiently cleaved o r  
uncleaved respectively (Moorthy and Thorley-Lawson, 1993 a). 
Furtherm ore, neither mutant could efficiently transform Rat-1  
cells to anywhere near the levels of WT LMP-1. The first 3 0 a a  and 
last 2 3 oca of the C-terminus were also shown to be essential fo r  
transform ation  of rodent fibroblasts. These results th e re fo re  
indicate that all 3 domains of LMP-1 are required for th e  
transforming ability of the protein.
In B cells, initial analysis indicated that the N-terminal p lu s  
the first 4 transmembrane loops are needed for functional a c t iv i ty  
of LMP-1 (Wang et al., 1988). This region was further dissected b y  
creating more N-terminal and transm em brane mutants (L iebow itz  
et a l ., 1992) which revealed that the N-terminus, 1st, 3rd and 4 th  
transmembrane domains each contribute to the effect of LMP-1 on 
B lymphocytes. N-terminal truncated proteins were created t h a t  
could not initiate or maintain primary B cell transform ation (Kaye 
et a l ., 1993).
However, further mutational assessment of the role of th e  
am ino-term inal cytoplasmic domain (Izumi et a l ., 1994) sh o w ed  
that the only mutant that was slightly retarded in its ability to  
transform  primary B lymphocytes was one which had th e  
transmembrane anchor sequence deleted. This result suggests t h a t  
it is most likely that the N-terminal domain of LMP-1 is n o t  
essential to B lymphocyte transform ation, but probably plays a 
structural role of anchoring the amino terminus of the 1 s t  
transmembrane domain of LMP-1 to the plasma membrane.
With this report, attention switched to focus on the c a rb o x y -  
terminal domain of LMP-1 with regard to B cell t r a n s fo rm a t io n  
activity (Kaye et al., 1995). Mutants with the whole of the C- 
term inus deleted could never be expressed without WT LM P-1 
being present indicating that the C-terminus of LMP-1 is e s se n t ia l  
for B lym p hocy te , transformation. Using a panel of d e le t io n  
mutants it was shown that the first 4 4 a a  are required for g ro w th  
transform ation and the last 1 5 5 a a  are required to provide a 
growth factor like effect. The C-terminal mutants are o r ie n ta te d  
correctly in the plasma mem brane in wild-type LMP-1 fashion ,
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but are completely unable to induce ICAM-1 upregulation (P eng -  
Pilon et al., 1995).
The conclusion from these results is therefore that the N- 
terminus plays a structural role in tethering the e sse n t ia l  
transmembrane domain to the plasma membrane. This is r e q u i r e d  
to allow the C-terminus to give the transform ing signals. The C- 
terminus will be further dissected in the following two sections to  
demonstrate the precise regions involved in cell transformation.
ID .6.2 Analysis of the C-terminus of LMP-1 for NF-kB and 
TRAF activating ability .
LMP-1 deletion mutants have been analysed to a sce r ta in  
which domain(s) is required for activating NF-kB. The a n a ly se s  
revealed that the amino terminus held no intrinsic NF-kB 
stimulatory ability (Mitchell et a l ., 1995). The membrane sp a n n in g  
domain and the carboxy terminal domain were however e sse n tia l  
and more precisely, the last 5 5 a a  of the carboxy terminus w e re  
required for maximal stimulation. This implicates the C -te rm ina l  
5 5 a a  of LMP-1 as being the NF-kB inducing region.
Further analysis using similar LMP-1 deletion m u ta n ts  
confirmed the previous report and also noted that deletion of th e  
first 3 8 a a  and the last 3 5 a a  of the C-terminal half s e v e re ly  
inhibited NF-kB induction (Huen et al., 1995). These regions w e re  
called CTAR-1 (residues 194-232) and CTAR-2(residues 3 5 1 - 3 8 6 )  
meaning 'C-terminal activating regions'. Both domains a re  
required for maximal NF-kB stimulation but the CTAR-2 w a s  
shown to be the major effector.
Mutational analysis indicated that the first 4 4 a a  of the C- 
terminus of LMP-1 was sufficient to interact with TRAF3. T he 
TRAF3 binding site was then pinpointed to the 1 2 a a ‘s 2 0 1 -2 1 2 .  
This region contains a core sequence of PxQxT (Devergne et al.,
1996). Systematic mutation of these 1 2 a a  revealed th e  
importance of certain amino acids, but more im portantly sh o w ed  
that all three TRAFs bind to this same core site.
This same proximal region of the LMP-1 carboxy te rm in u s  
cytoplasmic tail is also known to activate NF-kB activity, albeit a t  
much lower levels than the distal 4 5 a a  of the cytoplasmic tail. 
Mutation of P-204 and Q-206 of the core binding seq u en ce , 
m arkedly reduced NF-kB activity. This strongly suggests t h a t  
TRAF binding is linked to NF-kB activation in part, and also  
favours a role for TRAFs 1 and 2, since TRAF3 binding is on ly
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slightly affected by mutations to P-204 or Q-206, but TRAF1 and 2 
binding is greatly affected. Indeed TRAF3 repressed LM P-1 
m ediated NF-kB activity from this region, presum ably b y  
displacing TRAF1 and TRAF2 from the site.
This hypothesis was substantiated by experim ents show ing  
that co-transfection of TRAF1 and L M P - l ( a a l - 2 3 1 )  into EBV 
negative B cells, resulted in a several-fold increase of NF-kB 
activity, but TRAF2 had no such effect, however TRAF2 is 
constitutively expressed. When a dominant negative m utant o f 
TRAF2 is co-transfected with LM P-1 ( a a l -2 3 1 ) ,  75% of the NF-kB 
activity is lost (Kaye et cil.t 1996). This implicates TRAF2 also w ith  
an NF-kB activating role. Mutational analysis of TRAF1 and TRAF2 
showed that the TRAF-N domain was essential for this increase in 
NF-kB activity (Devergne et al ., 1996; Kaye et a l ., 1996). T h ese  
findings suggest that either both TRAF1 and TRAF2 activate NF-kB 
independently , or more likely that a heterodim er of TRAF1 a n d  
TRAF2 activates NF-kB with TRAF1 associating directly with LMP- 
1 .
An LMP-1 mutant lacking the proximal 6 4 a a  of the ca rb o x y  
term inal cytoplasmic tail could not induce EGFR expression w h ils t  
a m utant lacking the distal 3 4 a a  of LMP-1 could (Miller et al.,
1997). This reveals two things. Firstly, that EGFR is unlikely to b e  
induced by NF-kB activation because the mutant with the d is ta l  
portion of LMP-1 intact could not induce EGFR and this reg ion  
contains the majority of the LMP-1 NF-kB activating ability . 
Secondly, EGFR induction probably involves signalling via TRAF 
molecules since the TRAF interaction domain on LMP-1 must b e  
intact for EGFR expression. The m utant with the TRAF in te ra c t io n  
domain intact, but the distal portion of LMP-1 missing could still 
induce A20 in the absence of EGFR, indicating that although NF-kB 
activity is available, it does not account for EGFR expression. This 
also suggests that TRAF signalling from LMP-1 extends to  
activators of transcription other than NF-kB, giving two d is t in c t  
signalling pathways.
The last sections have indicated the importance of the C- 
term inus in signalling by LMP-1. A TRAF interaction domain h a s  
been identified which binds all three TRAFs. This domain o v e r la p s  
one of the two NF-kB activating sites and results imply that TRAF 
interaction and activation of NF-kB are intimately linked.
In conclusion LMP-1 is a viral oncogene capable o f 
transform ing different cell types and capable of inducing a w id e  
range of cellular gene expression changes. LMP-1 enhances cell
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survival, activates NF-kB, and interacts with the TRAF family of 
signalling proteins. That LMP-1 is involved in so many events a n d  
is expressed in 60% of NPC cases can be no co-incidence. T he  
potential role of LMP-1 in NPC will now be discussed.
IE. LMP-1 and NPC.
I E .  1 Alterat ions  in NPC LMP-1 v a r i a n t .
Since LMP-1 is a likely candidate for involvem ent in th e  
pathogenesis of NPC, research has focused on this protein and th e  
role it might have in the nasopharngeal epithelium  t h a t  
predisposes it to tumorigenesis. The LMP-1 gene from a genom ic 
library of a nude mouse propagated NPC biopsy was se q u e n c e d  
and found to differ from the prototype B95-8 LMP-1 sequence in 
certain im portant regions (Hu et al ., 1991). This NPC LMP-1 h a d  
lost many restriction sites including an informative Xho  1 site in 
exon 1 of the gene. This site was also absent in 36 out of 3 7 
Chinese NPC biopsies tested, but was intact in 17 out of 19 A frican  
NPC biopsies strengthening the idea that Chinese NPC is a ssoc ia ted  
with a particular strain of EBV.
Substitutions at the N-terminus alter the overall charge of 
LMP-1. At the carboxy terminus the NPC LMP-1 isolate d isp la y e d  
a cluster of 7 perfect repeats of l l a a  compared to the 4 im p e r fe c t  
repeats found in B95-8 LMP-1. Also at the C terminus, a 3 0 bp 
deletion was present downstream from the 7 repeats. Many o th e r  
single point mutations have resulted in the gain or loss o r  
restriction sites. Overall the changes produce a 4 0 4 a a  p ro te in  
compared to the 3 8 6 a a  B95-8 LMP-1 prototype version.
The LMP-1 gene from a Taiwanese NPC genomic library h a s  
also been sequenced and again showed differences compared to  
B95-8 LMP-1 (Chen, M.L., et al ., 1992). In the carboxy te rm in u s  
there were 5 perfect l l a a  repeats and a 33bp deletion in th e  
same region as the 30bp deletion described above. There was also  
an 18bp insertion. This Taiwanese NPC LMP-1 is therefore d is t in c t  
from B95-8 LMP-1 but closely resembles the Chinese NPC LM P-1 
gene.
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1 E .2  NPC LMP-1 is more oncogenic  and less
im m u n o g en ic  than the B95-8 p r o t o t y p e .
To test the theory that the LMP-1 variant in NPC m ig h t  
confer greater oncogenicity to the virus in respect to NPC, the NPC 
LMP-1 gene was transfected into Balb/c 3T3 cells or Rhek-1 cells 
(Chen, M.L., et a l ., 1992; Zheng et a l ,  1994b) and revealed g r e a te r  
oncogenic potential in v itro  than the prototype B95-8 LM P-1 
gene. Furtherm ore, the LMP-1 expressing cells were m o re  
tumourigenic in nude mice.
However, these results do not determ ine whether it is 
sequence differences within the NPC LMP-1 gene itself, o r  
sequence differences in the promoter region of the NPC LM P-1 
gene. This question was addressed by characterising the 5 '-  
upstream  region of NPC LMP-1 (Chen, M.L., et al., 1995). It w a s
r
shown that the NPC LMP-1 promoter is actually between 3x a n d  
9x less active than the B95-8 promoter (Chen, M.L., et a l ., 1995; Li 
et a l ., 1996). Furthermore, prom oter-gene hybrid c o n s tru c ts  
revealed that the increased oncogenicity resided within the NPC 
LMP-1 coding region. Interestingly, the NPC LMP-1 also appears to 
be less immunogenic than B95-8 LMP-1 (Trivedi et al., 1994).
1 E .3  1 Oaa deletion is respons ib le  for the enhanced
o n c o g e n i c i t y .
The C terminus of NPC LMP-1 was shown to be sufficient to  
transform  cells in hybrid constructs suggesting that it is th e  
carboxy terminus of NPC LMP-1 that is im portant (Li et al., 1996). 
Any change in the jnumber of l l a a  repeats in NPC LMP-1 had no  
effect on transform ing ability. However, replacing the 30  bp  
deleted in NPC LMP-1 with the matching 30bp sequence f ro m  
B95-8 LMP-1 negates the enhanced transform ing ability, a n d  
creating a 30bp deletion in B95-8 LMP-1 confers the sa m e  
transform ing potential as NPC LMP-1. This strongly suggests, t h a t  
the absence of those 1 0 a a  gives NPC LMP-1 it's greater oncogenic 
po ten t ia l .
I E . 4 Sequence variation within the LMP-1
gene: Pertinence to disease.
It was reported that the 30bp deletion in the C-terminus of 
LMP-1 was prevalent in diseases other than NPC such as Hodgkin's 
Disease (Knecht et\al., 1993). This led to a more extensive sea rch
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for LMP-1 mutations in a variety of lym phopro lifera tive  d iso rd e rs  
(Knecht et al ., 1995). A high frequency of non-random  p o in t  
mutations at preferential sites within the 3' carboxy te rm in a l  
region of LMP-1 was shown.
Further analysis of mutations within the C-terminus of LMP- 
1 revealed that the 30bp deletion was present at high incidence in 
aggressive Hodgkin's Lymphoma and malignant lymphomas b u t  
not in sporadic EBV associated lymphoid hyperplasia 's suggesting  
that the deleted form may be preferentially  selected in 
lym phom atous processes (Kingma et al., 1996). A new 6 9 bp 
deletion, in conjunction with the 4 common point mutations, w as  
also reported (Klein et a l ., 1995).
That these mutations in the C-terminus of LMP-1 are n o t  
uncommon was shown by a study of LMP-1 in healthy in d iv id u a ls  
and neoplastic conditions in the Japanese population (Itakura e t
a l ., 1996) where 74% of cases carried the 30bp deletion. WT v iru s  
infected LCL's (Sandvej et a l ., 1996) and all the LCL's from h e a l th y  
individuals (Itakura et a l ., 1996) contained the 30bp deletion also. 
Only one case had identical sequence to the B95-8 prototype LMP-
1. Therefore, the 30bp deletion m utant may represent the m o s t  
prevalent LMP-1 variant in Japan. Thus, the 30bp deletion m u ta n t  
does not define a tumour specific EBV strain, but may h o w e v e r  
still be important for the tumorigenicity of LMP-1.
1 E .5  Potential  role of LMP-1 in NPC.
Im m unohistochem ical analysis showed that both th e  
Epidermal Growth Factor Receptor (EGFR) and the cell cycle 
associated molecule Ki67 are both present in NPC biopsies (Zheng 
et a l ., 1994b). EGFR was present in 100% of cases but was m o re  
strongly expressed in advanced tumour stages. Ki67 e x p re ss io n  
was likewise enhanced in these m etastasised tu m o u rs .
Interestingly  the highest expression was seen in the LMP-1 
positive cases implying a direct link between LMP-1 e x p re ss io n  
and increased Ki67 and EGFR expression. Since p ro l i fe ra t iv e
activity and EGFR expression have been linked to the size a n d  
stage of various neoplasm's (Brown and Gatter, 1990; Santini et al.,
1991), it could be concluded that LMP-1 expression may e n h a n c e  
proliferation and EGFR expression thus leading to a m o re  
m alignant course.
This suggestion was substantiated when a clinical study of
the features of LMP-1 expressing and non-expressing NPCs f ro m  
Southern China was carried out (Hu et a l ., 1995). The LMP-1
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positive tumours grew faster and more expansively than the LMP- 
1 negative tumours. The LMP-1 positive tumours also tended to  
invade more frequently outside the nasopharynx, especially in to  
the lymph nodes. However there were more LMP-1 n e g a t iv e  
samples in the highly advanced NPCs. This report th e re fo re  
suggests that LMP-1 increases proliferation resulting in a m o re  
m alignant tumour, but indicates that LMP-1 is e i t h e r  
downregulated in some way or not involved at all when NPCs a re  
at their most advanced.
Thus a great deal of information now exists concerning th e  
action of LMP-1 in B cells. Also, in recent years several s tu d ie s  
have begun to reveal the signal transduction pathways that a r e  
used by the protein to achieve it’s effects. Never the less, the ro le  
of LMP-1 in NPC is still poorly understood. This project was b e g u n  
in order to attempt to address this question using an in v iv o  
model system- transgenic mice, in order to overcome th e  
continuing difficulties of studying disease in humans and a t is su e  
which is difficult to obtain.
IF. LMP-1 expression in transgenic mice.
Most of the experiments described so far have been c a r r ie d  
out in v itro  and in B cells and have highlighted many of th e  
problem s associated with extrapolating the results to NPC. For 
example, the dramatic variety of effects mediated by LMP-1 h a v e  
not been shown in any one cell type but rather are a collection o f  
results from a panel of cell types, each cell line tested g iv ing  
d ifferent results. The results are most definitely cell line and cell 
lineage specific and are often confusing and contradictory. Because  
of this, analysis of the effects of LMP-1 expression in v iv o  in an  
appropria te  cell type is vital. The technology involved in c re a t in g  
transgenic mice has facilitated such in v ivo  studies and p ro v id e d  
a method of studying genes of interest at work in a living an im al. 
For this reason transgenic mice were created to follow th e  
consequences of the expression of LMP-1 in epithelial cells, as well 
as B lymphocytes in vivo (Wilson et a l ,  1990).
Expression of the PyLMP transgene in stratified e p i th e l iu m  
has the major advantage of allowing functional characterisation o f  
the product through a complete sequence of differential s ta te s .  
Each differential layer of the epithelium  expresses different p a i r s  
of keratins, and these sets of keratins vary between e p i th e l ia  
(Reviewed in Byrne et a l ., 1994). The keratins are th e re fo re
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excellent markers of the differentiation/growth state of e p ith e l ia l  
cells. As such, alterations in keratin expression can also indicate a 
disruption of differentiation or the induction of h y p e rp la s t ic  
e v e n ts .
Two separate transcriptional control elements, PyLMP a n d  
EpLMP, were used to express LMP-1 with the aim of d irec tin g  
expression to epithelial cells or B cells respectively. PyLM P 
consists of the B95-8 strain LMP-1 coding sequence preceded b y  
the early region promoter and enhancer of the murine p o ly o m a  
virus (Py), and EpLMP consists of the B95-8 strain LMP-1 coding 
sequence preceded by the polyoma virus promoter and the m o u se  
immunoglobulin heavy chain (IgH) intronic enhancer (Eji).
1 F. 1 PvLMP-1 transgenic  m i c e .
The PyLM P-1 mice were created using the p o ly o m a  
prom oter and enhancer regions to drive expression of the LM P-1 
transgene to the epithelial com partm ent (Wilson et a l ., 1990). 
Lines of mice were generated in the C57B1/6 strain of mice (one  
which is genetically well characterised). Two lines of mice f ro m  
founders 5 and 53 displayed a common phenotype of e p id e rm a l  
hyperplasia and showed expression of the transgene in e p id e rm is  
and at low level in tongue epithelium.
The PyLM P-1 transgenic mice from lines 5 and 53 w e re  
runted and had in common a distinct phenotype of d e rm a to s is  
giving an overall appearance of wrinkled, scurfy skin soon a f t e r  
birth. This phenotype was always evident by d3 and was at i t ’s 
most obvious by d7. Line 5 showed greater levels of LM P-1 
expression than did line 53. Accordingly the skin phenotype in  
line 5 was more extensive. The epidermal hyperplasia  in line 5 
mice continued through to adulthood and in patches became v e r y  
highly hyperplastic. In addition, the mice remained small (1/2 th e  
body weight compared to negative mice) and produced small a n d  
infrequent litters (Wilson et al., 1990). However, this line su f fe re d  
an additional complication. The transgene integrated into the X- 
chrom osome mutating a cellular locus leading to sex linked c le f t  
palate (Wilson et al ., 1993). Finally, due to poor viability the line  
became extinct. Thereafter the focus of work in this thesis rests on 
experiments using mice of line 53.
Mice in line 53, after d l2  quickly gained the weight and size 
of their LMP-1 negative littermates, and by weaning age the m ice  
could not be distinguished by eye. The epidermal h y p e rp la s ia ,  
marked in adults of line 5, is much less evident in adult mice of
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line 53. However, as the animals aged a return to the obv ious  
hyperplastic phenotype occurs in hairless regions, appearing as a 
“ring-tail” phenotype often also evident on paws and genitalia . 
LMP-1 positive mice of both lines also showed increased c law  
g ro w th .
Keratin K6 is normally expressed in the hair follicles of th e  
skin and in the proliferating epidermis of wounds, but has b e e n  
seen to be expressed in the suprabasal epidermal layers in 
hyperplastic, neoplastic and psoriatic skin. It was therefore v e r y  
interesting to observe the induction and aberrant expression of K6 
in the suprabasal epidermal layers in the PyLMP-1 t ran sg en ic  
mice as well as extension of the expression of K14 (normally a 
marker of basal cell proliferation) to the suprabasal layers also.
Expression of LMP-1 RNA was restricted to the e p id e rm is  
and levels of expression correlated with appearance of th e  
phenotype where the only two lines to have readily d e te c ta b le  
LMP-1 mRNA were the only two lines to develop h y p e rp la s ia .  
Despite the persistence of hyperplasia throughout the an im als  
lifetime (notably in line 5), no evidence of skin papillomas o r  
carcinomas was ever observed. This may reflect expression be low  
a critical level or perhaps a requirement for other factors (viral o r  
cellular) for progression to neoplasia.
1 F . 2 EuLM P-1 T ra n s g e n ic  m ic e .
The EpLMP-1 transgene includes the polyoma v i ru s  
prom oter and the mouse imm unoglobulin heavy chain (IgH) 
enhancer in order to direct expression of the LMP-1 oncogene to  
the lymphoid com partm ent (Wilson et al.y 1990). Of 15 p u p s  
carrying the transgene, eight viable EpLMP-1 mouse lines w e re  
generated from these mice. One EpLMP-1 founder displayed th e  
phenotype of epidermal hyperplasia already described for th e  
PyLMP-1 transgene series, however this founder did not breed to  
generate a line. Transgenically positive offspring from a n o th e r  
line (Line 33) also dem onstra ted  this phenotype, but only 4 / 5  2 
LMP positive offspring were produced (demonstrating the fo u n d e r  
was transgene mosaic) and these had low viability, were all d e a d  
within 24 weeks and were not able to breed and maintain the line. 
Another 3 founder mice were dead within 2 weeks. Together, th e  
poor viability of mice in this series suggests a probable toxicity o f 
the E pL M P -1 transgene (Wilson et al., 1990).
The three mRNA species which could be expressed from th e  
PyLMP-1 and EpLM P-1 transgenes include the 2.5kb LM P-
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encoding message; a 2.25kb message driven from an in te rn a l  
prom oter at late times during the EBV lytic cycle; and a 0 .6 k b  
message driven from a second internal prom oter at early t im e s
during the EBV lytic cycle. It was shown that the 2.5kb LM P-
encoding message was abundantly expressed in a broad range o f
tissues, including skin, in the Ep.LMP-1 mouse line 33. Thus, th e  
expression of the 2.5kb LMP-encoding transcript in the sk in  
suggests that it may be the cause of the hyperplastic p h e n o ty p e ,  
but the broad range expression of this transcript may be r e le v a n t  
to the early lethality seen in the EpLMP-1 mice (Wilson et al.,
1990).
4 lines of mice in this series displayed initially a very m ild  
phenotype, one of which EpLMP-1 line 39 is described in m o re  
detail and is the subject of study in chapter 5.
1G. Prologue and Aims.
The transgenic mice used in experiments presented in th is  
thesis were of the PyLMP-1 line 53 and the EpLMP-1 line 39. 
Despite persistence of the phenotype throughout the life in som e 
areas of skin (as described) in line 53, no progression to p a p il lo m a  
or carcinoma was noted. As the developm ent of cancer is a m u l t i ­
stage process other factors are likely to be required for th e  
progression from hyperplasia to cancer. The aim of this work h as  
been to address what these factors might be and how LM P-1 
might be exerting it’s oncogenic potential using this t ran sg en ic  
m ouse epidermal model.
Given the potential role of LMP-1 in NPC, expression of th e  
PyLMP-1 transgene in the epidermis of line 53 transgenic m ice  
can be used as a model for the early stages of the d ise a se  
(expression of the other viral genes involved in NPC may fo rm
subsequent stages in the developm ent of the model). A lth oug h
expression is not specifically directed to the nasopharynx, th e
epidermis is the most accessible and best studied epiderm al t is su e  
in the mouse providing the most appropriate in v iv o  m o d e l  
system  in the first stages of study. The difficulties involved w ith  
investigating the effects of LMP-1 in epithelial cells in vitro can  
consequently be overcome with this transgenic mouse model. T he  
experim ents described here are therefore useful in d e te rm in in g  
the basic function of LMP-1 in epithelial cells in v iv o  w h i ls t
perhaps giving some insight as to what may be occurring in th e  
EBV positive nasopharynx that can lead to NPC.
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The investigative strategy is threefold.
Firstly an investigation into the expression pattern of PyLMP-1 in  
the transgenic epidermis and the effects of expression of th e  
PyLMP-1 transgene has been conducted (Chapter 2). This 
procedure was designed to ascertain the cause of the o b s e rv e d  
phenotype in line 53 with respect to the mode of action of LM P-1 
in otherwise normal epidermis. Accordingly, the c a re fu l ly  
controlled processes of epidermal proliferation and d if fe re n t ia t io n
in line 53 mice are examined in order to discover if LMP-1 h a s
any effect on either process.
Secondly, transgenic PyLMP-1 line 53 mice have been subjected to
the chemical multistage skin carcinogenesis model (Chapter 3). 
This model allows an examination of the consequences of LM P-1 
expression during the evolution of malignancy. Such in v e s t ig a t iv e  
procedure is invaluable in determining at what stage(s) during th e  
carcinogenic process LMP-1 exerts its effects, and what th e s e  
effects might result in. Therefore, L M P -l’s ability to act as e i t h e r  
initiator, promoter or enhancer of tumour formation is examined.
Thirdly, an examination of the co-operation of LMP-1 in  
tum ourigenesis with other proteins of interest via c ro s s -b re e d in g  
experiments has been conducted (Chapter 4). Such c ro s s -b re e d in g  
experim ents may reveal co-operation, counteraction, or e v e n  
redundancy of two proteins, with a subsequent e n h a n c e m e n t ,  
ablation, or failure to alter an observed phenotype. C o nsequen tly , 
PyLMP-1 line 53 was crossbred with transgenic lines ex p re ss  ing 
H a -ras  and TGFpl epidermally, and with mice lacking p 5  3 
function, in order to check for alterations to the day 7 line PyLMP- 
1 phenotype, and thereafter progression from this to malignancy.
LMP-1 may play a role in the developm ent of Hodgkin’s d ise a se  
and B-cell lymphomas arising in im m unocom prom ised  and AIDS 
patients. The EpLMP-1 line 39 transgenic mice, where e x p re ss io n  
is directed to the B-cell com partm ent, had no im m e d ia te ly  
apparent phenotype and no obvious phenotype by one year o th e r  
than being less fit and fertile than negative siblings. H ow ever, 
expression of LMP-1 was so low as to be barely detectable and th e  
mice had not been monitored beyond one year of age. The aim o f  
the final part of this project, chapter 5, was therefore to m o n i to r  
line 39 for a full 24 month period in order to address t h e  
possibility of late developm ent of any abnormalities. I n
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conjunction with this study, cross-breeding line 39 mice w ith  
EpEBNA-1 (line 59) mice was carried out to reveal any p o te n t ia l  
co-operation between LMP-1 and EBNA-1 in lymphomagenesis.
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CHAPTER 2:- Investigation into the
PvLMP-1 phenotype.
2 A I n t r o d u c t i o n
In this chapter the phenotype of the PyLMP-1 mice is 
further investigated. To set this into context the in tro d u c to ry  
section covers the biology of the skin, the changes in g en e  
expression which occur during carcinogenesis and other transgenic 
models of skin carcinogenesis.
2 A . 1 B iology of the  s k i n
The skin is the largest organ of the body and p ro v id e s  
essential protection against ultraviolet radiation and o th e r  
chemical and biological injury. The skin is composed of two m a jo r  
parts, namely the dermis and epidermis (Reviewed in Zinkel a n d  
Fuchs, 1994; Brown and Balmain, 1995). Fibroblasts, the m a in  
component of the dermis, secrete a dense network of collagen 
fibres which provide support for the epidermis and a p ro te c t iv e  
cushion for the inner organs of the body. The dermis is h ig h ly  
vascularised, consisting of an extensive network of blood v esse ls  
necessary to supply both the dermis and the n o n -v a s c u la r iz e d  
epidermis. The epidermis is separated from the dermis by a 
basem ent m em brane and consists of stratified sq u a m o u s  
epithelium, the primary cell type being the k e ra t in o c y te .  
Keratinocytes produce keratins, the cytoskeletal protein w h ich  
forms networks within the epidermis giving it strength a n d  
flexibility. The epidermis is continually undergoing a process o f 
terminal differentiation, where proliferating basal layer cells 
detach from the basem ent m em brane to become te rm in a l ly  
d ifferentiated and, moving through the epidermis eventually a re  
shed and replaced. This process is highly organised a n d  
characterised by sequential changes in gene expression.
The actively jproliferating keratinocytes of the basal l a y e r  
co-express the cytokeratins (K) 5 and 14. An unknown signal 
initiates detachm ent of a proliferating keratinocyte from its  
contact with the basement membrane and exit from the cell cycle, 
whereby the keratinocyte now migrates upward into th e  
suprabasal layer. The keratinocyte now changes m orphology a n d  
flattens out with subsequent increased desm osom al con tac ts  
between neighbouring cells. This gives the appearance of sp inou s  
cells and the suprabasal layer can be divided into three c a teg o ries  
based on the shape and characteristics of the k e ra t in o c y te s
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present. In the suprabasal layer K5 and K14 are d o w n re g u la te d
and another pair of keratins, K1 and K10 become expressed. This
switch is associated with an increase in bundling of k e ra t in  
filaments in the cytoplasm.
The keratinocytes leave the spinous layer and enter th e  
granular layer, where they synthesise a protein called filaggrin . 
Filaggrin associates with K1/K10 filament bundles, causing th e m  
to form large complex bundles of fibres and thus giving m o re  
strength to the epidermis. K1 and K10 are now downregulated and 
three other proteins, namely involucrin, loricrin and k e ra t in o c y te  
transg lu tam inase  are upregulated. Involucrin is a substrate fo r  
transg lu tam inase  enzyme m ediated crosslinking and th is  
croslinking adds strength to the cornified cell envelope. Loricrin is 
the last protein to be expressed, and just like involucrin, is 
crosslinked by transglu tam inase  action. Concomitant with th is  
crosslinking is the massive destruction of cell integrity. T he  
perm eable  cornified cell envelope of highly crosslinked p ro te in s  
replaces the nuclear m em brane in cells. The nuclei a n d  
cytoplasmic organelles are lost. The mature squames which r e a c h  
the skin surface leave as empty shells full of keratin f i la m e n t  
bundles. The whole differentiation process takes between 2 to 4 
weeks to complete.
There are other proteins of the epidermis which are e q u a l ly  
essential for the overall function of the organ, but are n o t  
expressed in a differentiation stage specific manner. These inc lude  
the family of adhesion molecules called integrins (Reviewed in  
Varner and Cheresh, 1996). This family mediates cell-extracellular
matrix and cell-cell interactions and are thought to regulate cell
growth and differentiation. When integrins are specifica lly  
activated through contact with their corresponding m a tr ix  
proteins, they influence regulation of gene exp ress io n , 
d ifferentiation, growth control and cytoskeletal architecture. As 
well as adhesive properties integrins are also potent signalling  
molecules (Dedhar, 1995) and so provide many functions to th e  
normal homeostasis of the skin.
Desmosomes also play an essential part in m aintenance of a 
normal situation in the epidermis (Reviewed in Garrod, 1995). 
Desmosomes consist of a variety of proteins which serve a m o n g s t  
other things as adhesion molecules to keep cells tightly bound a n d  
organised. Two desmosome constituents are desmocollin a n d  
desmoglein. Desmosomes are essential for cell architecture as th e y  
provide the anchoring point for the keratin in term ediate  f i la m e n t  
network of the keratinocytes. Desmosomal adhesion is hom ophilic  
and by m aintaining the architecture of the epidermis, a llow s 
keratinocytes to communicate with each other and to re c e iv e  
signals. Thus th.e normal situation of proliferation a n d
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differentiation which continues throughout a lifetime is e x tre m e ly  
complex and relies on the co-operation and correct expression of 
certain proteins. An imbalance in this system could con ce iv ab ly  
lead to a breakdown in the process and possibly contribute to  
m alignan t transform ation .
2 A . 2 Cancer of the s k i n
The changes in gene expression during d if fe re n t ia t io n  
provide useful markers of the different stages of d i f fe re n t ia t io n  
and identification of an in tac t/unaltered  differentiation process . 
Alterations in this process could be identified as aberrant, a b s e n t  
or over-expression of these differentiation markers and w ou ld  
reflect a deregulated pathway of differentiation and p r e -  
neoplastic events. For this reason analysis of these proteins in  
transgenic mice and human skin cancers has proved invaluable in  
investigating a role for them in aberrant differentiation (Reviewed 
in Christofori and Hanahan, 1994; Zinkel and Fuchs, 1994; a n d  
Brown and Balmain, 1995 ) .
2A.2.1 Alterations in k e ra t in s
Keratins, the structural backbone of the keratinocyte, h a v e  
been shown to be aberrantly expressed in certain cases. In  
situations of faster ; cell turnover suprabasal expression of K6 a n d  
K16 has been shown in humans. These keratins are normally o n ly  
expressed in hair follicles and sites of wound repair reflecting cell 
proliferation. As previously described, K6 is also found e x p re s s e d  
in the suprabasal layers of the epidermis of PyLMP m ice  
exhibiting hyperplasia (Wilson et a l ,  1990).
K8 and K18 are characteristic of simple epithelia and e a r ly  
stages of embryogenesis. They are found in sweat glands but n o t  
expressed elsewhere in normal adult epidermis (Bosch et al., 
1988) however they are re-expressed in some human sk in  
cancers (Laurijsen et al., 1989). Transfection of a m utant h u m a n  
H -ras  oncogene into the immortalised mouse epidermal cell l ine  
MCA3D induces the anomalous expression of K8 and K18 (Diaz- 
Guerra et a l ., 1992) and it was shown that K18 was a direct t a rg e t  
of the ras signal transduction pathway (Pankov et al., 1994). Thus, 
oncogene activation provides an explanation for the u n e x p e c te d  
expression of K18 in these skin carcinomas.
K13 is normally associated with terminal differentiation o f  
internal stratified epithelia, but was shown to be c o n s is ten t ly  
expressed in squamous cell carcinomas of the skin induced in  
mouse epidermis by chemical manipulation (Nischt et al ., 1988). 
The stage before carcinoma, i.e. papilloma, was heterogeneous fo r
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K13 indicating that its aberrant expression may correlate w i th  
conversion to malignancy.
2A .2 .2  Alterations in adhesion m olecu les
The importance of integrins and desmosomes in cancer is 
that, as mediators of cell adhesion, variation in their abundance o r  
tem porary or perm anent modulation of their binding affin ity , 
could result in changes of cell behaviour facilitating invasion a n d  
metastasis. As an example, normal epithelial cells express a l ,  a2 , 
a 3 ,  a 6 ,  (31 and (34 integrin subunits whereas breast carcinoma cells 
show variable losses, disorganised expression or d o w n re g u la t io n  
of these subunits (Varner and Cheresh, 1996).
Both basal and squamous cell carcinomas display a d e c re a se  
in cell surface area occupied by desmosomes indicating that t h e i r  
deregulation may be an important factor in neoplasia (Garrod, 
1995).
This brief look at some of the proteins of the epidermis h a s  
shown that they are often aberrantly  expressed in human c a n c e r  
and highlights the importance of a balance between p ro l ife ra t io n  
and differentiation [ to maintain healthy skin. That more than 80% 
of tumours occurring in man are carcinomas and the incidence of 
skin cancer is steadily rising further strengthens the idea that th e  
homeostasis of the epidermis is vitally im portant (R eichm ann, 
1994). Use of transgenic mouse models has dramatically p ro m o te d  
the study of candidate oncogenes in the epidermis providing a 
method of evaluating the roles they might play in ca rc ino genes is  
in vivo.
2A.3 Transgenic  mouse models of c a r c i n o g e n e s i s
The use of transgenic mouse models has shown that, w h i ls t  
certain proteins or oncogenes are necessary for the transformation 
process, they are not sufficient alone to cause carcinogenesis a n d  
require additional events before tumours arise. For example, th e  
H -ras  oncogene (a potent oncogene in tissue culture assays) h a s  
been successfully 'over expressed in transgenic mouse skin b y  
three groups and shown to cause marked hyperkeratosis (Bailleul 
et al ., 1990; Leder et al., 1990; and G reenhalgh  et al ., 1993a). T he  
mice subsequently  developed papillomas particularly at sites o f  
wounding or abrasion such as the tail and ears suggesting t h a t  
activation of ras  is a necessary initiating step in ca rc in o g en es is  
and that wounding acts as a promotion step.
Several other transgenic mice have been produced w h ich  
exhibit an initiated phenotype similar to that seen for the H a -ras  
transgenics. For example TGF-a overexpression in t ra n sg e n ic
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mouse skin resulted in hyperkeratosis and hyperplasia w ith  
spontaneous papillomas occurring at sites of wounding o r  
mechanical irritation (Wang et al., 1994).
Individual integrin subunits oc2, a5 , and p i  were e x p re s s e d  
in the epidermis of transgenic mice (Carroll et al., 1995). p i  
expression alone gave rise to epidermal hyperproliferation. By 
intercrossing the three lines of mice, bi-transgenics e x p re ss in g  
a 2 p i  or a 5 p l  were created and these also exhibited e p id e rm a l  
hyperplasia. These findings also suggest that imbalance in in te g r in  
expression could be causal in skin carcinogenesis.
Various components of desmosomes have b e e n  
overexpressed in transgenic mice or removed in knockout mice to  
investigate this possibility. For example, plakoglobin k n o c k o u t  
mice presented with hyperkeratosis (Bierkamp et al., 1996). 
Desmogleins are members of the cadherin superfamily and fo rm  
the core of desmosomes. When mutant desmoglein w a s  
overexpressed in mouse epidermis the number of d e sm o so m e s  
was greatly reduced and the mice developed abnormalities in  
epidermal proliferation and differentiation (Allen et al., 1996). 
Desmoglein associates with plakoglobin so these two studies a lone  
dem onstra te  how imbalance in desmosomal protein levels can  
have severe consequences.
Overexpression of involucrin in transgenic mice produces an  
abnormal phenotype in both the epidermis and hair follicles (Crish 
et al., 1993), presum ably because it is an early scaffold p ro te in
essential for correct cornified envelope formation. Loricrin h a s  
also been overexpressed in transgenic mice but in this case all o f  
the protein was incorporated into the cornified envelope and no
phenotype was observed (Yoneda and Steinert, 1993). As the fina l 
protein expressed in differentiation it therefore does not a p p e a r  
to affect the flexible structure or function of the epithelial tissues.
Other transgenic mice which display a marked h y p e rp la s t ic  
skin phenotype include v-fos (Greenhalgh et al., 1993b), f ib ro b la s t  
growth factor receptor, FGFR1 (W erner et al., 1993), k e ra t in o c y te  
growth factor, KGF (Guo et al., 1993) and LMP-1 (Wilson et al., 
1990). Thus, the over-expression of several known oncogenes a n d  
normal epidermal proteins results in a very similar phenotype in 
each case, and supports the idea that these oncogenes and g ro w th  
factors do not act alone in the process of carcinogenesis, but rather 
are part of a multi-step pathway.
2 A . 4 P v L M P -l  transgenic  lines 5 & 5 3
As described in section IF, two lines of PyLMP-1 t ra n sg e n ic  
mice (lines 5 and 53) were shown to have in common the d is t in c t  
phenotype of epidermal hyperplasia (Wilson et al., 1990). T he
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viable line, line 53, has been used for study here, in which th e  
phenotype is apparent soon after birth, most evident at d7, a n d  
then indistinguishable from negative littermates by three w e e k s  
of age, although often re-appearing in furless areas later in 
adulthood (noted on the tail as the "ring tail" phenotype).
In wild-type mice the cytokeratin K6 is expressed only in  
the continually proliferating hair follicles or in areas o f 
proliferation brought on by wound repair. As such it is a u se fu l  
m arker for proliferating epidermis. The discovery of K6 
expression in the epidermis of offspring from line 5 as early as a t  
the day 1 old pup stage indicated disruption of normal e p id e rm a l  
homeostasis. Line 5 showed a 10 fold higher steady state level o f 
K6 transcript than negative controls and line 53 a 2.5 fo ld  
in c rease .
The aberrant expression of this hyperpro lifera tive  k e ra t in  
K6 and the hyperplastic thickening of the epidermis is s t ro n g ly  
suggestive of aberrant cellular proliferation. The aim of th is  
particular investigation was therefore to determine if in c re a s e d  
proliferation was indeed responsible for the PyLMP-1 p h e n o ty p e ,  
since the phenotype may be a result of one of three events:-
1) Increased cell proliferation
2) Block in apoptosis
3) Disruption/alteration in the differentiation pathway
All of the above could conceivably give rise to an increase in 
overall cell number and therefore be responsible for the PyL M P-1 
phenotype of hyperplasia.
2 B RESULTS
2 B .  1 B r o m o d e o x v u r id in e  (BrdU) labell ing of  line 53
e p i d e r m i s .
Nuclear incorporation of Brom odeoxyuridine (BrdU) into th e  
epiderm is of mice provides an excellent marker of levels o f 
cellular proliferation. Dividing cells in vivo incorporate BrdU 
supplied by intra-peritoneal injection. This technique was used to  
compare the proliferating capacity of line 53 transgenic e p id e rm is  
(dorsal skin) with that of negative control (sibling) mice. As th e  
line 53 transgenic phenotype is most apparent in d7 old p u p s , 
mice at this age were used in the study. Transgenic and n e g a t iv e  
control mice were injected with BrdU and tissues taken one h o u r  
later (as described in section 7B.1.7). BrdU uptake is visualised as 
a brown stained nucleus against a blue counterstain (figure 2.1). 
Cell counts were made (under x 312.5 power (see section 7B.4.5)),
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counting the number of stained cells in an intact stretch o f  
epidermis in one field of vision. 10 fields of view were counted for 
each tissue section and the mean number calculated (the r e s u l ts  
are presented in table 2.1). Where possible, counts were taken fo r  
epidermis from sections of dorsal skin and tail and the to n g u e  
epithelium. Where more than one section was stained and c o u n te d  
for the same tissue sample the counts are included in the sa m e  
table box.
Tissue sections were stained for BrdU and an a ly se d .  
Comparing stained sections of PyLMP-1 line 53 epidermis w ith  
those of control litterm ates it is clear that the transgenic m ice  
display greater numbers of positively stained cells than th e  
controls (table 2.1).
The relative numbers of cells showing BrdU uptake is 
elevated two to threefold in line 53 epidermis compared to  
negative controls. The mean number of stained cells in the 7d old 
dorsal skin epidermis group for the transgene positives is 2 5 .5 3  
(with a range of 14.3-31.8) compared to the negative con tro ls  
12.52 (range 6.6-17.1) (figure 2.2). Statistical analysis of th is  
result with the two-sample T-test gives a highly significant T 
value of 6.57 with a P value of 0.0001 and 16 degrees of freedom.
For this and every other statistical analysis used in th is  
thesis I have used a confidence limit of 95%. This means that for a 
result to be significant the P value must be less than 0.05. As th e  
T value increases and the P value decreases the result b eco m es  
more and more significant and less likely to be due to chance. T he  
degrees of freedom is calculated by subtracting one from the to ta l  
num ber of counts used to calculate T. Therefore there were 17  
counts used to calculate this particular example of a T-test. T h e  
statistical package Minitab was used to generate these and all 
other statistical analyses used in this thesis. (A more d e ta i le d  
explanation of the < uses of the Minitab program can be found in 
section 3B.2.4).
Although  relatively few adult samples were taken, the 2 
fold difference seen with pup skins remains. In general the a d u l t  
skins show much reduced proliferation (as would be e x p e c te d )  
compared to 7d old pup skin. Nevertheless, the mean fpr th e  
transgene positives is 4.24 compared to 2.1 for the n e g a t iv e  
control littermates (figure 2.2 and table 2.1). Using the tw o -  
sample T-test the difference between these two scores proved to  
be significant with a T value of 4.44 and P value of 0.0005 u s ing  
15 degrees of freedom. Therefore, this result is highly significant.
Therefore line 53 epidermis (dorsal skin) reveals 2x  
elevation in cellular proliferation compared to controls in b o th  
pup and adult dorsal skins.
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Fig 2 . 1 : -
Primary antibody was a monoclonal anti-BrdU (Sigma) Ab. 
Detection was via the Vectastain elite kit which uses an a n t i ­
mouse biotinylated IgG Ab, followed by an a v id in /b io t in y la te d  
horseradish peroxidase complex step. Final detection is with 3 ,3 ’- 
diaminobenzidine (DAB-Sigma) to reveal the brown stained nuclei. 
Counterstain is with haematoxylin.
Fig 2 . 3 : -
Primary antibody was a rabbit polyclonal anti-human Ki67 (Dako). 
Secondary antibody was goat anti-rabbit IgG-FITC con juga ted  
(Sigma).
Fig 2 . 4 : -
Primary antibody was a rabbit polyclonal anti-loricrin Ab. 
Secondary antibody was goat anti-rabbit IgG-FITC con juga ted  
(Sigma).
Fig . Z mS I z
Primary antibody was a rabbit polyclonal anti-LMP-1 peptide A b  
(gift from B.Sugden).
Secondary antibody was goat anti-rabbit IgG-FITC con juga ted  
(Sigma).
LMP-1 +ve LMP-1 -ve
Fig 2.1
BrDu
Fi^ _ 2.3
Ki 67
Fig 2.4 
Loricrin _  . ...
Fig 2.5 
LMP-1
F igures 2.1. 2.3, 2.4, and 2 .5 : -  Comparison  of LMP-1 p o s i t i v e  
dorsal  e p id e r m is  with negat ive  control  l i t te rm ates .  D e te c t io n  
details  are given in sections 7B.4.5 and 7B.4.6
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Comparison of mean BrdU scores for line 53 PvLMP-l 
positive dorsal skin versus negative controls
BrdU count
F igure 2.2
7 |im  sections of BrdU injected dorsal skin were stained with an 
anti-BrdU antibody (section 7B.4.5), and positive cells (brown) in the 
epidermis were counted per field of vision at x312.5 magnification. 
This figure shows the mean score for each transgenic group studied, at 
both day 7 and adult ages. Each mean was derived from at least 5 
different sections from at least 3 different mice. Each section was 
counted for 10 fields of vision and then averaged (mean). Each average 
was then totalled to calculate the overall mean score for each group. 
Error bars represent the standard error of the mean.
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Sections were also cut from tail and tongue and stained cell 
counts taken from epidermis and epithelium  (respectively). A gain  
the PyLMP-1 line 53 mice had higher BrdU labelling scores th a n  
their negative control littermates. The mean score for d7 LM P-1 
positive tail epidermis was 52.00 com pared to 17.50 for d 7  
controls. The mean score for d7 LMP-1 positive tongue e p i th e l iu m  
was 28.70 compared to 19.39 for d7 controls. Both of th e s e
differences proved to be significant by two sample T-test a n a ly s is  
despite the sample size being small in these cases. The T - te s t  
result for tail was T=3.82 with a P=0.019 and 4 degrees o f  
freedom. The T-test result for tongue was T=2.98 with P=0.015 
and 9 degrees of freedom.
It is notable that the tail in the d7 pups shows the la rg e s t  
increase (3x) when comparing transgene positives and n e g a t iv e  
control littermates. Indeed it is in the tail epidermis that th e
phenotype is most persistent in the adult ("ringtail"). H ow ever,
this proved to be a difficult tissue to analyse, the bones making i t
problematic to obtain good perpendicular sections to obtain a 
suitable cross-section of epidermis and as such many s ta in e d  
sections were not readable. Indeed, the counts which w e re  
obtained came from tail sections cut by trained technicians at th e  
pathology department of the Glasgow University Vet. School.
Nevertheless, all tissues analysed show a c o n s is te n t  
elevation of BrdU stained cells in the epithelium reflecting ce llu la r  
proliferation in the LMP-1 positive mice compared to controls.
It was also noted that there were some suprabasal s ta in e d  
nuclei in the PyLMP-1 line 53 transgene positive dorsal sk in  
epidermis although accurate analysis was not carried out. No 
suprabasal staining was noted in the negative control l i t t e rm a te s  
as expected.
2 B . 2  I m m u n o f lu o r e s c e n t  exam in at ion  of epiderm al
p r o l i f e r a t i o n .
The BrdU incorporation data indicate that there is in c re a se d  
proliferation in the LMP-1 positive epidermis which is p ro b a b ly  
responsible for the hyperplastic thickening of line 53 e p id e rm is .  
To investigate this hypothesis further, im m unostaining for Ki67, a 
m arker of proliferative potential (Brown and Gatter, 1990), w a s  
carried out.
7 pm  sections of d7 line 53 transgenic and d7 n e g a t iv e  
control dorsal skin were cut and im m unostained  for Ki67 
expression (as described in 7B.4.6). The proportion of s ta in e d  
(fluorescing) cells in the PyLMP-1 line 53 epidermal sections w a s  
much greater than the proportion of stained cells seen in con tro l
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sections (see figure 2.3). This is further evidence of in c re a s e d  
proliferation in line 53.
Furthermore, the pattern of staining differed between LM P- 
1 positive and negative sections. The positive cells in the d 7 
negative control section were found in the basal layer as expec ted . 
However, as well as having more positive cells in the basal lay e r ,  
the LMP-1 transgenic mice also displayed Ki67 staining in th e  
suprabasal layers. Thus LMP-1 is also causing a b e r r a n t  
proliferation in the suprabasal layers (which should be t e rm in a l ly  
d i f fe re n t ia t in g ) .
2 B . 3  Im m u n o f lu o r e s c e n t  exam inat ion  of  epidermal
d i f fe re n t ia t io n  m a r k e r s .
Several pieces of evidence indicate an increase in th e  
proliferation rate is contributing to the line 53 phenotype. I n 
order to address if the pattern of epidermal differentiation h a s  
been effected in this imm unostaining for various protein m a r k e r s  
of d ifferentiation  or normal epidermal homeostasis was c a r r ie d  
out.
Antibodies to desmoplakin and desmocollin were used to  
stain epidermal sections. These were then sent to Prof. D.Garrod a t  
the University of M anchester for expert examination. In Prof. 
Garrod's expert opinion, there was no difference in the e x p re s s io n  
or levels of expression of these two proteins of d e sm o so m a l  
complexes between line 53 positives and negative controls.
Antibodies against loricrin were used to stain sections of d 7
line 53 epidermis. As described earlier, loricrin is the last p ro te in
to be expressed in the differentiating epidermis and s ta in in g  
occurs in the upper terminally differentiated  layer. As line 5 3
epiderm is is considerably thicker than control epidermis (due to  
the increase in proliferation) it initially appears as though there is 
an observable difference in staining pattern for loricrin. H ow ever, 
Prof. Garrod explained that in both cases loricrin was expressed in  
the upper suprabasal layers and that there was no difference in  
the im m unostaining for loricrin (figure 2.4). At this level o f  
detection the staining pattern was identical in both d7 line 5 3
epidermis and negative control.
The first markers of terminal d ifferentiation expressed in  
the suprabasal layers, K1 and K10, have previously b e e n  
examined (Wilson et al., 1990). Again no differences w e re
observed between PyLMP-1 positives and negative con tro l  
l i t te rm a te s .
Therefore it would appear from the markers o f  
d ifferentiation studied that the differentiation process in th e  
epidermis of PyLMP-1 line 53 mice progresses unimpeded.
60
2 B . 4  I m m u no s ta in in g  for L M P - 1 .
Although LMP-1 has been shown to be expressed at b o th  
the RNA and protein levels in PyLMP-1 line 53 transgenic m o u se  
epidermis, the exact cellular layer in which LMP-1 is e x p re s s e d  
has not been established. The Polyoma virus prom oter a n d  
enhancer were linked to the LMP-1 gene in order d i r e c t  
expression of the transgene to the epidermis. Unlike the k e ra t in  
prom oters K l, K10 and K14 used for other transgenic s tu d ie s  
(Dominey et al., 1993; Cui et al ., 1996; and V a ssa r  et a l ., 1 9 9 2 )  
where expression is directed to a known discrete e p id e rm a l  
com partm ent, the specificity of the Polyoma virus p r o m o te r  
activity has not been analysed. In order to establish the location 
of the LMP-1 protein within the various epidermal la y e rs  
im m unofluorescent staining for LMP-1 using the CS1-4 
monoclonal Ab was attempted on d7 line 53 epidermis.
This revealed LMP-1 expression in an unexpected s ta in ing  
pattern in the upper suprabasal layers of the epidermis ( f igu re  
2.5). The staining appeared at regular intervals along th e
suprabasal layer but was not consistently detected throughout th e  
layer. Predictably the positive cells showed m em brane staining. 11
is possible that the inconsistent staining observed is due to th e  
low levels of protein expressed or perhaps the staining p ro c e d u re  
requires further optimisation. No staining was noted in any of th e  
negative control sections.
It would therefore appear that LMP-1 protein is e x p re s s e d  
in the upper suprabasal layers of the epidermis of the PyLM P-1 
line 53 transgenic mice. It is not clear if lower levels of p ro te in  
are expressed in the basal or other suprabasal layers.
2C. Discussion o f  chapter 2 .
The wrinkly, flaky, hyperplastic epidermis seen in line 5 3 
was strongly suggestive of a disruption of the normal e p id e rm a l
homeostasis. The aberrant expression of the h y p e rp ro l i f e r a t iv e  
keratin K6 described previously (Wilson et a l ,  1990) and th e  
suprabasal layer staining of Ki67, a cell cycle associated m olecu le  
and also an excellent marker of proliferation, suggests that th is  
disruption might be caused by an increase in cellular p ro l ife ra t io n  
of the epidermis.
Direct evidence that LMP-1 is increasing ce llu la r  
proliferation in this tissue comes from the BrdU staining results. 11 
was immediately apparent just from looking at the stained line 5 3 
sections that there were more stained nuclei in the LM P-1 
positive sections than there were in the negative control sections.
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When accurate counts were made, a 2 to 3-fold increase w a s  
found in BrdU labelling in the PyLMP-1 line 53 compared to  
negative controls. This difference was shown to be s ta tis t ica lly  
significant by th e 1 student's two sample T-test. These r e s u l ts  
dem onstra te  that LMP-1 induces an increase in the p ro l ife ra t io n  
of epidermal cells in these PyLMP-1 transgenic mice. Since line 5 3 
expressed lower levels of LMP-1 than the extinct line 5 as well as  
displaying a less severe phenotype, it is possible that line 5 h a d  
greater increases in proliferative rates. This idea would b e  
supported from the expression of K6 (lOx increase in line 5, a n d  
2.5x increase in line 53).
The lack of observable alterations to any of th e  
d ifferentiation markers studied suggests that the d i f fe re n t ia t io n  
process has not been impeded. There were no gross alterations in  
desm osom e staining pattern (desmoplakin and desmocollin). T he  
staining pattern of K1 and K10 was similar to that of con tro l 
mouse epidermis suggesting that the first stages of te rm in a l  
differentiation proceed in the LMP-1 positive epidermis. T he  
later stages of terminal differentiation also appear to b e  
continuing since loricrin expression in line 53 epidermis w a s  
similar to that found in control epidermis.
Taken together the data indicate that the p h e n o ty p e  
observed in line 53 PyLMP-1 transgenic mice is due to an increase 
in proliferation and not due to inhibition of differentiation. T he  
visibly disorganised epidermis (seen in line 5) might be e x p e c te d  
with increased proliferation without a concomitant increase in  
d ifferentiation. Increased cellular proliferation with in c re a se d  
differentiation has been proposed (Cui et al ., 1995) for KlO-TGFpl 
transgenic mice where the net result was zero o b se rv a b le  
p h e n o ty p e .
Dawson and colleagues (1990) suggested that LM P-1
inhibited differentiation as determined from assays in c u l tu re  
using a squamous icell carcinoma cell line. This differs from th is  
study in that our work was conducted in vivo. More recen tly ,
Nicholson and co-workers (1997) furthered the work of Dawson e t
a l ,  (1990). From these studies, no inhibition of differentiation w a s  
observed. Furthermore, suppression of LMP-1 expression r e s u l te d  
in an inhibition of proliferation (Mattia et al., 1997). As r e p o r te d  
here, LMP-1 expression results in an increase in the expression o f  
Ki67, a finding also suggested by correlation for the disease s ta te  
of NPC.
The level of apoptosis in the epidermis of the PyLMP-1 m ice  
was not investigated and it is possible that a block in a p o p to s is  
may also be partly responsible for the line 53 phenotype. LM P-1 
has been shown to induce CD40 and A20 (Dawson et al., 1990; 
Miller et a l,  1995) in epithelial cells both of which in h ib i t
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program m ed cell death (although CD40 also p ro m o te s  
proliferation). Furtherm ore, CD40 activation also induces A 2 0  
(Sarma et ciL, 1995) potentially amplifying the a n t i -a p o p to t ic  
signal. Both CD40 and LMP-1 operate through the TRAF family of 
signalling proteins implying that the pathways overlap. A lthough  
LMP-1 is capable of inducing A20 through its NF-kB a c t iv a t in g  
ability, the use of the TRAF family may also allow LMP-1 to u s u r p  
the TNF/CD40 pathway causing constitutive cell growth a n d  
inhibition of apoptosis. Investigations into this possibility r e m a in  
to be addressed.
The detectable expression of LMP-1 in the upper s u p ra b a s a l  
layers by fluorescent staining is difficult to correlate with th e  
impact of the phenotype in the lower layers and may reflect a 
detection problem. As BrdU and Ki67 staining was observed in th e  
basal layer, LMP-1 expression in the basal layer might also b e  
expected. The im m unohistochem ical detection of LMP-1 th e re fo re  
requires  verifying.
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CHAPTER 3:- Chemical carcinogenesis .
In this chapter the PyLMP-1 line 53 mice are subjected to  
protocols of chemical carcinogen treatm ent to establish what ro le  
LMP-1 may be playing in the mouse model of chemically in d u c e d  
carcinogenesis. The introductory section will therefore cover th e  
history of this model and the known changes in gene e x p re ss io n  
which occur during; the chemical treatment. This will lead into u se  
of transgenic mouse models in the context of chemical carc in ogen  
treatm ent to establish the exact role of each transgene, and in  
particular PyLMP-1, in the process of m ulti-stage sk in  
carc inogenes is .
3A.1 Mouse skin c a r c i n o g e n e s i s .
The mouse model of m ulti-step carcinogenesis has ta k e n  
researchers a long way towards understanding the m o le c u la r  
events which underlie the transition from a normal cell to a
transform ed cell and neoplasia. As previously described, s e v e ra l  
oncogenes and growth factors have been expressed in th e  
epidermis of transgenic mice to investigate the possibility t h a t  
activation of specific genes may correlate with p a r t ic u la r
biological events. These transgenic mice have been shown to  
produce phenotypes reflecting the early stages of carc inogenes is , 
but in every case required further events to progress to a fu lly  
transform ed phenotype. Carcinogenesis is therefore a m u l t i - s ta g e  
process, but the molecular analysis of tumorigenesis is o f ten  
hampered by the unavailability of tissue specimens from th e  
multiple stages. For this reason the study of mouse sk in  
carcinogenesis using chemical carcinogens has been in v a lu a b le
and shown that the process can be broken down into the stages o f
initiation, promotion and malignant conversion (fig 3.1).
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3 A. 1.1 Tum our  in i t ia t ion .
Initiation occurs as a result of a single topical application of 
a mutagen to the dorsal skin of a susceptible strain of m ouse . 
Initiated cells can remain dorm ant for a considerable period o f  
time until activated by the promotional stage (Reviewed in B row n 
and Balmain, 1995). The initiated cell is phenotypically  in d is t in c t  
from normal cells but because it can remain initiated for such a 
period of time it is believed to belong to one of the population o f  
long lived stem cells. At the molecular level, mutation of the Ha- 
ras  proto-oncogene has been identified as a common in it ia t in g  
event in skin tumours produced by some carcinogens (B alm ain  
and Brown, 1988) . Over 90% of mouse skin tumours initiated with 
D im ethylbenzanthracene  (DMBA) display a transversion m u ta t io n  
(A-T) at codon 61 of the H a -ras gene (Sukumar, 1989 & 1990; 
Brown et a l ., 1990; Kemp et a l ., 1994) with a smaller p e rc e n ta g e  
also showing mutation in codon 12. Along with the H a -ras  
transgenic mouse studies this is compelling evidence for th e  
activation of the ras oncogene as a principle event in in itia tion . 
TG F-a transgenic mice can develop carcinomas upon tu m o u r  
promotion and without prior chemical initiation (Wang et al., 
1994) indicating that TGFa does indeed operate through the Ras 
p a th w a y .
3 A .1 .2 Tumour promotion:- immediate e ffec ts
The promotion step consists of repeated trea tm ent o f  
initiated mouse skin with a tumour promoter, a chem ica l  
carcinogen which is not necessarily a mutagen, and results in  
persisten t general hyperplasia which is seen within 24h, is 
maximal at 48-72hrs, and can last for up one week (Esherick e t  
al ., 1993). The most potent promoters of mouse skin are th e  
phorbol esters such as 1 2 -0 - te t r a d e c a n o y lp h o r b o l - 1 3 -a c e ta te  
(TPA).
TPA treatm ent of adult mouse skin produces a r a p id  
induction of TGFpl mRNA in the suprabasal keratinocytes as e a r ly  
as 2-3Hrs post TPA (Akhurst et a l ., 1988) with a c o n c o m ita n t  
increase in TGFpi protein levels, also localised to the s u p ra b a s a l  
keratinocyes (Fowlis et a l ., 1992). TPA treatm ent however c a u se s  
a decrease in the levels of both TGFP2 and TGFP3 by 24hrs a n d  
6hrs post TPA respectively (Esherick et a l ., 1993). Thus, a l th o u g h  
TGFpl is induced in TPA treated mouse skin, the c o n c o m ita n t  
decrease in TGFp2 and P3 may remove the overall g ro w th
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inhibitory effect of the TGFp's and give rise instead to th e  
observed hyperpro lifera tive  response.
TPA promotion of mouse epidermis has been shown to  
activate the epidermal growth factor receptor (EGFR) a m em ber o f 
the erb B family (Rho et al., 1994; Xian et a l ., 1995) and also  
another m em ber of that family, erb B2 (Xian et al ., 1997). As a 
probable consequence of the elevated levels of activated EGFR a n d  
erb B2, c-src  kinase activity was also observed to be elevated.
TPA is known to bind directly to protein kinase C (P K C )a n d  
cause its activation (Nishizuka 1984 & 1986). This activation of 
PKC by TPA must also be vitally im portant as it in v o lv es  
activation of such proteins as raf and mitogen activated p ro te in  
kinase kinase (MAPKK) (M arquardt et a l ., 1994). Since ras is 
already activated by the application of DMBA in these chem ical 
carcinogen studies, and ras binds to raf, targeting raf to th e  
m em brane and activating it, this may amplify the PKC p a th w a y  
f u r th e r .
TPA appears to increase cross boundary c o m m u n ica tio n  
between the dermis and epidermis (Kam and Pitts, 1988) c o n tr a ry  
to in v itro  reports of TPA blocking celkcell com m un ica tion . 
Therefore TPA is not promoting carcinogenesis by d is ru p t in g  
normal c e llx e ll  interchange.
In cell culture experiments TPA treatm ent of k e ra t in o c y te s  
has been shown to block the calcium -m ediated  induction of K1 
and K10 (Dlugosz and Yuspa, 1993); induce both TGFpi (Fowlis e t  
a l ., 1992) and TGFa mRNA (Imamoto et al., 1991); and in d u ce  
sequential transcription of the fos  and  m y c  oncogenes (B alm ain  
and Brown, 1988).
Thus, TPA promotion of susceptible mouse skin results in a 
plethora of events and the induction of the visible h y p e rp la s t ic  
response. The events which occur after promotion are as y e t  
unclear. One particular facet of phorbol ester trea tm ent may b e  
wholly responsible for papilloma formation, such as the in d u c tio n  
of hyperplasia, or many of the resultant events may be r e q u i r e d  
in tandem. Certainly the activation of PKC and the s u b s e q u e n t  
signal transduction pathways which will be stimulated may b e  
im p o r ta n t .
3 A . 1.3 Tumour promotion:- developm ent of p a p il lo m a s
Repeated applications of TPA to DMBA initiated mouse sk in  
results in the formation of multiple discrete benign tumours called 
papillomas (figure 3.2). Papillomas are thought to be clonal, 
arising from a single initiated cell which has increased its rate o f  
proliferation with a concomitant decrease in the rate o f 
differentiation (Brown and Balmain, 1995).
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A number of genetic alterations have been detected d u r in g  
the promotion stage in mouse skin tumours, including th e  
frequent trisomy of chromosomes 6 and 7 (sum m arised in f ig u re  
3.1). The H a -ras gene is located on chrom osome 7 th e r e f o re  
trisomy of chromosome 7 results in the duplication of the m u ta n t  
ras  allele and suggests that increased activated ras might b e  
fu rther required (Bremner and Balmain, 1990). Duplication of th e  
chrom osome carrying the normal Ha -ras  allele has never b e e n  
detected, nor trisomy of chromosome 7 in tumours where H a -ras  
is not mutated.
The benign papillomas formed by DMBA and TPA t r e a tm e n t  
display numerous alterations compared to normal m o u se  
epidermis. Levels of both TGFa and its receptor EGFR w e re  
e levated in 100% and 90% respectively of papillomas tested (Rho 
et a l ., 1994) at both mRNA and protein levels. Therefore the in it ia l  
elevation of TGFa following TPA adm inistration is m aintained a t  
high levels suggesting that this is an im portant event in th e  
formation of papillomas.
Both insulin-like growth factor (IGF-1) and IGF-1 r e c e p to r  
(IGF-1R) were shown to be elevated in papillomas induced by TPA 
trea tm ent of initiated mouse epidermis (Rho et al ., 1996). TPA 
trea tm ent of normal epidermis failed to induce any increase in  
levels of either protein suggesting that these changes occur u p o n  
papilloma formation and not as a direct result of TPA in d u ce d  
p ro l ife ra t io n .
Examination of the retinoic acid receptor (RAR) content o f  
papillomas compared to normal epidermis showed a decrease in  
levels in the benign tumours (Darwiche et a l ., 1995) whilst leve ls  
of another nuclear receptor, RXR, increased in the benign tu m o u rs .  
Close examination of the RAR transcripts in papillomas from TPA 
prom oted skin showed a slight decrease in RARa levels with a 
complete absence of RARy (Darwiche et a l ., 1996). Since re t in o id s  
are essential for normal epidermal d ifferentiation, reduction o f  
their receptor levels may contribute to carc inogenes is . 
Transfection of primary keratinocytes with an activated H a -ras  
construct also reduced RAR levels suggesting that this d e c re a s e  
m ight occur at the stage of initiation and activation of ras  
(Darwiche et al ., 1996).
Tumour promotion can be further divided depending on th e  
type of prom oter used. This led to the clasification of stage 1 
prom oters (also called full or conversion prom oters) and stage 2 
prom oters (propagation promoters). TPA and wounding belong to  
stage 1 promoters, whereas chemicals such as mezerein or 1 2 -  
retinoyl 13-acetate! (RPA) function as stage 2 promoters. Stage 2 
prom oters have only moderate or weak promoting activities b u t
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can give rise to tumours following short trea tm ent with a stage 1 
promoter (Hennings and Boutwell, 1970).
3 A. 1.4 Tumour conversion:- papilloma to squamous
cell c a rc in o m a
The m alignant conversion of a benign papilloma to a 
carcinom a is a relatively rare event with around 5-10% of 
papillomas converting to carcinomas. This conversion, a l th o u g h  
spontaneous, is not thought to be random  as not all p a p il lo m a s  
have an equal chance of conversion. Subsets of papillomas h a v e  
been identified which display an increased risk of progression a n d  
these papillomas have differences in their TGF-(3, a6p4 in teg rin , 
K13 and R A R a expression levels (sum m arised in figure 3.1) (Glick 
et a l ., 1993; Tennenbaum  et a l., 1993; Nischt et al., 1988; a n d  
Darwiche et al., 1996).
The majority of papillomas forming from TPA treatm ent o f 
initiated mouse epidermis never progress to squamous cell 
carcinom a and these are classed as low risk. In low r i s k  
papillomas, 90% of the proliferating cells are confined to the b a sa l  
cell compartment and the lesions express TGFpi, whereas in m o s t  
of the high risk papillomas TGFpi is dow nregulated in the lesions 
as soon as they arise with up to 40% of the proliferating cells in 
the suprabasal com partm ent (Fowlis et al., 1992; Glick et al., 
1993). Squamous cell carcinomas are also devoid of TGFpi 
suggesting that they arise from the TGFpi deficient high r i s k  
papillomas (Glick et al., 1993).
High risk papillomas displayed basal and suprabasal a 6 p 4  
expression which coincided with an expansion of the p ro l i fe ra t in g  
com partm ent into the suprabasal layer, whereas low r i s k  
papillomas dem onstra ted  only basal a 6 p 4  expression and b a sa l  
layer proliferation (Tennenbaum et al., 1993).
Keratin 13 (K13) is normally associated with te rm in a l  
d ifferentiation  of internal stratified epithelia and is v i r tu a l ly  
absent from the entire body epidermis. However K13 has b e e n  
shown to be present in a subset of papillomas arising f ro m  
chemical carcinogen treatm ent (DMBA + TPA) and th e s e  
papillomas represent a high risk group for malignant co n v e rs io n  
(Nischt et al., 1988).
Papillomas have an overall decrease in levels of RAR's. 
However low risk papillomas have only a slight decrease in RARa 
levels whereas high risk papillomas have a much greater d e c re a s e
in RARa levels (Darwiche et al., 1995). Therefore it is likely to b e  
the R A R a isoform that is most important in progression.
The squamous cell carcinomas that do arise d e m o n s t r a te  
further alterations. The loss of TGF(3 from high risk papillomas is 
m aintained in carcinomas (Glick et al., 1993) as is the a b e r r a n t  
expression of K13 (Nischt et al., 1988). The elevated IGF-1, IGF-1R, 
EGFR, and TGFa levels seen in papillomas are m aintained in th e  
carcinom a stage (Rho et al., 1994 and 1996). Furtherm ore, t h e r e  
are altered patterns of Gi cyclins and c y c l in -d e p e n d e n t  
kinases(cdk's) (Zhang et al., 1997).
S tro m e ly s in - l(S T -l)  is a m a t r ix -d e g ra d in g
m etalloprote inase , a family of proteins thought to contribute to  
the process of invasion and metastasis via their ability to d e g ra d e  
the basem ent m em brane and extracellular matrix barriers th u s  
allowing tumour cells access to the lymphatic system. The leve ls  
of ST-1 were indeed increased from 8% in benign papillomas to  
71% in m alignant squamous cell carcinomas (Matrisian a n d  
Bowden, 1990). ST-1 expression was shown to be localised to th e  
stromal tissue surrounding the tumour cells in both papilloma a n d  
carcinoma (Wright et al., 1994).
Frequent loss of the remaining wild-type ras allele is o f ten  
noted (Bremner et al., 1990). In addition, loss of h e te ro z y g o s i ty  
(LOH) on chromosome 11 (which harbours the p53 gene in m o u se )  
is detected in 30% of cases. In every case where LOH on 
chrom osom e 11 was noted, the remaining p53 gene had s u f fe re d  
point m utations (Burns et al., 1991). Most of these m u ta t io n s  
resulted in loss of function of the gene. By comparison p5  3 
he terozygous(+ /-) and hom ozygous(-/-)  knockout m ice  
(Donehower et al., 1992) were subjected to initiation with DMBA 
followed by 15 weeks of promotion with TPA (Kemp et al., 1993a). 
Heterozygous knockout mice had equal numbers of p a p il lo m a s  
com pared to control mice, but p53 null mice strangely had f e w e r  
papillomas. However, the heterozygous knockout m ice  
dem onstra ted  a 3-fold increase in the progression frequency o f  
papillomas to carcinomas, and loss of the remaining WT p53 a lle le  
was noted. The p53 null mice had a dram atically  a c c e le ra te d  
progression frequency despite having fewer papillomas to b e g in  
with. This clearly indicates that loss of one or both copies o f  
functional p53 is associated with conversion of papillomas to  
carcinomas. With the absence of WT H a -ras , the presence of tw o  
copies of activated Ha-ra.v , plus inactivated p53, this stage of th e  
carcinogenic process produces highly m alignant squamous cell 
ca rc ino m as .
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3 A. 1.5 Tumour conversion:- squamous cell carcinoma to 
spindle cell c a rc in o m a
A further conversion step occurs with the progression f ro m  
a squamous cell carcinoma to the more aggressive spindle cell 
tum our in which all organisation and markers of e p i th e l ia l  
differentiation are completely lost. This conversion step is v e r y  
rare with only 0.07 spindle cell carcinomas formed per mouse (o f 
the SENCAR strain) following DMBA and TPA treatm ent (Klein- 
Szanto et a l., 1989).
This conversion is associated with a further increase in th e  
ratio of mutant to WT ras  genes, caused by an amplification of the 
m utant (active) H a -ras  gene (Buchmann et al., 1991). Thus, f ro m  
initiation right through to the most aggressive form of carc inom a, 
alterations in the H a -ras  play significant roles in this m u l t i s ta g e  
progress towards carcinoma.
Additional genetic changes include LOH on chromosomes 4, 
6, and 7 in areas thought to harbour tumour suppresser g en es  
(Kemp et al., 1993b). It would appear therefore that in h ig h ly  
m alignant spindle cell carcinomas, more and more h o m e o s ta s is  
controlling mechanisms are found to be failing.
The levels of ST-1 are m aintained at an elevated level in  
spindle cell carcinomas, but in contrast to the squamous cell 
carcinoma stage ST-1 is now expressed in the tumour cells as w ell 
as in the adjacent stroma (Wright et al., 1994). This suggests t h a t  
the change in expression from surrounding stroma to the t u m o u r  
itself is associated with the conversion of squamous to sp in d le  
carcinoma. The high levels of ST-1 expressed in both the tu m o u r  
and surrounding tissue may allow these spindle cell tumours to  
invade and metastasise.
Spindle cell carcinomas have also been shown to lack  
expression of the cell adhesion molecules E- and P-cadherin a n d  
the desmosomal component desmoplakin (Stoler et al., 1993). T he  
keratin filament network is also often completely absent in m a n y  
spindle cell carcinomas and where it is still present, is very p o o r ly  
organised. Expression of the integrin a6p4 is completely lost in  
spindle cell carcinomas (Gomez et al., 1992). The loss of s t r u c tu r e  
and the loss of expression of these epidermal d i f fe re n t ia t io n  
markers correlates with the squamous to spindle transition.
The ultimate stage of carcinogenesis is the ability of th e  
tum our to invade the surrounding tissue and m etastasise  to  
distant sites. The increased expression of ST-1 may a id  
breakdown of m em brane barriers and the loss of many a d h es io n  
molecules allow the tumour cells to detach from the tum our m a s s  
and enter the lymphatic system (reviewed in Portella et al., 1994).
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3 A .1 .6 Chemical c a r c in o g e n  t rea tm en t  of t ransgenic mice.
The study of carcinogenesis in the mouse skin u s ing  
chemicals has revealed a wealth of information concerning th e  
complex stages and genetic events. This has been expanded a p o n  
using the same chemical treatm ent regime in mice which a re  
already transgenic for an activated gene involved in th e
carcinogenic process, such as activated H a -ras  (Bailleul et a l,  
1990). Treatm ent of these mice with tumour promoting a g e n ts  
resulted in the progression from papilloma to carcinoma f u r t h e r  
indicating that activation of ras is an im portant event but t h a t
other events are subsequently required for neoplasia. Just as w i th
the H a-ras  mice, TGFa transgenic mice (Wang et a l ,  1994) d id  
not develop carcinoma but carcinomas could be induced follow ing 
tumour promoter treatment of the mice.
Mice expressing TGFpi in the epidermis (described later in  
chapter 4) have been subjected to chemical carcinogen t r e a tm e n t  
and shown to be more resistant to the induction of b e n ig n
papillomas than were controls (Cui et al., 1996). The p a p il lo m a s  
forming on the transgenic mice were however much more l ike ly  
to convert to a malignant phenotype. Thus, chemical ca rc in ogen  
studies of these transgenics has shown that TGFpi shows d u a l  
action in that it acts initially as a tumour suppresser b u t
subsequently (later tumour stages) as a tumour enhancer.
Several groups have examined the role of TGFa in sk in
carcinogenesis using transgenic mice. K14-TGFa transgenic m ice  
developed hyperplasia, hyperkeratosis  and papillomas (V a ss a r  
and Fuchs, 1991; Vassar et al., 1992) as did K l-T G Fa t ra n sg e n ic
mice (Dominey et al, 1993; Wang et al., 1994). TGFa t ra n sg e n ic
mice have been subjected to chemical carcinogen treatm ent. T he
K l-T G F a  transgenic mice were adm inistered TPA t r e a tm e n t
without prior DMBA initiation, and succumbed to p ap il lo m as , 
suggesting that TGFa overexpression can bypass the need for H a- 
ras  activation and thus act as an initiator of carcinogenesis (W ang  
et al., 1994). Metallothionein prom oter driven TGFa t ra n s g e n ic  
mice were initiated with a single dose of DMBA w i th o u t
subsequent promotion and virtually all of the TGFa t ra n sg e n ic
mice succumbed to papillomas with some infrequent c a rc in o m as
(Jhappan et al., 1994). Thus, chemical carcinogenesis studies o f
TGFa transgenic mice led to the discovery that enhanced TGFa 
expression can act in both the initiation and promotion of sk in
tu m o r ig en e s is .
Other transgenic mice to be challenged with ch em ica l  
carcinogens include Kl-v-/ir;.v mice. These mice d e v e lo p e d
7 2
epidermal hyperplasia  but only as a result of a p ro m o tio n  
stimulus from wounding (Greenhalgh et a l ., 1993). These m ice  
were treated with TPA but developed papillomas only after a long 
latency (20-30 weeks of promotion) and in relatively few  
numbers per animal (Greenhalgh et a l ., 1995). Furtherm ore th e s e  
lesions were TPA independent as they persisted and converted to  
malignancy after TPA withdrawal. The tumours also h a rb o u r e d  
H a -ras  mutations in codons 12 and 61. Thus, chemical carc inogen  
studies of K l -v - /a v  transgenic mice revealed that v-fos m a y  
induce a sensitivity to TPA promotion, but that additional genetic  
events, such as mutation of Ha-ras, are required for tu m o r ig e n e s is  
to progress.
3 A .l  .7 Rationale for chemical carcinogen studies in PvLMP-1
line 53 transgenic mice.
Since LMP-1 has been likened to mutant H a -ras in t is su e  
culture experiments (Dawson et al., 1990) the question arises, can  
LMP-1 replace the function of mutant H a -ras in ca rc in o m a  
initiation and progression? DMBA can activate H a -ras  so can th e  
expression of LMP-1 replace the function of DMBA? This q u e s t io n  
could be addressed by treating PyLMP-1 transgenic mice w ith  
TPA promotion only (See regime 2), and if LMP-1 could in d e e d  
replace the need for activated H a -ras, it would be expected t h a t  
papillomas and carcinomas would arise in the classical DMBA + 
TPA fashion.
In chapter 2 LMP-1 was shown to induce proliferation, so 
could LMP-1 expression in the PyLMP-1 transgenic m ice  
substitute for the proliferative effects induced by TPA t r e a tm e n t?  
This question can be addressed by initiating the PyLM P-1 
transgenic mouse skin with a singe application of DMBA (See 
regime 3). If inducing proliferation was the most im p o r ta n t  
attribute of all the events induced by TPA in the p ro m o tio n a l  
effect of the chemical, and if the level of proliferation induced b y  
LMP-1 expression was appropriate, then it would be p re d ic te d  
that the LMP-1 transgenic mice would develop papillomas a n d  
subsequent carcinomas following DMBA initiation alone. 
A lternatively, LMP-1 may be able to act as a secondary (second  
stage) promoter following limited TPA treatment (See regime 4).
Adm inistration of the PyLMP-1 mice with the s t a n d a r d  
DMBA + TPA protocol of treatment (Regime 1) could provide m o re  
information as to the role of LMP-1 in later stages o f 
carcinogenesis, such as, does LMP-1 act to increase the co n v ers io n  
rate of papilloma to carcinoma and malignancy?
The use of chemical carcinogen studies on the PyLMP-1 mice 
is of particular relevance to the disease state of NPC. As
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previously mentioned in section 1C. 1.2, the salting process in  
areas of high incidence of NPC, gives rise to the production of 
volatile nitrosamines which have been shown to have tu m o u r  
promoting effects. Thus it may be the combination of the p re s e n c e  
of EBV and these tumour promoters that initiates NPC. T rea tin g  
the PyLMP-1 mice with tumour promoting agents will d e te rm in e  
if this hypothesis has any grounding, at least with respect to LM P- 
1 expression.
One single application of DMBA followed by twice w e e k ly  
(for 20 weeks) applications of TPA leads to papilloma fo rm ation , 
5-10% of which convert to carcinomas. This standard protocol w as  
used as well as variant regimes to attempt to answer p e r t i n e n t  
questions about the possible role for LMP-1 in carcinogenesis.
3B RESULTS
3 B .  1 I n t e r c r o s s in g  to a c a rc in o g e n  s u s c e p t ib le
s t r a i n .
The PyLMP-1 mice were originally bred into a C57B1/6 
strain background. It has been well documented that there a re  
marked strain differences in response to epidermal tu m o u r  
prom otion using chemical carcinogens (reviewed in DiGiovanni, 
1989 and 1991), most of this information having b e e n  
accumulated from studying the effects of TPA. This led to an order 
of susceptibility to lesion formation being identified such th a t  
SENCAR> FVB> DBA/2> CD-1> C57B1/6 where C57B1/6 is the m o s t  
resistant strain studied. Furthermore, C57B1/6 are also resistant to  
tum our promotion by full thickness skin wounding follow ing 
initiation with DMBA (DiGiovanni et al., 1993) a method shown to
be previously tumour promoting in both K10-ra.y and K l-T G F-a
transgenic mice (Bailleul et a l ., 1990; Wang et a l ., 1994). 
Therefore, the C57B1/6 mice are resistant to skin ca rc in o g en es is  
involving more than one tumour promoting method. It w as  
therefore necessary to cross the PyLMP-1 mice into a s t ra in  
background which would respond to the protocol of DMBA a n d  
TPA treatment.
Initially the PyLMP-1 line 53 was intercrossed with stock
DBA/2 mice but the FI offspring proved to be poor breeders a n d
too few mice were being born for the experim ent to proceed w ith  
sufficient speed. The mice in the 50:50 C57Bl/6:D BA /2
background had exactly the same phenotype as the 100% C57B1/6 
mice and did not appear to suffer any greater p h e n o ty p ic  
p ro b lem s .
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At this time the FVB strain of mice became available to th e  
lab (both through importation and subsequently  through th e  
company Harlan Olac). FVB mice were found to breed well a n d  
also show greater susceptibility to chemical carcinogens than th e  
DBA/2 strain. Therefore line 53 PyLMP-1 mice were in te rc ro s s e d  
with mice of the FVB strain with greater success. Notably, again  
there were no differences in the LMP-1 induced p h e n o ty p e  
between the strains C57B1/6 and FVB. FI positive o ffsp r in g  
(backcross 1) from the original line 53 x FVB cross were id e n t i f ie d  
by day 7 phenotype and subsequent southern blot of genomic ta i l  
DNA. These mice were backcrossed to FVB strain mice a n d  
positive offspring identified in the same manner (backcross 2). A 
further backcross to the FVB strain was conducted before m ice  
were entered into the chemical carcinogen study. Mice of 
backcross 3 (87.5% FVB and 12.5% C57B1/6) should be ch em ica l 
carcinogen sensitive, since FI mice have previously b e e n  
demonstrated to be sensitive (Burns et a l ., 1991).
Mice were entered into the treatm ent protocols at 8 w e e k s  
of age and in the majority of cases the transgenic status w a s  
unknown at this point. This helped to eliminate any bias in  
assessm ent in the formation of lesions. Subsequently t h e  
transgenic status for all the mice was assessed and e q u iv a le n t  
numbers of transgenic positive and negative siblings were entered 
into each study (except regime 1 where additional negatives w e re  
entered before status was ascertained). Four regimes of t r e a tm e n t  
were used with the following numbers of mice:-
Regime 1) DMBA + TPA- 29 LMP +ve and 31 LMP -ve. This
regime was conducted for 55 
weeks which included 20 weeks of 
DMBA + TPA treatment and 35 weeks 
of observation
Regime 2) TPA alone- 15 LMP -i-ve and 20 LMP-ve. This
regime was conducted for 46 weeks 
which included 20 weeks of TPA 
treatment and 26 weeks of 
observation
Regime 3) DMBA alone- 15 LMP +ve and 15 LMP-ve. This
regime was conducted for 35 weeks 
which included a single application of 
DMBA and 35 weeks of observation
Regime 4) DMBA followed- 7 LMP -i-ve and 6 LMP-ve. This
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by 4 weeks only of TPA experiment was initiated towards th e
end of my Ph.D. studies so was 
subject to time constraints and thus 
was conducted by myself for only 20 
weeks, of which 4 weeks were 
treatment and 16 weeks observation. 
Thereafter, Donald Campbell 
continued the observation.
As detailed in the methods (section 7B.1.4), DMBA at a 
concentration of 5 x l0 _5M (25pg) in acetone was applied to sh a v e d  
dorsal skin followed one week later by twice weekly ap p lica t io n s  
for twenty weeks of TPA also at a concentration of 5 x l 0 _5M in 
ace tone .
The mice were housed as mixed groups in the same cages to  
minimise possible environm ental or treatm ent factors. E v ery  
week the mice were assessed in a blinded fashion (to av o id  
observer bias through knowledge of what the particular m o u se  
showed the previous week) for the appearance of lesions. T he  
num ber and size of papillomas and carcinomas formed w e re  
counted. Each lesion was designated a num ber from 1 -4  
depending on its diameter. Thus:- 
4= >  1cm2
3= >  0.5cm2 but <  1 cm 2 
2= >  0 .2cm 2 but <  1cm2 
1= <  0.2cm2
After about 15 weeks of treatm ent the papilloma load b e c a m e  
such that occasionally the larger papillomas masked some of th e  
small papillomas and it was impossible to count the number o f  
small size 1 papillomas accurately. For this reason they are n o t  
included in any calculations. All records and calculations th e re fo re  
are based on the average number of papillomas of size 2-4 fo r  
both LMP-1 positive and LMP-1 negative mice per week.
3 B .2  C hem ica l  c a rc in o g e n  reg im e  1:- DMBA plus 20
w eeks o f  T P A
3B.2.1 Formation of pap il lom as
Small nodules began to appear during week 5 or later o f  
TPA treatm ent and all mice had developed lesions by week 11. 
These lesions took on the recognisable papilloma shape w h ich  
could be described as “cauliflower” like in that the papillomas h a d  
a large wrinkly head and were attached to the dorsal skin by a
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thin “stalk” (Figure 3.2). The pattern of papilloma formation w a s  
unique for each mouse. Siblings housed within the same cage t h a t  
had received identical doses of carcinogen at the same tim e, 
displayed wide variation in the number and size of p a p il lo m a s  
formed indicating that initiation is a random event and t h a t  
prom otion of initiated cells may vary (Tables 3.1+3.2 and f ig u res  
3.2+3.3).
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Figure 3.2
Figure 3,3
Figure 3.9
F igures  3.2. 3.3. and 3 . 9 : - Figures  3.2 and 3.3 show the s h a p e  
of  p ap i l l oma s  which fo rm and highl ight  the r a n d o m n e s s  o f  
p ap i l l oma  fo r ma t i on  as the mice in these f igures  were  h o u s e d  
wi thin the same  cage  and received identical  doses  of  chemicals .  
Figure  3.9 indica tes  the shape  of  a c a r c i noma  and highl ights  t h e  
d i f f e r ence  be twee n  p a p i l l oma  and carc inoma.
T ab le  3 .1 : -  LMP-1 positive mice used in chemical ca rc inogen  
treatment regime 1 (DMBA + TPA treatment), indicating the age of 
the mice when treatment commenced (weeks), the age of the m ice  
when papillomas and subsequently carcinomas developed, th e  
m axim um  numbers of each lesion appearing, and the c o n v e rs io n  
rates of papilloma to carcinoma.______________________________
M o u s e  
i . d .
Age at  
s tar t  of 
t r e a t ­
m e n t
LMP
{
Wk of 
t r e a t ­
ment  at  
d e a t h
1 s t
p a p s
( w k )
m a x .
p a p s
1 s t
c a r c .
( w k )
m a x .
c a r c .
%
c o n  v 
e r s i 
o n
53F.183 1 6 + 53 8 24 34 1 4.2
53F.186 16 + 55 6 27 34 1 3.7
53F.191 1 6 + 35 7 26 2 1 5 19.2
53F.214 8 + 26 7 53 26 ? /
53F.221 8 + 34 7 50 29 4 8
53F.226 8 + 38 7 43 29 1 0 23.3
53F.234 8 + 36 8 52 23 5 9.6
53F.236 8 + 24 8 35 25 1 2.9
53F.238 8 + 3 5 8 5 0 27 7 1 4
53F.239 8 + 5 4 8 27 24 2 7.4
53F.243 8 + 5 3 6 26 33 2 7.7
53F.245 8 + 24 8 30 25 3 10
53F.246 8 ’ + 38 8 3 3 27 6 18.2
53F.248 8 + 3 5 1 0 27 24 2 7.4
53F.252 8 + 54 7 24 30 2 8.3
53F.253 8 + 38 7 10 27 2 20
53F.255 8 + 36 7 26 2 9 5 19.2
53F.260 8 + 3 1 6 3 8 3 1 5 13.2
53F.268 8 + 1 9 6 3 3 1 2 1 3
53F.269 8 + 3 1 6 36 28 1 2 33.3
53F.278 10 + 43 5 3 5 37 2 5.7
53F.279 10 + 43 5 3 8 22 3 7.9
53F.287 10 + 34 5 40 24 2 5
53F.289 10 + 2 9 5 3 5 24 1 2.9
T o t a l  Av. Av. Av. Av. Av.
= 2 4 = 7 =34.5 =27 =3.65 =1 1 . 0 5
N.B. M ouse 53F .214 was found dead prior  to the developm ent o f  ca rc inom as and thus 
w as  e x c lu d e d  from  conve rs ion  ca lcu la t ions
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T ab le  3 .2 : -  LMP-1 negative mice used in chemical ca rc in o g en  
treatment regime 1 (DMBA + TPA treatment), indicating the age of 
the mice when treatm ent commenced (weeks), the age of m ice  
when papillomas and subsequently carcinomas developed, th e  
m axim um  numbers of each lesion appearing and the c o n v e rs io n  
rates of papilloma to carcinoma.______________________________
M o u s e  
i . d .
Age at 
start of  
t r e a t ­
m e n t
LMP Wk of  
t r e a t -  
ment at 
d e a t h
1 s t  
p a p s  
( w k )
m a x .
p a p s
1 s t
c a r c .
( w k )
m a x .
c a r c .
%
co n v 
e r s i 
o n
53F.180 1 2 - 32 8 32 27 4 12.5
53F.181 1 5 - 26 8 25 23 1 4
53F.182 1 6 - 39 6 25 26 4 1 6
53F.184 1 2 - 54 8 22 39 3 13.6
53F.185 1 2 - 45 8 17 36 5 29.4
53F.187 1 2 - 40 9 1 27 1 100*
53F.188 1 6 - 3 1 8 48 7 7 /
53F.189 1 6 - 35 8 42 27 1 2.4
5 3F.194 1 6 - 32 8 3 1 26 4 12.9
5 3F.195 1 6 - 3 5 8 22 26 5 22.7
53F.196 1 6 - 3 9 9 40 32 5 12.5
53F.204 10 - 4 5 9 3 5 27 1 2.9
53F.205 10 - 35 1 0 20 24 6 30
53F.208 10 - 42 8 4 3 36 0 0
53F.210 10 - 4 3 9 3 1 3 1 2 6.5
5 3 F . 2 1 1 8 - 5 0 1 1 1 2 47 1 8.3
53F.212 8 - 2 5 7 28 1 8 1 3.6
53F.213 8 - 26 7 24 1 8 1 4.2
53F.215 8 - 4 5 1 1 1 7 37 2 1 1.8
53F.216 8 - 3 1 9 20 25 4 20
53F.217 8 - 47 7 24 37 4 16.7
53F.218 8 - 40 7 23 35 1 4.3
53F.219 8 - 1 2 7 1 5 7 ? /
53F.220 8 - 28 7 3 3 28 2 6.1
53F.222 8 - 42 7 27 3 3 6 14.8
53F.223 8 - 3 5 10 22 1 8 5 22.7
53F.225 8 - 4 1 7 36 28 4 11.1
53F.227 8 - 1 7 7 28 7 7 /
53F.228 8 - 3 0 7 4 1 2 9 2 4.9
53F.229 8 - 34 7 7 34 1 14.3
T o ta l  Av. Av. Av. Av. Av.
=3 0 =8 =26.37 =29 =2.81 =15.40
N.B. M ice 53F. 188, 53F .219  and 53F .227  were found dead before c a rc in o m a s  h a d  
fo rm ed  and thus were not included in the pe rcen tage  convers ion  ca lcu la t ions .
*= M ouse 53F187 only ever developed  one p ap i l lo m a  w hich  s u b se q u e n t ly  co n v e r ted  to  
ca rc inom a .  This gives the a r t i f ic ia l ly  high conve rs ion  rate  of 100%. R em oving t h i s  
mouse from the calculat ion  decreases the average conversion  rate to 1 2 . 1 5 %
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Comparison of mean papilloma load between LMP-1
positive mice and LMP-1 negative control groups
(Regime 1)
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Papillomas were first detected in the LMP-1 positive mice in 
week 5 of treatment. All mice in this group had papillomas b y 
week 10, with an average time to onset of 7 weeks post DMBA 
treatm ent. The first papillomas to arise in the LMP-1 n e g a t iv e  
group were in week 6 of treatment. All mice in this group h a d  
papillomas by week 11, with an average time to onset of 8 w e e k s  
post DMBA. Thus, it would appear that the LMP-1 positive m ice  
developed papillomas slightly faster than the LMP-1 n e g a t iv e  
mice. This difference proved to be statistically significant w h e n  
the data was used in a two sample T-test. A T value of 3.45 w a s  
obtained with a P value of 0.0012 and 49 degrees of freedom.
As can be seen from figure 3.4, the average number o f  
papillomas on the LMP-1 positive mice rose rapidly to 15 
papillomas on average by week 10 of treatm ent, whereas at w e e k  
10 the LMP-1 negative mice had an average of only 12  
papillomas. For the duration of the study (55 weeks), the a v e ra g e  
num ber of papillomas on LMP-1 positive mice was c o n s is te n t ly  
higher than the average number of papillomas on LMP-1 n e g a t iv e  
m ice.
After consultation with a scientific statistician and a 
mathematical statistician the most appropriate method of dec id ing  
whether there was significant difference in papilloma load  
between the two groups was reached. This involved taking each  
week at a time and conducting a Rankits plot. Rankits plots are a 
method of determining if values conform to a normal d is tr ib u t io n .  
If normal distribution was found then a two sample T-test or Box- 
plot could be carried out to look for significant differences. All 
statistical analysis is discussed in greater depth in section 3B.2.4 
whilst the results of the analysis are given here.
It was decided that the period between week 10 and w e e k  
25 showed the most differences between the groups and so 
attention was focused on this period. Analysis was carried out on  
weeks 10, 15, 20 and 25. At week 10 of treatm ent there was no  
significant difference between the two groups. At week 15  
however, the two groups were significantly d ifferent with a T 
value of 2.15 a P value of 0.036 and 55 degrees of freedom. A t  
week 20 no significant difference was noted. A s ign if ican t  
difference between the groups at week 25 was however noted. A 
T value of 2.44 was obtained with a P value of 0.018 and 5 5 
degrees of freedom.
After week 25 of the study, the average number o f  
papillomas on both LMP-1 positive and LMP-1 negative m ice  
declined at roughly the same rate. This reduction is due to som e  
papillomas converting to carcinomas (and therefore b e in g  
rem oved from the papilloma count) and some reg re ss in g .
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However, the papilloma load on the LMP-1 positive mice, h a v in g  
reached an overall higher maximum average number, w a s  
maintained at higher levels than the LMP-1 negative mice for th e  
remainder of the study. When mice were removed from the study, 
the number of papillomas at death for each mouse was included in 
all subsequent weekly counts. This was done because to r e m o v e  
the counts entirely as the mouse was sacrificed would a r t if ic ia l ly  
reduce the average papilloma load subsequently scored. Figure 3.4 
therefore clearly shows that during chemical promotion, th e  
average number of papillomas on the LMP-1 positive mice ro se  
more quickly and to a higher level than the average num ber o f  
papillomas on the LMP-1 negative mice.
In accordance with the Home Office licensing of th is  
procedure, mice must be sacrificed when they reach a m a x im u m  
acceptable papilloma/carcinoma load or when a carcinoma reaches 
2cm in diameter. This maximum papilloma load is su b je c t iv e ly  
determ ined by experienced animal house staff and therefore is 
not subject to any bias of transgene status. As a c o n seq u en ce ,  
from week 12 of the study onwards mice were removed from th e  
study. This included 4 LMP-1 positive mice (53.F224, 230, 2 3 2 , 
and 233) which were removed at week 18 of the study. T h e ir  
papilloma scores at death were included in every s u b s e q u e n t  
count and therefore make up part of the average for the LM P-1 
positive group. However, these mice (plus mouse 53.F254 w h ich  
died of a prolapse at week 12 and whose scores were not in c lu d ed  
thereafter) were not included in table 3.1. Thus 29 LM P-1 
positive mice started this program of treatment. Fig 3.5 shows th e  
num ber of mice remaining in the study for each week. I n 
accordance with the increased num ber of papillomas in LM P-1 
positive mice compared to LMP-1 negative mice, the LM P-1 
positive mice were removed from the study at earlier time p o in ts  
than the LMP-1 negative mice. It should be noted therefore t h a t  
the m axim um  papillomas recorded has an artificial limit d ic ta te d  
by the requirement to set a limit for animal welfare. For ex am p le , 
at week 15 of the study there are >95% of the mice alive w h e r e a s  
after week 40 there are <25% of the mice alive in both groups. 
Nonetheless, up to week 25 (the main period of statistical a n a ly s is  
of the data), there are still >75% of both LMP-1 positive and LM P- 
1 negative mice left in the study.
From analysis of these results, the LMP-1 positive m ice  
develop more papillomas at a faster rate than their LM P-1 
negative counterparts and that this difference is s ta t is t ic a l ly  
significant.
Death curves for LMP-1 positive mice and 
WT controls, both DMBA+TPA treated
40
LMP-1 +ve mice
LMP-1 -ve mice
30-
o
> <x>oo
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o o o o o«n
Week of treatm ent
F igure 3.5
This graph indicates the rate of withdrawal from the study program 
for both LMP-1 positive and negative control littermates. Mice were 
removed from the study on the basis of advice given by the animal 
technicians. Causes of removal were prolapse, sickly looking mice, 
too large a papilloma load, large papillomas which hindered the 
anim als movement, and formation of carcinoma.
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Figures 3.6-3.8 show that there is also a difference in th e  
average number of each size category of papillomas fo rm e d  
between the LMP-1 positive mice and their LMP-1 n e g a t iv e  
siblings. Figure 3.6 shows that the curves for the average n u m b e r  
of size 2 papillomas are very similar to total numbers shown in 
figure 3.4. The LMP-1 positive mice develop more size 2 
papillomas at a faster rate than do the LMP-1 negative mice. This 
difference is statistically significant. At week 10 there is no  
significant difference, but at weeks 15, 20 and 25 the d if fe re n c e s  
become significant with T values of 3.03, 2.51, and 3.54, and P 
values of 0.0038, 0.015 and 0.0008 respectively. The degrees o f 
freedom  were 52, 55 and 54 respectively for these three t im e  
points. Again this separation arises at the start and is m a in ta in e d  
for the duration of the study (a further 45 weeks). It should b e  
noted that at 20 weeks of the study there are 21.68 size 2 
papillomas on the PyLMP-1 positive mice. There are however only 
2.04 size 3 papillomas and 0.64 size 4 papillomas at the same 2 0 
week stage. Thus the graphs for figures 3.6-3.8 have different Y 
axis numberings with figure 3.6 ranging from 0-30 and figure 3 .8 
from 0-4.
Figure 3.7 reveals that the average number of size 3
papillomas is the same for both LMP-1 positive and LM P-1 
negative mice. No statistically significant difference was o b s e rv e d  
at any time point. Figure 3.8 shows that there are on a v e rag e ,  
more size 4 papillomas on the LMP-1 negative mice than on th e  
LMP-1 positive mice. Although this difference is easily a p p a r e n t  
from figure 3.8, no statistically significant difference w a s  
observed until week 25 of the study. From week 15 of t r e a tm e n t  
to week 35 of treatment, there are consistently higher a v e ra g e  
num bers of size 4 papillomas on the LMP-1 negative m ice  
compared to the LMP-1 positive mice. However, as can be seen in
figure 3.5 there are fewer LMP-1 positive mice in the s tu d y
during this period and certainly some of these mice had to b e  
rem oved because of home office regulations regarding th e  
size/number and positioning of papillomas.
8 5
Comparison of size 2 papilloma load between LMP-1
positive and LMP-1 negative control groups
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LMP-1 NEGATIV
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F igure 3.6
This graph shows the average number of papillomas of size 2
( >  0 .2 c m 2 <  0 .5 c m 2) for both of the experimental groups at each 
week of the study. Error bars show the standard error of the mean 
for these figures. The analysis was terminated at week 55 of the 
s tu d y .
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Comparison of size 3 papilloma load between LMP-1
positive and LMP-1 negative control groups
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F igure 3.7
This graph shows the average number of papillomas of size 3 
( >  0 .5cm 2 <  1.0cm2) for both of the experimental groups at each 
week of the study.
Error bars represent standard error of the mean.
N.B. There were markedly fewer size 3 papillomas than size 2 in 
general, hence the expanded vertical axis.
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Comparison of size 4 papilloma load between LMP-1
positive and LMP-1 negative control groups
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F igure 3.8
This graph shows the average number of papillomas of size 4
( >  1 .0 cm 2) for both of the experimental groups at each week of the
study.
Error bars represent standard error of the mean.
N.B. There were markedly fewer size 4 papillomas than size 2, hence 
the expanded vertical axis.
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3B.2 .2  Conversion of  papil loma to c a r c i n o m a
Whilst papillomas are attached to the dorsal skin via a 
“stalk” (easily moved by finger), carcinomas appear flat and a re  
almost flush to the skin surface (figure 3.9). Papilloma a n d  
carcinoma were not always easily distinguishable by eye, b u t  
closer inspection of the attachm ent of the lesion fac i l i ta ted  
distinguishing the type of lesion. For example, a lesion attached to  
the body by a “stalk” which could be “wobbled” was classed as a 
papilloma and this classification was confirmed by s u b s e q u e n t  
histopathology analyses of tissue sections. If the lesion was f i rm ly  
attached over a larger area, in general this proved to be a 
carcinoma and was recorded as such. Most carcinomas were eas i ly  
identified by a large area of necrosis on their surface some o f  
which were open wounds. Mice were sacrificed on the advice o f  
the animal technicians based on home office regulations.
Formation of carcinomas was recorded for all mice in th e  
study. Figure 3.10 shows the average num ber of carcinomas p e r  
mouse through the test period. In general, soon after ca rc in o m a  
formation it was necessary to remove the mice from the s tu d y , 
either because of excessive papilloma load or because of the size 
or location of the carcinoma. As such, the numbers of ca rc in o m as  
formed is artificially low (for both LMP-1 +ve and LMP-1 - v e  
mice). Nevertheless, the average numbers formed in LM P-1 
positive mice (3 .65/m ouse) is slightly higher than the LM P-1 
negative mice (2.81/mouse).
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Comparison of carcinoma load between LMP-1
positive mice and LMP-1 negative control groups
LMP-1 POSITIVE
LMP-1 NEGATIVE
P  Po 3- o
5
.000000
1-
©o.
co 2 -
Eoc
oI-
COo
c
CO
©
E
Treatment Period
© © ©© © ©
VO
week of treatment
Figure 3.10
Each week the number of carcinom as arising on each  individual 
m ouse w as counted. The m ean carcinoma load for each  week was 
then calculated by taking the total num ber of carcinom as in each 
group, including the last recorded carcinom a scores  for mice 
sacrificed due to Home Office guidelines, and dividing by the 
num ber of mice in each  group.
This graph indicates the average  carcinom a load for both of the 
experimental groups at each week of the study. The graph shows 
that there is no clear difference between the  two groups.
Error bars represent standard error of the m ean.
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In order to estimate the conversion rate of papilloma to  
carcinoma the carcinoma load was compared to the p a p il lo m a  
load. A note of the m axim um  number of papillomas formed on 
each individual mouse (which was generally greater than th e  
num ber of papillomas on the mouse at death) as well the to ta l  
num ber of carcinomas on that same individual when it w a s  
sacrificed was made. From this the conversion rate for each m o u se  
was calculated and the mean is shown in tables tables 3.1 and 3.2. 
The average percentage conversion for LMP-1 negative con tro ls  
was 15.40% and the percentage conversion for LMP-1 p o s i t iv e  
mice was 11.05%. Although the percentage conversion of b e n ig n  
papilloma to malignant carcinoma appears higher in the LM P-1 
negative mice, much of this difference can be attributed to a 
single mouse, 53F.187, that only ever developed one single  
papilloma which subsequently converted to carcinoma. This g ives 
a misleadingly high 100% conversion for this particular mouse. As 
an outlying value, it is statistically acceptable to consider th e  
average figure whilst discounting this one mouse, giving a f ig u re  
of 12.15% for LMP-1 negative mice compared to 11.05% in  
positive mice. There was no significant difference between th e s e  
conversion rates when assesed by the two sample T-test. Both 
LMP-1 positive and LMP-1 negative mice have conversion r a t e s  
apparently higher than the previously published rates of 5-10%.
3B.2.3 Study of carcinomas fo rm e d
As described in the materials and methods, carcinomas w e r e  
excised immediately following sacrifice of the animal. Some o f 
these were taken into tissue culture in order to derive cell l ines  
(7B.2.1). Where possible, sections from all of the carcinomas a n d  
some of the papillomas were snap frozen and stored at -70°C fo r  
m olecular analysis and similarly sections from all of th e  
carcinomas and some of the papillomas were placed in fixative fo r  
h istopathological analysis.
The carcinomas in fixative were sectioned and h a e m a to x y l in  
and eosin (H+E) stained. The process of a papilloma converting to a 
carcinoma can be broken down into many stages based upon th e  
appearance of the tumour. Papillomas have been assigned to fo u r  
groups, from the well d ifferentiated  type 1 through to the less  
well d ifferentiated  type 4 with high proliferative ac tiv ity , 
necrosis, and the beginnings of progression to Squamous Cell 
Carcinoma (SCC). Keratoacanthom a represents a separate group of 
lesions and resembles a cup or saucer shaped lesion with m a s se s  
of overlaid keratin. Squamous cell carcinomas are divided into 4 
groups also. Unlike papillomas there are no masses of k e ra t in
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produced and there are clear indications of a breakdown in 
normal epithelial tissue structure. Well differentiated SCC’s a r e  
classified as type 1 and poorly d ifferentiated  as type 4 w h e re  
there is very little evidence of differentiation and o rgan isa t ion . 
The amount of invasion into subcutaneous tissue and m u sc le  
increases from SCC type 1 to type 4. The spindle cell t u m o u r  
represents the final stage of tumour progression where th e  
tumour becomes more aggressively invasive and has lost m a r k e r s  
of normal epithelium. The tumour takes its name from th e  
“spindle” shape of the cells showing no epithelial organisation. A 
review of some of these stages can be found in Bogovski, 1994.
In total 111 suspected carcinomas were sectioned and H+E 
stained. These included 51 tumours from 14 LMP-1 positive m ice, 
and 60 tumours from 20 LMP-1 negative control mice. LM P-1 
positive mice had more definitive carcinomas amongst the 5 1 
tumours counted than did the LMP-1 negative controls. Table 3.3 
shows the distribution of tumour types after h is to pa tho log ica l  
exam ination amongst those counted. As can be seen 70% of th e  
tumours counted from the LMP-1 positive group proved to b e  
carcinoma, whereas only 51% of the tumours counted from th e  
LMP-1 negative group were classified as carcinoma. These les ions 
which were classified as carcinoma by gross observation and y e t  
appeared to be papilloma by histopathology may have been in th e  
process of converting. Most lesions contain mixtures of ca rc in o m a  
grades and papillomatous areas, and it could be in these that a
carcinoma region was missed in the diagnostic section. 
A lternatively they may have been late stage papilloma a n d  
misdiagnosed at the gross level. If this is the case, then th e  
difference noted between the carcinoma averages (higher in th e
LMP-1 positive mice) would be greater, while the conversion r a t e  
difference (slightly higher in the LMP-1 negative group) would b e  
less.
2/51 tumours were spindle cell carcinoma in the LM P-1
positive group with 1/60 spindle cell carcinoma in the LM P-1
negative control group. As previously mentioned, a n im a l  
technicians have advised when a mouse was to be sacrificed a n d  
as a result full carcinogenic progression could not be followed in  
many cases. However, formation of this highly m alignant v a r i a n t  
of skin carcinoma is rare with reported incidences of 0 . 0 7 /m o u s e  
in DMBA+TPA treated SENCAR mice (Klein-Szanto et a l ., 1989). The 
frequency is not dramatically increased in LMP-1 mice c o m p a re d  
to controls.
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T ab le  3.3:- Summary of the types of tumour developing on LMP- 
1 positive and LMP-1 negative mice following chemical carcinogen 
I regime 3 treatment (DMBA + TPA), indicating the number of
: tumours in each category and the percentage of the total.
! i P K C l C2 C3 C 4 Sp.C
LMP-1
+
12
(24%)
2
(4%)
2 0
(40%)
9
(18%)
5
(10%)
1
(2%)
2
(4%)
LMP-1 2 7
(45%)
2
(3%)
1 6
(27%)
4
(7%)
6
(10%)
4
(7%)
1
(2%)
KEY:-
P =  P a p i l lo m a  
K =  K e r a to a c a n th o m a  
' C l - 4 =  S q u a m o u s  cell c a rc in o m a  g ra d e  1-4
| S p .C =  S p in d le  cell c a rc in o m a
Iii
i
|
iI
i
I
I
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T ab le  3.4:- Description of primary carcinoma cell lines and the
carcinomas they were derived from.
C e ll
L i n e
L M P C a r c i n o m a
s i z e
C a r c i n o m a
t y p e
Cell L in e  
A p p e a r a n c e
F 1 9 1  a + 1.3 cm 2 3 S pindly  with very long 
p s e u d o p o d ia  ( a r m - l ik e  
p r o j e c t i o n s )
F 2 0 4 - 1.2cm 2 2 S p ind ly  w ith  shor t  
p s e u d o p o d ia  e x t e n t io n s
F 2 1 7 - 0 .7 c m 2 3 Spindly  with very long 
p s e u d o p o d i a
F 2 2 6 a + 2 .0 c m 2 2 M ix  of sp indly  ce lls  with 
long  pseudopod ia ,  and 
c u b o i d a l ( n o n - s p i n d l v )  c e l l s
F 2 2 6 b + 1.0 cm 2 1 C ubo ida l  w ith s ing le  
p r o t r u s io n  ( s p e r m - l ik e )
F 2 2 6 c + 0 .7 c m 2 1 C uboida l  with long 
p s e u d o p o d i a
F 2 3 4 a + 1.2 cm 2 3 Spind ly  but m ore  cuboidal 
than long and thin
F 2 7  8 a + 2 .0 c m 2 Sp S p in d ly  ( s p e r m - l ik e )
F 2 7 8 b + 1.5 cm 2 2 S pindly  with long 
p s e u d o p o d i a
F 2 7 9 + 2 .0 c m 2 3 S pindly  but m ore  cuboidal 
than long and thin
NB:- All carcinomas were Squamous cell carcinomas except F278a 
which was a Spindle (Sp) cell carcinoma.
LMP-1 +ve LMP-1 -ve
5 3 F . 1 9 1 A 5 3 F . 2 0 4
5 3 F . 2 2 6 A 5 3 F . 2 1 7
F ig u re  3 . 1 1 : -  Exampl e s  of  s o m e  of  the p r i m a ry  cell l i n e s  
g e n e r a t e d  f r o m e xp lan t ed  c a r c in o ma s .  The  t u m o u r s  we r e  e x c i s e d  
u n d e r  s ter i le  condi t i ons  into e x p l an t  m e d i u m  for t r a n s p o r t  f r o m  
the an i ma l  house .  These  were  then c h o p p e d  up and left  to a d h e r e  
to t i s sue  c u l t u re  f lasks (in g r o w i n g  m e d i u m )  for  2 w e e k s .  
T h e r e a f t e r  cel l s  began to grow out  f rom the t u m o u r  and t h e  
t u m o u r  l umps  could be d i s ca rd ed .  Once the cell  line w a s  
e s t a b l i s h e d  it was m a i n t a i n e d  as d e s c r i be d  in sec t ion 7B.2 .1 ,  
7B.2 .3  and 7B.2 .4
8 LMP-1 positive and 2 LMP-1 negative carcinoma cell l ines  
were established from excised carcinomas from eight d i f f e r e n t  
mice (See table 3.4). The original carcinomas varied in size f ro m  
0 .7 c m 2 to 2 c m 2 and were subsequently shown to represent a 
range of SCC from type 1 to type 3 plus one spindle cell carcinoma. 
There were no obvious differences between cell lines d e r iv e d  
from LMP-1 expressing or non-expressing tumours (figure 3 .11). 
All grew rapidly in both the 20%FCS growing medium used to  
establish the cell line and the 10%FCS medium used to m a in ta in  
the cell line, although proliferation rates were not d e te rm in e d .  
The cells were long and thin in the typical spindle m o rp h o lo g y  
with numerous pseudopodia. Unlike normal epithelial cells w h ich  
grow in the characteristic  “cobblestone” appearance with d is t in c t  
cellxell boundaries, the carcinoma cell lines overlapped a n d  
overgrew each other clearly showing the loss of contact in h ib i t io n  
characterised by epithelial tumour cell lines. With in su f f ic ien t  
time remaining to further characterise the properties of th e s e  
carcinoma cell lines, they were frozen down for storage u n t i l  
analysis could be conducted and represent a useful source o f  
m a te r ia l .
3 B . 2 . 4  Statist ical  ana lys is  o f  R e g im e  1
Due to the nature of this experim ent it was ex cep tio n a l ly  
difficult to find a statistical test which would allow me to a n a ly se  
figure 3.4 as a whole e.g. looking at significant difference in r a t e s  
of change. After discussion with two statisticians it was d e c id e d  
that the best approach was to analyse each time point s e p a ra te ly .  
With Professor Wardlaw of the Cell Biology department, I used the 
Rankits program to determine if the data for each time point w a s  
randomly distributed. An example of a Rankit plot is given below , 
and for each point examined the data was found to be n o rm a lly  
d is t r ib u te d .
As the data was normally d istributed this allowed a tw o  
sample T-test to be applied (on the advice of Prof. Wardlaw). T h e  
data was entered into the Minitab computer program d a ta  
spreadsheet. This is a statistical analysis program which is c ap a b le  
of applying many different statistical tests on raw data. E xam ples 
of the results from a two sample T-test are also given below.
R a n k i ts  p l o t : -
If the data does not deviate significantly from the straight line i t  
can be assumed that the data is normally distributed. This is an
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example of a rankits plot for the LMP-1 positive mouse group a t  
week 15.
Figure 3 .12:-
2.5 --
o . o - -
- 2 . 5 - -
400 10 20 30
observat ions
Basic S t a t i s t i c s  + Two sa m p le  T - t e s t : -
Minitab has a function that will give the following basic s ta tis t ic s  
on the data entered and the results of a two sample T - te s t  
analysis. These results are from week 15 data.
Two Sample T-test:-
For W kl5  LMP-1 positive v ’s W kl5  negative controls
N MEAN STDEV SE MEAN 
W kl5 + 28 22.43 9.77 1.8
W kl5 - 30 16.70 8.32 1.5
Using 95% confidence limits, T-Test results :- 
T= 2.40 P=0.020 DF= 53
Descriptive statistics for Week 15:-
N MEAN MEDIAN TRMEAN STDEV SEMEAN
W kl5 + 28 22.43 25.00 22.50 9.77 1.85
W kl5 - 30 16.70 17.50 16.77 8.32 1.52
MIN MAX Qi Q3
W kl5 + 3.00 40.00 13.75 29.75
W kl5  - 0.00 33.00 12.00 22.50
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3 B .3  C hem ica l c a rc in o g e n  reg im e  2:-TPA  for 20
w e e k s
To check if LMP-1 can substitute for DMBA induced H a - ras  
mutation, mice were treated with TPA for twenty weeks w i th o u t  
prior DMBA initiation.
Of the 35 mice that were put in the TPA treatm ent course , 
11/15 LMP-1 positive and 17/20 LMP-1 negative mice r e m a in e d  
46 weeks after the first TPA treatment, when the experim ent w a s  
terminated. Of the seven mice that were removed from the s tu d y , 
four had to be sacrificed due to anal prolapses and three died of
unrelated causes (See tables 3.5a+b). Prolapses are quite co m m o n
in topically challenged mice because the acetone fac ili ta tes  
spreading of the chemicals all over the treatm ent area (d o rsa l  
skin). However, some spreading to the anus is unavoidable a n d  
can cause eventual problems (such as prolapse). These mice (4  
LMP-1 positives and 3 LMP-1 negatives) were sacrificed b e fo re  
the end of the 20 week treatm ent period and none of these m ice  
had any signs of papillomas.
After 46 weeks none of the LMP-1 positive mice h a d  
developed any papillomas (table 3.5a). Surprisingly, 1/17 LM P-1 
negative mice (53F.308) had one single size 2 papilloma on its
dorsal skin at the termination of the experiment, which h a d  
appeared at week 29 of treatm ent and remained throughout th e  
observation period (See table 3.5b). Two other LMP-1 n e g a t iv e  
control mice (53F.306 and 53F.315) had displayed sing le
papillomas during the experiment, appearing at 16 and 14 w e e k s  
respectively, but these subsequently  regressed and d i s a p p e a r e d  
(See table 3.5b).
These results indicate that LMP-1 expression in th e s e  
transgenic mice cannot substitute for DMBA treatm ent and h e n c e  
Ha - ras  activation.
T a b l e  3 . 5 a : -  LMP-1 positive mice in chemical  c a r c i n o g e n
t rea tm e n t  reg ime 2 (TPA promotion  twice weekly  for 20 w e e k s
without prior D M B A  initiation).___________________
M o u s e  
i . d .
Age at  
s t a r t  of 
t r e a t ­
m e n t
LMP Wk of 
t r ea tment  at  
d e a t h
1 s t
p a p s
( w k )
m a x .
p a p s
5 3 F . 2 9 4 9 . 5 + 4 6 / /
53 F . 2 9 5 9 . 5 + 4 6 / /
53 F . 3 00 9 . 5 + 10* / /
5 3 F . 3 0 9 8 + 4 6 / /
5 3 F . 3 1 1 8 + 4 6 / /
5 3 F . 3 1 7 8 + 40* / /
5 3 F . 3 2 2 8 + 4 4 / /
53 F .3 23 8 + 4 4 / /
5 3 F . 3 2 7 8 + 4 4 / /
53 F . 3 28 8 + 4 4 / /
53 F . 3 49 8 + 3 8 / /
53 F .3 50 8 + 3 8 / /
5 3 F . 3 5 2 8 . + 3 8 / /
5 3 F . 3 5 3 8 + 8* / /
53 F . 3 5 4 8 + 24* / /
* = mouse removed from study due to ill health 
/ = Zero papillomas
T a b le  3 .5b:-  LMP-1 negative mice in chemical  carc inogen
trea tment  regime 2 (TPA promotion twice weekly for  20 weeks
without  prior D M BA  initiation).______________
M o u s e  
i . d .
Age at 
s t a r t  of 
t r e a t ­
m e n t
LMP Wk of 
t r e a t ­
ment  at  
d e a t h
1 s t
p a p s
( w k )
m a x .
p a p s
5 3 F . 2 9 8 9 . 5 4 6 / /
5 3 F . 3 0 2 8 4 6 / /
5 3 F . 3 0 3 8 4 6 / /
5 3 F . 3 0 4 8 4 6 / /
5 3 F . 3 0 5 8 4 6 / /
5 3 F . 3 0 6 8 2 9 * 1 6 1
5 3 F . 3 0 7 8 4 6 / /
5 3 F . 3 0 8 8 4 6 2 9 1
5 3 F . 3  10 8 4 6 / /
5 3 F . 3  12 8 4 6 / /
5 3 F . 3  13 8 4 4 / /
5 3 F . 3 1 4 8 4 4 / /
5 3 F . 3 1 5 8 4 4 1 4 1
5 3 F . 3 1 6 8 3 5 * / /
5 3 F . 3 1 9 8 4 4 / /
5 3 F . 3 2 0 8 4 4 / /
5 3 F . 3 2 1 8 4 4 / /
5 3 F . 3 2 4 8 4 4 / /
53 F .3 25 8 15* / /
5 3 F . 3 2 6 8 - 4 4 / /
* = mouse removed from study due to ill health 
/ = Zero papillomas
1 0 0
3 B . 4  C h e m i c a l  c a r c i n o g e n  r e g i m e  3:- DMBA a l o n e
The PyLMP-1 transgenic mice have a phenotype o f  
epidermal hyperplasia which is rem arkably  similar to t h a t  
described for mouse dorsal skin following TPA t r e a tm e n t  
(DiGiovanni, 1992). TPA has many effects on mouse dorsal sk in  
(described earlier), but if its principle function as a tu m o u r  
prom oter is to increase proliferation, then it might be p o ss ib le  
that LMP-1 could substitute for the actions of TPA. To put this to  
the test LMP-1 positive mice and their LMP-1 negative con tro l  
siblings were given a one off treatm ent with the initiator DMBA. 
This experim ent was to address whether LMP-1 can act in th e  
promotion stage of carcinogenesis, to promote tumour fo rm a tio n  
in conjunction with DMBA initiated cells.
Of the 30 mice which received the DMBA treatment, 1 4 /1 5  
LMP-1 positives and 12/15 LMP-1 negatives remained when th e  
experim ent was term inated 35 weeks after DMBA initiation. Of 
the 4 mice which were removed from the study (1 LMP-1 p o s i t iv e  
mouse and 3 LMP-1 negative mice), 3 had prolapses and 1 w a s  
found dead. None of these 4 mice had developed any signs of 
papillomas by the time they were removed from the sa m p le  
population (See tables 3.6a+b).
None of the LMP-1 negative control mice showed any signs 
of papillomas forming throughout the observation period and no  
tumours were evident at the end of the experiment. In co n tra s t ,  
4/14 LMP-1 positive mice had developed small (size 2- see  
section 3B.1) papillomas by the end of the experim ent (See ta b le  
3.6a). 2 mice (53F.367 and 53F.388) had single papillomas, a n d  
the other two (53F.361 and 53F.368) had 5 and 2 p a p il lo m a s  
respectively. Mice 53F.361 and 53F.388 also had the “ringta il” 
phenotype which often appears in the LMP-1 positive mice w ith  
maturity, and the developm ent of this phenotype may h a v e  
coincided with the appearance of the papillomas (date o f  
appearance of ringtail phenotype not noted accurately). Som e 
papillomas were also noted in the tail base region. Although th e  
DMBA is not applied directly to the tail, some chemical will h a v e  
reached the base of the tail because the acetone helps to s p re a d  
the chemical all over the back thereby possibly initiating cells in 
the tail base region also.
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T a b le  3 . 6 a : -  LMP-1 positive mice in chemical
treatment regime 3 (One single application of  DMBA).
M o u s e
i . d .
Age at  
s t ar t  of 
t r e a t ­
m e n t
LMP Wk of 
t r e a t ­
ment  at  
d e a t h
1 s t
p a p s
( w k )
m a x .
p a p s
53 F .3 55 8 + 3 5 / /
5 3 F . 3 5 8 8 + 3 5 / /
5 3 F . 3 5 9 8 + 3 5 / /
53 F .3 6 1 8 + 3 1 2 8
5 3 F . 3 6 2 8 + 2 3 * / /
5 3 F . 3 6 5 8 + 3 1 / /
5 3 F . 3 6 6 8 + 3 1 / /
5 3 F . 3 6 7 8 + 3 1 3 1 1
53 F .3 6 8 8 + 3 1 2 8
5 3 F . 3 7 5 8 + 3 () / /
5 3 F . 3 7 6 8 + 3 0 / /
5 3 F . 3 7 7 8 + 3 () / /
5 3 F . 3 8 5 8 + 2 6 / /
5 3 F . 3 8 7 8 + 2 6 ./ /
5 3 F . 3 8 8 8 + 2 6 2 3 1
* = mouse removed from study due to ill health 
/  = Zero papillomas
c a r c i n o g e n
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T a b l e  3 . 6 b : -  LMP-1 negat ive mice in chemical
t reatment regime 3 (One single application of  DMBA).
M o u s e
i . d .
Age at  
s tar t  of 
t r e a t ­
m e n t
LMP Wk of 
t r e a t ­
ment  at  
d e a t h
1 s t
p a p s
( w k )
m a x .
p a p s
53 F . 3 5 6 8 - 16* / /
5 3 F . 3 5 7 8 - 3 5 / /
53 F . 3 6 0 8 - 3 5 / /
53 F . 3 6 9 8 - 9* / /
5 3 F . 3 7 0 8 - 18* / /
5 3 F . 3 7 1 8 - 3 0 / /
5 3 F . 3 7 2 8 - 3 0 / /
5 3 F . 3 7 3 8 - 3 0 / /
5 3 F . 3 7 4 8 - 3 0 / /
5 3 F . 3 8 0 8 - 2 6 / /
5 3 F . 3 8 1 8 - 2 6 / /
5 3 F . 3 8 2 8 - 2 6 / /
5 3 F . 3 8 3 8 - 2 6 / /
5 3 F . 3 8 4 8 - 2 6 / /
53 F . 3 8 6 8 - 2 6 / /
* = mouse removed from study due to ill health 
/ = Zero papillomas
c a r c i n o g e n
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3 B .5  C hem ica l c a rc in o g e n  reg im e  4:- DMBA and  1st
s tage  (4 w eek) TPA t r e a t m e n t .
DMBA initiation and prolonged TPA promotion are r e q u i r e d  
for papillomas and carcinomas to form in wild-type, su sce p tib le  
strains of mice (Brown and Balmain, 1995). Limiting th e  
prom otion stage of chemical carcinogenesis to 4 weeks is 
insufficient for tumour formation. Promotion takes on average 8 
weeks to yield papillomas in normal mice therefore the protocol of 
DMBA and limited TPA will not give rise to tumours in n o rm a l  
mice (Brown and Balmain, 1995). This treatm ent however fo rm s  
the basis for identifying second stage promoters (as described in 
section 3A. 1.3), which alone are not sufficient to induce lesions
The results from the analysis of the ability of LMP-1 to ac t  
as a promoter (regime 3- section 3B.4), perhaps suggest that LM P- 
1 in these mice can act as a weak or second stage promoter. I n 
addition, while LMP-1 increases the papilloma load (in regime 1), 
no evidence that LMP-1 can act as an initiator was r e v e a le d  
(regime 2). Together this suggests that LMP-1 may act as a 
prom oting agent of carcinogenesis. In a prelim inary study to t e s t  
if LMP-1 acts as a second stage promoting agent, 7 LMP-1 p o s i t iv e  
and 6 LMP-1 negative mice were subjected to a once on ly  
trea tm ent of DMBA followed by 4 weeks of TPA t r e a tm e n t  
(defined as 1st stage promotion) (Hennings and Boutwell, 1970). 
This analysis was conducted at a late stage in this project, and i t  
was not possible to conduct a more extensive program with m o re  
mice. The work was done with the co-operation of la b o ra to ry  
technician Donald H. Campbell (DHC).
None of the 6 LMP-1 negative mice developed any les ions 
by 16 weeks after DMBA treatment. In contrast, 7/7 of the LM P-1 
positive mice developed papillomas by this time point (See ta b le  
3.7). The first papillomas to appear were noted at week 9 and th e  
mean time to papilloma formation was 11 weeks. Taking w e e k  
sixteen as example, four mice (53F.402, 404, 409, and 412) h a d  
one single small papilloma in size range 1. A further two m ice  
(53F.410 and 411) had between 1 and 6 papillomas from size 
ranges 1-3. The final mouse (53F.401) had several (10) small size 
one papillomas and one size 2 papilloma. This particular m o u se  
which displayed the greatest number of lesions also had th e  
“ringtail” phenotype. The ringtail phenotype also correlated w i th  
increased num ber of papillomas in the DMBA alone regime. T he  
num ber of papillomas on the LMP-1 positive group continued to  
rise during the observation period whilst no papillomas were e v e r  
noted on the LMP-1 negative group (figure 3.12). This increase in
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papilloma load persists despite lack of continued TPA t r e a tm e n t  
None of these papillomas showed conversion to carcinoma (as yet)
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T a b l e  3 . 7 : -  LMP-1 positive mice and LMP-1 negat ive  mice in
chemical  carcinogen treatment regime 4 (One single applicat ion o f
M o u s e  
i . d .
Age at  
s tar t  of 
t r e a t ­
m e n t
LMP Wk of 
t r e a t ­
m e n t
1 s t
p a p s
( w k )
m a x .
p a p s
( s o
f a r )
5 3 F . 4 0 1 8 + 1 6 9 1 1
5 3 F . 4 0 2 8 + 1 6 1 0 1
5 3 F . 4 0 4 8 + 1 6 9 1
53 F . 4 0 9 8 + 1 6 9 1
5 3 F . 4 1 0 8 + 1 6 9 6
5 3 F . 4 1 1 8 + 1 6 9 3
5 3 F . 4 1 2 8 + 1 6 1 2 1
5 3 F . 4 0 3 8 - 1 6 / /
53 F . 4 05 8 - 1 6 / /
5 3 F . 4 0 6 8 - 1 6 / /
5 3 F . 4 0 7 8 - 1 6 / /
5 3 F . 4 0 8 8 - 1 6 / /
5 3 F . 4 1 3 8 - 1 6 / /
These records are shown up to 16 weeks of the study, which is 
still in progress.
/ = Zero papillomas
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Comparison of mean papilloma load between LMP-1 
positive and LMP-1 negative mouse groups following 
DMBA initiation and limited (4 week) TPA promotion.
6
LMP-1 POSITIVE
LMP-1 NEGATIVE
5 @@@
4
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2
1
Tr e a t me n t  
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0
o ©
M OTfo
F ig u re  3 .12  W eek  o f  s tu d y
This graph shows the formation of papillomas on LMP-1 positive 
mice compared to the complete lack of lesions arising on LMP-1 
negative mice. Every week (except week 16) Donald H. Campbell 
(DHC) counted the total number of papillomas on each individual 
mouse. From these, the mean papilloma score per week for each 
group was calculated and used to plot the above graph.
Error bars represent standard error of the mean 
N.B.
* at week 16 the scoring was done by m yself and not DHC, perhaps indicating 
that consistency in the scoring protocol is important.
@ at weeks 28-30 the mice under study were moved to a new animal house and 
scoring counts was not possible. The mean score for week 27 is shown for these 
w eeks.
$ at week 35 the mice were shaved for the first time since week 27 revealing 
several more small papilomas which the fur had previously hidden. This 
explains the sudden rise in mean scores.
1 0 7
2 £ D is c u s s io n  o f  c h a p t e r  3 .
Chemical carcinogen treatm ent regime 1 was designed to  
investigate the potential for LMP-1 to enhance the process o f 
carcinogenesis. As the protocol of DMBA initiation followed b y  
complete TPA promotion will yield papillomas and carcinomas on 
all susceptible strains of mice, this regime was used to analyse th e  
role of LMP-1 in all stages of tumour progression, from early to  
late.
The first lesions appeared on the LMP-1 positive group o n e  
week before they were noted on the negative control group. W h e n  
the mean time to lesion appearance was calculated for b o th  
groups the LMP-1 positive group achieved a mean time to onset of 
one week before the negatives. This suggests that LMP-1 m a y  
reduce the latency to lesion formation.
The number of papillomas on both groups rose for th e  
duration of the TPA treatment. Here the LMP-1 positive m ice  
developed more papillomas than their negative control l i t t e rm a te s  
and this difference proved to be statistically significant. T h e re fo re  
the LMP-1 positive group have an increased papilloma load  
compared to their negative control littermates.
These two results dem onstrate  that LMP-1 is acting to  
augment the action of the chemical carcinogens in lesion  
formation. Papilloma formation is a result of clonal expansion o f  
an initiated cell which has increased its rate of proliferation with a 
concomitant decrease in differentiation (Brown and Balm ain,
1995). Since the LMP-1 positive mice develop more papillomas a t  
a faster rate than the LMP-1 negative mice, this could suggest that 
LMP-1 can act as an initiator, or a promoter. Results from c h a p te r  
2 gave direct evidence that LMP-1 increases proliferation w h ich  
would support the idea that LMP-1 may act as a promoting agent.
Results from regime 2 dem onstrate  that LMP-1 (in th e s e  
mice) cannot substitute for DMBA treatm ent (and th e r e f o re  
activation of Ha-r«,y ) and is thus not acting as an initiating a g e n t  
in carcinogenesis. This was perhaps unexpected given th e  
similarities between LMP-1 and H a -ras  expressing SCC12F cells 
(Dawson et al ,  1990). It has also been suggested that LM P-1 
(signalling through the TRAF family) upregulates the expression of 
the EGFR (Miller et al ,  1997). This pathway is linked to the r a s  
pathway by p55Shc (Miller et al ,  1995).
Regime 3, where mice were initiated with DMBA but n o t  
followed up with TPA promotion, was designed to investigate th e  
possibility that LMP-1 could act as a promoter. Here 4/14 LM P-1 
positive mice developed papillomas. This result alluded to th e
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possibility that LMP-1 may be a tumour promoter, but would b e  
classed as a weak or second (late) stage promoter. Taking th is  
analysis further, mice were subjected to a treatm ent re g im e  
(initiation and limited (4 week) promotion) which is insufficient to  
yield papillomas in normal mice. The results from regime 4 
dem onstra tes that LMP-1 can act as a second stage p ro m o te r .  
Here 100% of the LMP-1 mice developed papillomas whereas 0% 
of the negative control littermates did so. The overall number o f 
papillomas formed in regimes 3 and 4 confirm that LMP-1 is a 
weak prom oter.
Taken together these results dem onstrate  that LMP-1 is a 
weak promoter, and that LMP-1 can act as a second s tag e  
promoter. The level of promotion by LMP-1 might be enhanced if  
the NPC variant of LMP-1 was used to create the PyLM P-1 
transgenic mice. This variant has already been shown to be m o re  
oncogenic than the B95-8 prototype LMP-1. Furthermore, th e  
level of expression of LMP-1 in line 53 is known to be low a n d  
this might effect the level of promotion by LMP-1. Finally th e  
observed suprabasal expression (chapter 2) may be relevant to  
the degree of promotional activity. Basal layer expression m ig h t  
have a stronger promoting effect. These points may also b e  
relevant to the observed lack of initiating activity by LMP-1.
These results may have direct relevance to the disease s ta te  
of NPC. Here an association between salted fish and incidence o f  
NPC has been documented. The salting process gives rise to  
volatile nitrosamines which have been shown to have tu m o u r  
promoting ability (Zou and Landolph, 1991; Yu et al ,  1989). T he  
combination of the tumour promoting ability of the n i t ro s a m in e s  
and the tumour promoting ability of LMP-1 may be critical in th e  
pathogenesis of NPC.
Regime 1 also revealed that LMP-1 did not influence th e  
conversion rate of papilloma to carcinoma or squamous cell 
carcinoma to spindle cell carcinoma in these studies. These r e s u l ts  
suggest that LMP-1 does not alter the course of ca rc in o g en es is  
once it has reached the papilloma stage. However, it may still b e  
required to promote proliferation. Examination of LM P-1 
expression in NPC cases shows that the protein is not c o n s is te n t ly  
detected. It has been proposed that LMP-1 is active early on  
during disease progression but is then switched off. LM P-1 
expressing NPC’s were shown to grow faster than n o n -e x p re s s in g  
NPC’s (Hu et al., 1995) suggesting that LMP-1 in c re a se s
proliferation early may not influence progression at later stages.
The dem onstra tions that LMP-1 is involved in the e a r ly  
stages of carcinogenesis may also be important concerning LM P-1 
detection in NPC samples. Perhaps the reason less than 100% of
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NPC cases express LMP-1 is because the action of LMP-1 has b e e n  
superseded during progression.
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CHAPTER 4;- Crossbreeding analysis of th e
interaction between LMP-1 and Ras. LMP-1 
and TGFB. and LMP-1 with loss of p53 .
4 A I n t r o d u c t i o n
Because H a -ras  , TGFJ31, and p53 have been shown to p la y  
im portant roles in carcinogenesis, including chemically in d u c e d  
skin carcinogenesis, transgenic mice harbouring the activated ras  
gene, TGF01, and null p53 were chosen for cross-breeding s tu d ie s  
with the LMP-1 mice. Therefore the general function of each  
protein is described in greater detail in the following sections.
4A.1 The Ha-Ras p r o t e i n
Studies of chemical carcinogen induced carcinomas of m o u se  
epidermis have shown that mutation in the H a -ras  gene at th e  
cellular level is a major initiating event in carcinogenesis. F u r th e r  
loss of WT H a -ras  alleles coupled with duplication of m utant H a- 
ras is also im portant in the progression from papilloma to  
squamous cell carcinoma to spindle cell carcinoma.
Ha-ras is one of four 21kDa proteins known collectively as  
the p21ras proteins. The other three ras family members are Ki- 
ras , N -ras , and R -ras  (Reviewed in McCormick, 1989). The r a s  
proteins bind guanine nucleotides with high affinity and act as 
GTPase's. Ras cycles between an active GTP-bound form and a n  
inactive GDP-bound form and serves as a molecular switch in  
signal transduction. Therefore ras proteins play an im portant ro le  
in the normal growth of cells. However, many cancers have b e e n  
identified where a mutation in ras has led to it b e in g  
constitutively active indicating that the regulation of ras is 
carefully monitored under normal circumstances.
p21 ras  is activated upon receptor tyrosine k in a s e  
stimulation (Reviewed in Pronk, 1994). For example, both EGFR 
and IGF-1R stimulation activate p21 ras measured by a shift f ro m  
rasGDP to rasGTP. This activation is rapid and parallels th e  
autophosphorylation of the receptor. The level and duration of ras  
activation depends on the cell type and the growth factor r e c e p to r  
that is activated.
The dissociation of GDP followed by the binding of GTP is 
slow as is the GTPase activity of ras in the hydrolysis of the b o u n d  
GTP. Increasing the guanine nucleotide exchange activity a n d / o r  
inhibiting GTPase activity would therefore result in activation o f  
ras. Both these mechanisms of activating ras are th e re fo re
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carefully controlled (Reviewed in Downward, 1992). GTPase 
activating proteins (GAP's) increase the rate of hydrolysis of GTP 
bound ras, thus keeping ras in a GDP-bound, inactive state. T h ese  
are therefore negative regulators of ras. (Reviewed in Tocque e t  
a l , 1997). The inability of m utant forms of ras to bind to ras-G A P 
would maintain ras in an active state. Inhibiting ras-GAP w o u ld  
also have the effect of maintaining the active state of ras. T he  
common m utation in codon 61 of H a -ras  caused by DMBA
treatment of mouse dorsal skin has the effect of reducing the r a t e  
of hydrolysis of GTP bound Ha-ras by blocking its stimulation b y 
GAP's. Thus, Ha-ras becomes constitutively activated.
Nucleotide exchange factors such as ras-GDP releasing fa c to r  
(ras-GRF), which control the rate of exchange of GDP for GTP, a re  
positive regulators of the ras cycle. Increasing the activity of r a s -
GRF would create more active ras. Activated p21 ras a ssoc ia tes
with the serine threonine kinase raf (via the ras effector reg ion )  
which is normally cytosolic, and translocates it to the p la s m a
m em brane (Leevers et al, 1994). Here raf becomes activated a n d  
phosphoryla tes either directly or indirectly, mitogen a c t iv a te d  
protein k inase-kinase (MAPKK) (Kyriakis et al, 1992). MAPKK is 
then activated and in turn phosphorylates MAP kinase (MAPK) 
causing it to become activated (Reviewed in Geilen et al, 1996). 
This pathway then conveys growth and differentiation signals to  
the nucleus, resulting in appropriate  gene expression for e x a m p le  
fos activation in the transcription factor complex A PI.
It has recently become clear that this linear model for r a s  
mediated signalling is not the only mechanism by which a c t iv a te d  
ras can send information. The PKC pathway has been im p lic a te d  
with an involvem ent in ras signalling which leads to  
reorganization of the actin skeleton (Tocque et al, 1997). The r a s  
story is therefore far from complete and awaits further work on  
downstream effectors of ras signalling.
Activated ras transgenics in a C57B1/6 background w e re  
generated in the laboratory of A.Balmain utilizing a truncated K 
promoter resulting in expression of an activated H a -Ras  oncogene  
in the hair follicles of the epidermis. These mice display a 
phenotype of hyperkeratosis  and developed sebacious a d e n o m a s  
at sites of irritation and wounding. Thus, benign tumours w e re  
frequently  seen on the ears, base of tail and around the eyes. 
These lesions however did not progress to malignancy. When th e  
mice were bred into an FVB strain background the p h e n o ty p e  
became more severe (Personal communication-K. Brown). As e a r ly  
as day 1, some transgenic positives showed signs of p a p i l lo m a to u s  
growth. This phenotype had a 30% penetrance and ranged f ro m  
severe, where large areas of papillomatous growths d e v e lo p e d  
and merged to cover the majority of the body (requiring sacrifice
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of the animal), to mild where very discrete patches o f 
papillom atous growth were observed. Other groups had s im ila r  
results from their transgenic analysis of the in vivo effects of ras  
(Greenhalgh, D.A., et al , 1993 and Leder, A., et al , 1990). T he  
conclusions drawn were that activated ras expression a b ro g a te d  
the need for an initiation step in carcinogenesis, but for tu m o u r s  
to form, promotion events such as wounding were still necessary.
4 A .2  The TGFpi p r o t e i n
The Transforming Growth Factor p (TGFP) family consists o f 
three m ultifunctional peptides with wideranging effects. T h ey  
have been implicated in many cellular processes such as cell 
proliferation and differentiation, embryonic d e v e lo p m e n t ,  
extracellular matrix formation, bone development, wound healing , 
hematopoiesis, and immune and inflam m atory cell r e s p o n s e s  
(Reviewed in Akhurst et al , 1992; and Okragly et a l , P ro m e g a  
Notes No.47). Each of the three isoforms has been h ig h ly  
conserved throughout evolution, suggesting specific roles for each. 
However, they are often co-expressed and it has therefore b e e n  
difficult to define a precise biological role for each in d iv id u a l  
iso fo rm .
TGFp’s are synthesized as biologically inactive l a te n t  
complexes. Active TGFp is processed from the C-terminus of a 
larger peptide, but the remaining portion, known as the la te n c y  
associated peptide, continues to associate non-covalently  w ith  
TGFp and only dissociation from this peptide results in full 
activity. The TGFp proteins bind to sets of two m em brane p ro te in s  
called TGFp receptors (TpRI and TpRII) (Reviewed in M assague ,
1992). TpRI does not bind TGFp when expressed alone but on ly  
when complexed to TpRII and it is thought that TGFp functions to  
recru it TpRI into a stable complex with TpRII (Wrana et al, 1 9 9 2  
& 1994). Signalling occurs through TpRII but this fails to h a p p e n  
in the absence of TpRI. Thus both receptors are essential for b o th  
the binding and subsequent signalling action of TGFp.
TGFpi knockout mice have been g e n e ra te d  (Kulkarni et al,
1993). There was clear embryonic lethality, but 1/3 of the fe tu s e s  
developed to term and appeared clinically normal at b ir th .
However, at 3-4 weeks these mice died showing m a s s iv e
inflam m atory  lesions in many organs, thus suggesting a role fo r  
TGFpi in the homeostatic regulation of the immune re s p o n s e
consistent with previous reports of TGFpi being a p o te n t
im m u no su p p re ss  or.
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There are also several reports of TGFpi t ra n sg e n ic  
overexpression with conflicting results. In one case an e p id e rm a l  
specific expression vector was used which did not express u n t i l  
d l5  of development because T G Fpi overexpression at early s tag es  
of embryogenesis can result in lethality in utero (S e l lh a y e r  et al ,
1993). This gave rise to mice born with a very shiny and ta u t ly  
stretched skin which affected their ability to move and b re a th e .  
BrdU analysis of the skin showed a marked reduction in th e  
num ber of replicating cells in the epidermis and hair follicles. 
Death occurred within 24hrs and it was assumed that TGFpi 
expression was acting as a potent inhibitor of epithelial cell 
proliferation and so, when expression was turned on at d 15 of 
embryogenesis the skin ceased to grow whilst the rest of the b o d y  
continued to grow and stretch the skin.
The opposite result was seen by another group using th e  
K10 prom oter to direct expression of TGFpi to s u p ra b a s a l  
keratinocytes (Cui et al , 1995). In these mice (termed line H) no  
phenotype was observed but BrdU analysis indicated a 2-3 fold  
elevation of DNA synthesis in the epidermis. This could be c au se d  
by a number of factors. Either T G Fpi directly induces proliferation, 
or a lternatively  it induces epithelial d ifferentiation and to  
com pensate for this, proliferation must also increase, thus g iving 
the net result of a normal phenotype. These KlO-TGFpi t ra n sg e n ic  
mice did not exhibit the normal wave of basal keratinocyte  DNA 
synthesis which normally occurs under conditions of p e r tu r b e d  
homeostasis following TPA treatment. Therefore T G Fpi is acting as 
expected in this case, as a negative regulator of growth w h e n  
hyperplasia  is induced. TpRII levels were shown to in c re a se  
following TPA treatm ent and prior to the growth in h ib i to ry  
response to TGFpi. Its level of expression correlated with th e  
growth sensitivity to TGFpi in v iv o  and in v i tro  suggesting t h a t  
TGFpi and TpRII are part of the endogenous h o m eo s ta tic  
regulatory machinery of the epidermis.
This was confirmed when a dom inan t-negative  TpRII w a s  
expressed in the epidermis of transgenic mice (Wang et al, 1997). 
The transgenic mice displayed a thickened and wrinkled sk in  
showing hyperplasia  and hyperkeratosis . BrdU labeling showed a 
2.5 increase in proliferating cells over controls. When the m ice  
were bred to homozygosity, perinatal lethality occurred due to th e  
hyperkerato tic  phenotype. These results therefore confirm t h a t  
TGFpi and TpRII are intimately involved in the m aintenance o f  
ep iderm al hom eostasis.
To study the effect of inducible TGFpi expression r a t h e r  
than constitutive TGFpi expression further transgenic lines w e r e
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created using the K6 promoter. K6 is known to be expressed in a n  
inducible manner in hyperplastic interfollicular epidermis, as w e ll  
as being present in the outer root sheath keratinocytes of h a i r  
follicles. Seven lines of mice were created using an in d u c ib le  
bovine K6 prom oter and either a constitutively activated form o f  
TGFpi or WT TGFpi (Fowlis et a l , 1996). In the lines produced i t  
was intended that TGFpi should only be expressed fo llow ing  
experim ental manipulation such as TPA stimulation through th e  
K6 promoter. Indeed there was no detectable e p id e r m a l  
expresssion of the transgene in any of the lines except line M 5 
which had constitutive, but low level, expression of T G F p i.  None o f  
the lines, including M5, showed any adverse health effects as a 
consequence of the transgene and their skin and hair w e r e  
morphologically and histologically identical to controls. Cell culture 
of K6-TGFP1 transgenic keratinocytes and TPA treatm ent of in ta c t  
dorsal skin both caused the induction of K6 and hence t ra n sg e n ic  
TGFpi expression, and this was highest in line M5. Line M5, l ik e  
that of line H (Cui et al , 1995), showed a 2 fold increase in BrdU 
labelling of untreated dorsal skin compared to controls in d ica t in g  
a positive effect on epidermal proliferation. A positive effect on  
epiderm al proliferation was also m aintained up until 24hr p o s t
TPA trea tm ent after which time the hyperplastic response w a s
attenuated. Therefore, TGFpi induction in this instance is 
negatively regulating keratinocyte proliferation. Thus, TGFpi can  
act as a positive or negative epidermal growth regulator
These experim ents have suitably dem onstra ted  th e
m ultifunctional role of TGFpi in d ifferentiation, p ro l ife ra t io n ,  
em bryogenesis  and im m u ne /in f lam m ato ry  responses. It is n o t  
a ltogether surprising therefore that imbalance of the h o m e o s ta s is  
of the epidermis due to carcinogenesis should involve a l t e r e d  
expression of TG Fpi. For example, TGFpi is rapidly induced in p o s t  
TPA treated suprabasal keratinocytes (Akhurst et a l , 1988) but in  
high risk papillomas and the squamous cell carcinomas that a r is e  
from these papillomas, TGFpi is down regulated (Fowlis et a l ,  
1992; Glick et al ,  1993). Furtherm ore, TGFpi expression in K10- 
TGFpi transgenics acted initially as a tumour suppressor b u t
latterly as a tumour enhancer (Cui et al,  1996). T h e re fo re  
expression of T G Fpi is indeed altered during carcinogenesis.
4 A .3  The p53 protein
p53 has been described as the "guardian of the genom e" 
(Lane, 1992) because of its role following DNA damage to a cell 
leading to apoptosis or a pause in cell cycle and repair. When i t
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was first discovered it was classed as an oncogene because it could 
transform  cells, but closer analysis showed that these p53 c lones 
harbored mutations while WT p53 inhibited cell g ro w th  
(Reviewed in Levine et a l , 1991). Many human tumors h a v e  
deletions of a small region of chromosome 17p which was l a t e r  
shown to include the p53 gene (Chromosome 11 for mouse). This 
led to the hypothesis that p53 was a tumour suppressor gene a n d  
indeed the p53 gene is the most commonly altered gene y e t  
identified in human tumors suggesting that loss of WT fu n c tio n  
removes the protection provided by p53. So whilst functional WT 
p53 might indeed be the "guardian of the genome", m utated p5  3 
is "a deadly inheritance" (Vogelstein, 1990).
The p53 protein is a DNA binding transcription factor t h a t  
enhances the rate of transcription of several known genes t h a t  
carry out, at least in part, the p5 3 -dependen t functions in a cell. 
Under normal circumstances p53 acts as a negative regulator o f  
cell growth (Perry and Levine, 1993).
Crystallographic studies on p53 have shown that many o f  
the frequently mutated amino acids in tumours have close c o n ta c t  
with the DNA in a protein-DNA complex. Therefore disruption o f  
the specific DNA-binding function is likely to be a critical event in  
the loss of WT p53 function.
p53 is mainly localized to the nucleus where levels are low  
in quiescent normal lymphocytes due to the protein's short h a lf -  
life, but increase ? upon a cell’s entry into the cell cycle. 
Overexpression of p53 in a variety of cell types results in arrest in  
the Gi phase of the cell cycle or induction of programed cell d e a th  
(apoptosis). Furtherm ore, DNA damage results in increased lev e ls  
of p53 and a block in Gi, suggesting that p53 functions as a 
com ponent of the cellular response to DNA damage, acting as a 
negative growth regulator (hence “ genome guardian”). U p s tre a m  
events which lead to p53 activation are m ediated by s tre ss ,
including DNA damage, hypoxia, heat shock, calcium p h o s p h a te
treatm ent, and ribonucleotide depletion (Ruaro et al, 1997; a n d  
Levine, 1997).
p53 functions to activate p21 which then binds to a n u m b e r  
of cyclin and cdk complexes to block cell cycle progression. p5  3 
may also be involved in cell cycle regulation at two o th e r
checkpoints. These are the G 2 /M phase checkpoint and the G0 - G 1 -S 
phase transition although evidence for this is still accumulating.
Regulation of the cell cycle and the role of p53 in con tro lling  
it is obviously very complex. However it is apparent that a fa i lu re  
in the pathway brought about by p53 m u ta tio n /inac tiva tion  could  
lead to uncontrolled growth, and if the DNA was damaged in so m e  
way yet not repaired because of the unchecked growth, th e n
neoplasia could result.
1 16
p53 activation gives rise to a second choice other than t h a t  
of cell cycle arrest, namely apoptosis. Under circum stances w h e r e  
DNA damage is unrepairable, survival factors for the cells a re  
limiting, or an activated oncogene is forcing the cell into a 
replicative cycle, p53-m ediated  apoptosis prevails. Therefore p5  3 
inactivation is im portant on two counts with regard to t h e  
developm ent of tumours. Firstly loss of p53 control of the cell 
cycle could increase the risk of m alignant conversion, secondly , 
once tumours are established, loss of p53 would inhibit a p o p to s is  
and allow the tumour cell to survive.
p53 has been shown to bind to a number of c e l lu la r  
proteins. For example, the proto-oncogene nuclear product c -A b l 
is activated for its kinase activity following DNA damage, and c- 
Abl binds to p53 and enhances its transcrip tional activity. This is 
therefore a positive regulatory role as it enhances the ability o f  
p53 to induce cell cycle arrest at Gi. MDM2 represents the p r o d u c t  
of another proto-oncogene which binds to p53. MDM2 is a c tu a l ly  
transcriptionally activated by p53 and its function is to in a c t iv a te  
p53 mediated transcription. This therefore forms an  
autoregulatory  loop so that p53 does not remain p e r m a n e n t ly  
activated longer than necessary and the cell can re-enter the cell 
cycle once the stress (DNA damage etc.) is removed.
The descriptions of p53 as the "Guardian of the genome" a n d  
the "Cellular gatekeeper for growth and division" are th e r e f o re  
well named. That 50-55% of human tumours display mutations in  
the p53 gene serves to illustrate the importance of m a in ta in in g  
two functional copies of the gene. Knockout mouse studies h a v e
further shown the importance of WT p53 in the inhibition o f
cancer (Donehower et a l , 1992). Mice deficient for p53 d e v e lo p e d  
normally. However these animals were prone to the sp o n ta n e o u s  
developm ent of a variety of neoplasms. 74% of h o m o zy g o u s  
knockout (-/-) mice developed neoplasms by 6 months of age  
with a mean time to tumour onset of only 20 weeks. These m ice  
succumbed to m alignant lymphomas most frequently  (70% of t h e  
tumours). Sarcomas were also identified. Heterozygous (+ /- )  
knockout mice also succumbed to tumour formation but with a 
delayed onset compared to the -/- mice (Harvey et a l , 1993). By 
12 months of age only 8% of the +/- mice had developed tu m o u rs ,
but from 12 months onwards the rate of tumour d e v e lo p m e n t
accelerated such that by 18 months of age, 50% of the +/- m ice  
had developed tumours. The tumour type most co m m o n ly  
observed in this group of mice was different to the -/- mice, w i th  
58% of the +/- mice developing osteosarcom a or sarcoma of so f t  
tissues and only 32% developing lymphom a. Of the tu m o u r s  
arising in the p53+/- mice, 55% showed loss of the remaining WT 
allele which was not associated with a particular tumour ty p e .
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Thus it is clear that loss of one or both copies of p53 can q u ick ly  
lead to tumour onset.
4 A . 4 Rationale  for cro ssb r ee d in g  studies with L M P - 1  
transgenic  m i c e .
Transgenic mice have enabled detailed study of the in v i v o  
effects of individual proteins expressed in the epidermis d u r in g  
the process of skin carcinogenesis. Creating bi-transgenics th e n  
allows analysis of possible synergenistic effects d u r in g  
carcinogenic progression, where lack of synergy might indicate the 
oncogenes act in the same or parallel pathways. B i- tran sg en ic s  
also allow identification of the stage of carcinogenesis w h e r e  
oncogene expression becomes causal, and allow determ ination  of 
the nature of the events required to achieve malignancy.
PyLMP-1 mice were crossbred with K5-Harr/.v , p53 null, 
K10-TGFpi(line H), and K6-TGFpl(line M5) mice in order to  
examine co-operation versus redundancy or interference.
Results from chapter 3 might predict that Ras and LM P-1 
co-operate as an initiator and a promoter. Results from chapter 2 
dem onstra te  that LMP-1 promotes proliferation. Therefore it w a s  
thought that it might be possible to mimic the carc inogen ic  
trea tm ent (e.g. DMBA induced ras mutation and TPA in d u ce d  
proliferation) instigated phenotype by mating activated ras  
transgenics with the PyLMP-1 mice. If LMP-1 was redundant with 
mutant ras (not seen in chemical carcinogen study regime 3) th e n  
no co-operation between these proteins would be expected. I f  
however, the LMP-1 induced hyperplastic phenotype acted in 
conjunction with activated ras, enhancem ent of the carc inogen ic  
process might be expected.
The potentially opposite effects of LMP-1 and TGFpi could  
predict opposite action to nullify the effects. The rationale b e h in d  
the crossbreeding of LMP-1 with K6-TGFP1 mice was th ree fo ld . 
Line M5 expresses TGFpl at very low levels (below those leve ls  
needed to detect the cellular source of the RNA by in s i tu  
hybridisation) and requires TPA induced hyperplasia  to in d u ce  
high levels of TGFpi. Therefore, can the LMP-1 in d u c e d  
hyperplasia  activate the expression of TGFpi? or indeed e n h a n c e  
the expression of TGFpi via its ability to induce K6 expression? I f  
TGFpl can block the proliferative response to TPA, can it a lso  
affect the hyperplastic phenotype of the LMP-1 mice via its ro le  
as a potent negative growth regulator? If TGFpi is im portant in  
carcinogenesis, does it have an effect on the oncogenic potential o f 
LMP-1? The question asked by the line H cross was, can
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suprabasal expression of TGFpi exert a negative regulatory e f fe c t  
and abrogate the hyperplastic response generated by LMP-1?
If LMP-1 can act in part to inhibit p53 action (see sec tion  
1D.4), then this cross might show a degree of redundancy. Thus, 
the rationale behind cross-breeding PyLMP-1 mice with p5  3 
knockout mice was to analyse the effects of the LMP-1 oncogene  
in the epidermis in the absence of tumour suppression from p53 . 
Although mutations in p53 are not found in NPC, they have b e e n  
shown to be a major component in the mouse skin model o f 
m ultistage carcinogenesis
The experim ents described in this chapter were th e r e f o re  
conducted to test these hypotheses.
4B RESULTS
4 B . 1 C o -e x p re s s io n  of LM P-1 and  a c t iv a te d  R a s
PyLMP-1 positive mice in a C57B1/6 background (line 5 3 )  
were bred with K5-Har«.v positive mice also in a C57B1/6 
background, and the offspring monitored. There was no d if fe re n c e  
between the L M P -l/r« ,v  transgene positives and the LM P-1 
transgene positives at day 7, the time point where the LMP-1 sk in  
phenotype is most pronounced. The mice which were positive fo r  
the ras  transgene only had no phenotype at an early age and so 
were indistinguishable  from the negative mice. Transgenic s ta tu s  
was determ ined by southern blot analysis of tail-tipped D N A a n d  
the four categories of mice were then analysed for the duration o f  
the study. These were:-
1) LMP-1 Iras bi-transgenic positives =29 mice (only 19 used)
2) ras single transgene positives =63 mice (only 20 used)
3) LMP-1 single transgene positives (=16 mice)
4) Negative controls (=28 mice)
These mice were not born in the expected 1:1:1:1 ratio (w ith  
expected 34 mice per group) but instead were more like a 2:4:1:2 
ratio. The bi-transgenics and negative control groups were s l igh tly  
below expected whilst the ras single transgene positive g ro u p  
was almost double the total expected. The LMP-1 single t r a n s g e n e  
positive group was less than half the total expected.
At three months of age the first mice started to develop K5- 
UtLras associated lesions around the eyes and ears (tables 4.1a+b), 
and these lesions were identified as sebacious adenomas.
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T ab le  4 .1 a : -  Table of mice positive for both the LMP-1 and Ras 
transgenes indicating the age of the mice when the first seb ac io us  
adenomas (polyps) appeared, and the accumulation of th e s e  
lesions.
I.D. 1 St
polyps
1
mo
2
mo
3
mo
4
mo
5
mo
6
mo
7
mo
8
mo
9
mo
10
mo
1 1
mo
1 2 
mo
1 3 
mo
14
mo
15
mo
max
1 4 1 6 0 0t 0 0 0 3 5 5 8 8 12 20 D 20
1 4 7 9 0 0 0 0 0 0 0 0 2 5 3 0 3 5 8 8
14  9 1 1 0 0 0 0 0 0 0 0 0 0 1 5 2 D 5
1 5 9 5 0 0 0 0 2 2 2 2 3 5 1 3 1 2 1 2 1 3 20 20
1 7 6 5 0 0 0 0 3 5 6 8 5 8 1 2 D 12
1 7  7 7 0 0 0 0 0 0 1 2 2 3 2 0 2 5 5 5
18  6 10 0 0 0 0 0 0 0 0 0 1 5 5 6 T 6
19  0 5 0 0 0 0 3 5 9 20 20 20 28 25 22 T 28
19  1 6 0 0 0 0 0 1 5 1 1 8 5 8 1 0 1 2 T 1 2
19  2 3 0 0 2 2 4 5 7 8 10 1 1 15 T 15
2 0 6 5 0 0 0 0 1 1 1 0 0 5 7 T 7
2 1 3 10 0 0 0 0 0 0 0 0 0 4 8 T 8
2 2 3 7 0 0 0 0 0 0 1 4 1 0 1 9 T 1 9
2 2 7 5 0 0 0 0 4 5 2 4 7 20 T 20
2 3  0 7 0 0 0 0 0 0 3 5 5 1 2 T 1 2
2 3  2 5 0 0 0 0 4 5 5 1 0 20 28 T 28
2 5 6 4 0 0 0 1 3 4 5 6 1 0 1 2 T 1 2
2 8 2 7 0 0 0 0 0 0 3 5 5 T 5
2 8 4 6 0 0 0 0 0 1 6 1 2 1 7 T 1 7
Av.= 6.47 Av.= 7.00 Av.= 13.63
Note:- D= dead
T= experim ent terminated
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T a b le  4 .1 b : -  Table of mice positive for the Ras transgene only , 
indicating the age of the mice when the first sebacious a d e n o m a s  
(polyps) appeared, and the accumulation of these lesions
I.D. 1 St 
polyps
1
mo
2
mo
3
mo
4
mo
5
mo
6
mo
7
mo
8
mo
9
mo
10
mo
1 1 
mo
1 2
mo
13
mo
14
mo
1 5 
mo
max
1 6 3 5 0 0 0 0 2 5 8 10 20 20 26 30 40 36 45 45
1 6  9 5 0 0 0 0 1 1 2 2 1 5 20 18 1 8 22 30 50 50
1 7 0 5 0 0 0 0 2 4 6 8 1 0 1 5 1 5 1 5 20 25 35 35
1 7  2 5 0 0 0 0 1 1 1 1 0 0 5 1 0 25 33 40 40
1 7 3 5 0 0 0 0 5 1 1 1 5 15 20 25 30 33 30 60 D 60
1 7 5 5 0 0 0 0 2 8 1 2 1 2 1 6 20 22 25 30 45 60 60
1 8 1 7 0 0 0 0 0 0 1 1 4 5 1 2 20 35 T 35
1 8 4 7 0 0 0 0 0 0 1 1 2 4 10 20 25 T 25
1 8  9 6 0 0 0 0 0 1 3 8 5 4 5 1 7 25 T 25
1 9  5 7 0 0 0 0 0 0 2 2 3 5 1 1 20 T 20
2 0 7 8 0 0 0 0 0 0 0 4 5 1 7 3 0 T 30
2 0 8 3 0 0 1 0 0 5 D 5
2 1 0 5 0 0 0 0 2 2 2 2 9 20 3 5 T 3 5
2 1 6 4 0 0 0 2 5 1 0 20 3 0 38 5 0 60 T 60
2 2 6 7 0 0 0 0 0 0 3 4 6 1 5 T 15
2 2 8 5 0 0 0 0 4 4 3 10 1 0 1 2 T 1 2
2 3 3 4 0 0 0 2 10 20 2 5 28 3 5 30 T 35
2 5 1 4 0 0 0 1 2 3 6 15 3 3 T 33
2 5 3 4 0 0 0 1 4 6 1 4 1 5 26 T 26
2 5 7 3 0 0 3 4 10 1 5 22 D 22
Av= 5.20 Av.= 14.28 Av.= 33.40
N ote:-  D= dead
T= experim ent terminated
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Average number of lesions on ras 
v's bi-transgenic mice.
lesions (bi-transgenic)
lesions (ras +ve)
40-
30-
2 0 -
10 -
o o
time (months)
Figure 4.1
Every two weeks the number of polyps (ears+eyes) on each 
individual mouse was counted. The counts for each group at each 
time point were totalled and the mean number of polyps per group 
per two week interval was calculated. These mean numbers were 
used to plot the above graph.
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By counting the number of lesions on each mouse at two w e e k
intervals, the average number of lesions for each group of m ice  
could be calculated and a graph of lesion formation against t im e  
could be plotted for each category (fig 4.1).
Neither the LMP-1 single transgene positive mice nor th e
negative control mice developed the K 5-H aras associated les ions 
as expected. The LMP-1/rfl.v bi-transgenic mice did not d e v e lo p  
any more lesions than the ras single positive mice and in s te a d  
developed fewer lesions overall. The average age to les ion  
formation for the bi-transgenic LMP-1 Iras  mice was 6.47 m o n th s  
and this group had an average of 7 lesions/m ouse at 9 months o f  
age. The ras single positive mice developed lesions slightly f a s t e r  
with an average age to onset of 5.20 months and this group h a d  
an average of 14.28 lesions/m ouse at the age of 9 months. This 
d ifference in average numbers of lesions proved to be s ign if ican t  
with a T value of 2.3, a P value of 0.030 and 25 degrees o f  
freedom. Thus the ras single positive mice develop s ta t is t ic a lly  
significantly greater number of lesions than do the b i - t r a n s g e n ic  
mice. It should be noted that the data used to draw th e s e  
conclusions covers a wide range. For example, at week 9 the b i -  
transgenic group has between 0-20 lesions and the ras  t ra n s g e n ic  
group between 0-38 lesions.
Some of the lesions progressed from the white n o d u le  
appearance of the adenomas to a larger more p a p i l lo m a to u s  
appearance. A small number of these adenomas and p a p il lo m a  
"like" lesions from both bi-transgenic and ras  single positive m ice
were stored in fixative awaiting future analysis. None of th e
lesions progressed further to carcinoma. Furtherm ore, no sk in  
papillomas in other areas were observed throughout the study.
In order to examine epidermal proliferation rates in th e s e  
mice 7 day old bi-transgenic and ras single positive mouse p u p s  
were BrdU injected and skin, tongue and tail tissues collected a n d  
analysed as described in section 7B.4.5. The BrdU staining a n d  
counting revealed that the bi-transgenics had significantly h ig h e r  
num bers of proliferating cells in the dorsal skin epiderm is t h a n  
did the ras  transgenics (see table 4.2). The mean BrdU score fo r  
b i-transgenic dorsal skin was 30.7 compared to 17.64 for K5- 
H a ras positive transgenic dorsal skin. A two-sam ple T - te s t  
analysis of the data in table 4.2 gave a significant T value of 3 .5 9  
with a P value of 0.0012 and 30 degrees of freedom  w h e n  
comparing bi-transgenic dorsal skin BrdU counts with K5-H aras 
transgenic dorsal skin BrdU counts.
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Figure 4.2
7 pm  sections of dorsal skin (from BrdU injected mice) were stained 
with an anti-BrdU antibody (section 7B.4.5), and positive cells 
(brown) in the epidermis were counted per field of vision at x312.5 
magnification. This figure shows the mean score for each transgenic 
group studied. The BrdU counts for LMP-1 positive and negative 
control epidermis are included to allow a direct comparison with 
the mean BrdU scores for LMP-1/Ras bi-transgenics and Ras 
transgenics. Each mean was derived from  at least 5 different 
sections from at least 3 different mice. Each section was counted for 
10 fields of vision and then averaged (mean). Each mean was then 
totalled to calculate the overall mean score for each group. Error 
bars represent the standard error of the mean.
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However, there was no significant difference between LM P- 
1 positive epiderm al BrdU counts and bi-transgenic e p id e rm a l  
BrdU counts (see figure 4.2) suggesting that the increased levels of 
proliferation noted in the bi-transgenics is induced a lm o s t  
exclusively by LMP-1. The mean BrdU score for b i - t r a n sg e n ic  
dorsal skin of 30.7 was only slightly higher than that for th e  
PyLMP-1 (line 53) dorsal skin mean BrdU score of 25 .53 . 
Comparing the BrdU scores for these two groups via the tw o -  
sample T-test resulted in a T value of 1.54 with P=0.14 and 2 7
degrees of freedom. The difference in mean scores between th e s e  
two groups is therefore not significant.
PyLMP-1 dorsal skin did however have a s ign if ican tly  
higher mean BrdU score than K5-Ha/Y/.v dorsal skin. The m e a n  
labelling score for line 53 dorsal skin was 25.53 compared to  
17.64 for the K5-Harr/.v transgenics. This gives a significant tw o -  
sample T-test T value of 2.95 with a P value of 0.0079 and 2 0
degrees of freedom. This therefore confirms that the in c re a s e d  
levels of proliferation noted in the bi-transgenic epidermis a re  
mostly accountable to the effects of the PyLMP-1 transgene.
Comparing the dorsal skin BrdU counts of the K5-Haras 
transgenic group (see table 4.2) with those of the LMP-1 n e g a t iv e  
control group (see table 2.1) shows a small but s ign if ican t
difference between these groups. A T value of 2.12 with P=0.048 
and 18 degrees of freedom suggests that the K10-Ha-rr/.? 
transgenic mice do indeed dem onstra te  a small increase in 
proliferation compared to negative controls and therefore m a y
contribute a small effect to the bi-transgenic BrdU mean d o rsa l  
skin score.
K5-Harr/.y mice in the FVB background were also mated with 
line 53 PyLMP-1 mice, but this was towards the end of my Ph.D. 
studies with inadequate time to achieve results.
4 B .2  C o -e x p re s s io n  of LM P-1 and  a c t iv a te d
TGFB1 .
i
It was decided to use both lines of TGF(3l expressing m ice  
because of the difference in their expression patterns. Line H 
TGFpl expression may overlap with Line 53 LMP-1 ex p re ss io n , 
therefore analysis of dual expression of the proteins could b e  
achieved. LMP-1 has been shown to induce K6 expression (W ilson, 
J.B., et al , 1990) therefore might also be able to induce line M5 
K 6-T G Fpi expression.
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4 B . 2 . 1  L M P -1  c r o s s e d  w i th  K6-TGFR1 l ine  M 5
Transgene homozygous K6-TGFpl line M5 were used to  
breed with PyLMP-1 line 53 mice, therefore 50% of the o ffsp ring  
should be LMP-1 p os it ive /T G F pi hemizygous positive. To o b ta in  
the maximal effect of TGFpl, these mice were then backcrossed to  
line M5 in an a ttem pt to create LMP-1 positive mice in a TGFpl 
hom ozygous positive background.
Mice were examined between 4-7 days after birth w h e re  
possible. No visible alteration or deviation from the typical d 7 
LMP-1 phenotype was detected, regardless of the T G Fpi t r a n s g e n e  
status. The LMP-1 positive mice presented with their s l igh tly  
runted size as judged by eye, and so were therefore at a 
d isadvantage over their larger LMP-1 negative litterm ates, b u t  
this was no different to the previously observed line 5 3 
appearance. The mice developed normally and no lesions w e re  
noted throughout the duration of the study (12 months). The on ly  
possible alteration to phenotype of the PyLMP-1 mice was in th e  
time taken before the “ring-tail” phenotype m anifested itself. This 
phenotype, which normally occurs in mature animals, was seen in  
mice carrying both transgenes at an earlier time point. H ow ever, 
this was not m onitored closely and remains a su b je c t iv e  
observation. Other than this observation, no differences w e re  
no ted .
The procedure of BrdU injections was conducted in th r e e  
groups of mice, with six mice per group. These groups were b i-  
transgenics with ringtail; bi-transgenics not showing ringtail; a n d  
LMP-1 nega tiv e /T G F p i positive (which show no p h e n o ty p e ) .  
Dorsal skin, tongue, and tail tissues were harvested  and p a ra f f in  
em bedded but time constraints meant the analysis could not b e  
taken further. The results from this BrdU study might explain th e  
apparent acceleration of the appearance of the ringtail phenotype.
4 B .2 .2  LM P-1 c ro sse d  w ith  K lP -T O F ft!  line H
Transgene homozygous line H mice were crossed with line  
53 LMP-1 positive mice. 50% of the offspring are th e re fo re  
expected to be LMP-1 positive/ T G Fpi hemizygous. However, f ro m  
192 FI mice born, only four LMP-1 positive mice were born (2%) 
and only 2 of these survived to weaning age and m aturity  (F igure  
4.3). The large majority of litters were completely devoid of LM P- 
1 positive mice, showing no signs of the LMP-1 line 53 p h e n o ty p e  
at d7, with transgene status later confirmed by southern blotting. 
The four LMP-1 positive mice all came from the same litter a n d  
were severely runted. The two positives that did not survive died
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T ab le  4.3:- Analysis of transgenic embryos from PyLMP-1 
(Line 53) crossed with K10-TGF|31 (Line H).
A ge  ta k e n M a l e F e m a l e No. of 
e m b r y o s
L M P - 1
p o s tn a ta l  
d 2
53G.25 H stock 1 2 0
e 1 8 53G.25 H stock 3, 15 0 ,0
e 1 6 53G .20 H stock 8 0
e 14 53G.4.1 H stock 9 1
Footnote:- The designation 53G was given to line 53 mice bred in a 
separate animal house, compared to most studies described here.
53G mice were of the strain background 25% C57Bl/6/75%  DBA
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soon after birth. Thus it would appear that the majority of b i -  
transgenic LMP-1 +ve/ K lO-TGFpl +ve mice have died in utero .
To investigate this embryonic lethality of the b i - t ra n sg e n ic s ,  
pregnant females from these crosses were sacrificed b e tw e e n  
embryonic (e)14 and e l 8 days of gestation (total gestation = 20  
days) and the em bryo’s analysed for transgene status. No LM P-1 
positive foetuses were present after e l 6, with 1/9 LMP-1 p o s i t iv e  
present at e l4  (Table 4.3) Surprisingly, with the exception of o n e  
extremely large and one extremely small litter, the litters were all 
within the normal size. One would expect a 50% reduction in l i t t e r  
size if none of the LMP-1 positive em bryo’s are born. Occasionally  
one or two of the foetuses appeared smaller than the rest but th is  
did not correlate with LMP-1 transgene positivity.
The two mice which were both LMP-1 and TGFpi p o s i t iv e  
(Male 53H.110 & Female 53H.117) were much smaller than th e i r  
LMP-1 negative littermates being half the size at dlO and still le ss  
than average weight by weaning age (13g & 11 g r e s p e c t iv e ly  
compared to an average weight of 17.4g for males and 15.6g fo r  
females of the same age). Nonetheless, the mice did not show signs 
of ill health and were fertile as adults (figure 4.3).
The only T G F pl/  LMP-1 bi-transgenics (4 mice, 2 su rv iv in g )  
in the initial FI crosses were all in one litter. This might suggest a 
heritable trait. The observation that LMP-1 positive mice are b o rn  
in the F2 generation from these two mice (figure 4.3) w o u ld  
support this. The PyLMP-1 phenotype was not altered in th e s e  
mice.
4 B .3  E ffect of LM P-1 e x p re s s io n  in the a b se n c e  of
p53 f u n c t i o n .
p53 knockout (p53-/-) mice (Line 92) in a mixed s t r a in  
background were donated by A.Balmain at the CRC B eatson  
Institute for Cancer Research after permission from the c re a to r s  
(Donehower, L.A., et al , 1992). PyLMP-1 mice were crossed w i th  
these p 5 3 -/- mice and the offspring from this LMP-1 x p5  3 - / -  
cross were heterozygous for p53. As such they are liable to an  
increased frequency of tumours compared to WT mice but s low  
forming compared to -/- mice. LMP-1 positive ofspring from th is  
FI cross were backcrossed to p53-/- mice in order to g e n e ra te  
LMP-1 +ve/ p53 -/- mice.
Due to the early onset of tumours in the p53-/- mice it w a s  
difficult to establish a line of mice that was LMP-1 -Hve in a p53 - 
/- background. Most information was gained from p53 +/- mice as  
detailed in appendix 1. However, no tumours other than th o se  
published (Donehower, L.A., et al , 1992; Harvey, M., et al , 1993)
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arose. In addition, tumour onset did not differ between LM P-1 
positive and LMP-1 negative siblings. The majority of the m ice  
developed a hunched appearance with paralysed or r e s t r i c te d
hind limb movement which proved to be due to sarcomas pressing 
on the spine (figure 4.4). No carcinomas were observed.
4C D iscu ss ion  of c h a p te r  4
4 C .1  Ras x L M P - 1
K 5 -H a r « j  transgenic mice developed lesions around the ears 
and eyes slightly earlier than did the bi-transgenic LM P-1 I ras
mice. In addition the accumulation of these sebacious a d e n o m a s
was decreased in the bi-transgenic mouse group with half t h e  
numbers of lesions at 9 months compared to the single t r a n s g e n e  
K5-Harr/.y group (7.00 v’s 14.28). Although fewer m ice
contributed to the data at later stages, the difference in these mice
continued to increase.
From these results it would appear that co-expression of 
LMP-1 and activated ras  reduces the num ber of benign les ions 
compared to activated ras  alone. This study would also imply t h a t  
there is no co-operation between these oncogenes. Indeed th e
reverse, LMP-1 seems to be inhibiting the effects of ras in  
generating this type of lesion, giving rise to a s ig n if ican t  
difference as judged by a two sample T-test. This finding w a s  
contrary  to expectations especially given the tumour p ro m o tin g
effects of LMP-1 noted in chapter 3 where LMP-1 could act as a 
weak or second stage prom oter providing H a -ras was a l r e a d y  
activated. How LMP-1 might inhibit the ras  induction of b e n ig n  
lesions is unclear and requires further analysis.
The lack of co-operation might be due to the e x p re s s io n  
patterns of both transgenes. H a -ras  is expressed in the h a i r
follicles and the results from chapter 2 imply that PyLMP-1 m a y
have a suprabasal expression pattern. It is possible that t h e  
effects of LMP-1 are not influenced by ras  ^because of th e  
different areas that they exert their effect.
Another consideration is the mouse strain background in
which these mice are bred. Neither the Ua-ras  or the b i -  
transgenics develop carcinoma but both lines of mice are bred in a 
C57B1/6 background which is not susceptible to c h em ica l ly  
induced carcinogenesis (DiGiovanni, 1991). It is therefore p o ss ib le  
that the strain background “masks” any co-operative e f fe c t  
between LMP-1 and ras . Crossing the PyLMP-1 mice in th e  
chemical carcinogen sensitive FVB background with the K5-Har«.y
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mice also in an FVB background might highlight c o -o p e ra t io n  
between these two proteins. This experim ent was initiated b u t
could not be completed due to time restraints.
BrdU analysis of day 7 old bi-transgenic and LM P-1
transgenic epidermis revealed no significant difference in m e a n
scores between these two groups. Furtherm ore, the K5-Har«5 
mice only showed a very slight significant increase in BrdU scores  
when compared to negative controls. This shows that activated ras  
(in these mice) does not significantly contribute to, or inhibit th e  
LMP-1 induced epidermal proliferation described in chapter 2. 
This suggests that the amplification of mutant rcis alleles seen in  
chemical carcinogenesis does not contribute to th e  
hyperp ro life ra tion  noted.
4 C .2  TGFpl x L M P - 1
TGFpi attenuates the hyperplastic response provided b y  
TPA treatment of line M5 within 24Hrs of application but does n o t  
negate the hyperplastic  response in the bi-transgenic m ice  
induced by continual LMP-1 expression.
It is possible that the LMP-1 induced hyperplasia does n o t  
activate the K 6-TG Fpl transgene. In this case the two-fold increase 
in BrdU labelling of untreated line M5 dorsal skin (Fowlis et al.,
1996) might be expected to add to the increased p ro l ife ra t io n  
induced by LMP-1 (from chapter 2).
A lternatively, the LMP-1 induced hyperplasia  may b e
sufficient to activate or enhance the activation of the K6-TGFP1 
transgene but the negative regulation by TGFpl is insufficient to  
overcome the effects of LMP-1. Given that the two lines of m ice  
individually  show increased epithelial proliferation, yet to g e th e r  
do not appear to show an additive effect (by p h e n o ty p ic  
exam ination), may suggest that LMP-1 does indeed activate K6- 
TGFpi which in turn suppresses the proliferative effect seen in  
untreated line M5 dorsal skin. This proposed suppression must b e  
insufficient to negate the PyLMP-1 induced phenotype. H ow ever,
the BrdU injected tissues from these mice were not analysed d u e
to time constra in ts ' and may yet show an increased p ro l i f e r a t iv e  
rate. Also, levels of TGFpl expression were not looked at.
The combination of LMP-1 and TGFpl as tested here d o e s  
not result in carcinogenic co-operation but no chem ica l 
progression studies were carried out to investigate this fu r th e r .  
LMP-1 and TGFpl may be co-operating, or indeed negating th e  
effects of each other, but in a m anner not detectable by th is  
experiment. Chemical carcinogen treatment of bi-transgenics could 
provide further information. It is known that TGFpi is
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downregulated in papillomas at high risk for malignant conversion 
to carcinoma, and in the carcinomas which arise from these h igh  
risk papillomas. Furthermore, chemical carcinogen treatm ent o f 
the KlO-TGFpi mice revealed that TGFpi inhibited p a p il lo m a  
formation. If LMP-1 is activating TG Fpl in the PyL M P-1/K 6-TG Fpi 
cross the prediction would therefore be that no carc inogen ic  
progression would be observed. However, I did observe th e  
PyLMP-1 skin phenotype with potential acceleration of the a d u l t  
“r ing -ta il” appearance.
Bi-transgenic mice from the PyLMP-1 x KlO-TGFpi c ross  
appear to be disadvantaged in u tero  such that embryonic d e a th  
results. The T G Fpl transgene is driven by the K10 promoter in l ine  
H mice to direct expression to the differentiating suprabasal cell 
compartment. K10 mRNA is first detected in developing e m b ry o 's  
at e l3 .5  but only in the nasal region. This expression sp re a d s  
slightly to encompass the whisker pads and paws by el4 .5 , b u t  
there is still no dorso-lateral epidermal expression. Expression of 
K10 however rises dram atically at e l5 .5  to cover most of th e  
embryo surface (Byrne et al ., 1994). This confirms earlier r e p o r t s  
and infers that active TGFpl will not be expressed in th e  
epiderm is before e l5 . This allows developm ent to p ro c e e d  
without the potentially lethal effects of overexpressed TGFpl to  
e m b ry o g e n e s is .
A previous study using the K1 prom oter (also expressed a t  
e l5 .5 )  to drive TGFpi transgene expression to the suprabasal l a y e r  
of the epidermis resulted in the birth of mice with e x t r e m e ly  
taught skin (Sellheyer et al., 1993). These mice had no m o b il i ty  
and died at d ay l.  The differences between the KlO-TGFpi and th e  
K l-T G Fpl studies probably reflects a difference in the level o f 
TGFpi protein expressed during em bryogenesis in the d i f f e re n t  
lines of mice.
Our bi-transgenic mice appear to have an even more s e v e re  
phenotype than the K l-TGFpl mice, with death in u tero  b e fo re  
e l6  rather than at day l. It is possible that TGFpi is b e in g  
switched on before e l 5.5. A suggestion that this might be the case  
was provided by analysis of K10 mRNA levels in new b o rn  
PyLMP-1 line 5 transgenic mice. At day 8 mRNA levels for K10 
are increased 3-4 fold in the PyLMP-1 mice over their n e g a t iv e  
siblings (unpublished results from our lab.). Although the levels o f  
K10 in the PyLMP-1 mice are comparable with controls at day  10, 
it is possible that the elevation noted at day8 also occurs d u r in g  
em bryogenesis. If this was the case then LMP-1 could b e  
upregulating the expression of K10 and thus TGFpi in the b i-  
transgenics during, a critical stage of developm ent, resulting in
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embryonic death. Direct evidence for this theory awaits an a ly s is  
of K10 mRNA from bi-transgenic or PyLMP-1 embryo's y o u n g e r  
than e l5 . A lternatively  there may be lethal consequences f ro m  
the dual expression of these transgenes.
The litter which provided 4 LMP-1 positive pups, 2 of w hich  
survived to breed and produce further LMP-1 positive o ffsp r in g  
may represent a line of mice which have escaped the lethality o f  
early TGFpi expression.
4 C .3  p53 Knockout x L M P - 1
No epidermal tumours arose in LMP-1 +ve mice in either a 
p53 +/- or p53 -/- background before they succumbed to p5  3 
deficiency associated tumours. This suggests several possiblities.
It may be that even with two ‘hits’, LMP-1 expression p lu s  
lack of p53, this is still insufficient to promote progression in th e  
skin. Since LMP-1 is a weak or late stage tumour p ro m o te r  
perhaps acting to augment more powerful tumour p ro m o te r s  
(Chapter 3), it may need prior oncogenic activation before it can  
operate. The absence of p53 is not an early event in  
carcinogenesis but associated with later stages. Therefore no c o ­
operation is noted at early stages of carcinogenesis in this case  
because LMP-1 may require activation of Ha-ra.v and som e  
tum our prom otion before it can exert its own tu m o u r  
p rom o ting /aug m en tin g  effects. Subjecting LMP-1 +ve/ p53 - / -
mice to chemical carcinogenesis, or intercrossing LMP-1/ ras  m ice  
with p53 deficient mice might provide additional information in 
this respect.
It is possible that LMP-1 may overcome WT p53 action as i t  
protects B-cells and epithelial cells from p53 triggered a p o p to s is  
mediated at non-permissive temperatures (Okan et al., 1995; Fries 
et a l ,  1996). This would imply a degree of redundancy with p5  3- 
/- in this assay as far as skin carcinogenesis.
Since p53 is apparently not mutated in NPC it is more l ik e ly  
that its tumour suppressing effects are overcome by other m e a n s  
(or perhaps it is not normally expressed in the NPC cell type) .  
Although p53 appears unaltered, the tumour suppressor gene p i  6 
has been shown to be mutated in NPC (Lo et a l ., 1995) and in  
other tumours of epithelial origin. Creating LMP-1 transgenic m ice  
with oropharyngeal expression and crossing them with p 16 
knockout mice might give rise to a more NPC like situation in th e  
o ro p h a ry n x .
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CHAPTER 5: Characterisation of line 3 9.
In this chapter the EpLMP-1 transgenic mice created b y  
Wilson et al., 1990, are investigated further. This series was n o t  
previously monitored for an extended period of time (over 1 y e a r  
of age). This chapter therefore briefly describes the history of
these EpLMP-1 mice before detailing the analysis of one p a r t ic u la r  
EpLM P-1 line over a 24 month time course.
5 A EfiLMP-1 T ra n s g e n ic  m ic e .
Expression of the EpLMP transgene mostly gave rise to n o n -  
viable mouse lines. Three founder mice were dead within 2 w e e k s  
of birth and a further founder female, EpLMP.33, gave rise to on ly  
4 LMP positive offspring from several litters, and these were n o t  
viable past 6 months. These 4 offspring did however display th e  
hyperplastic dermatitis phenotype. This left only eight v iab le  
mouse lines (Wilson et al ., 1990). Of these lines 39, 44, 48, and 4 9 
were bred to homozygosity. All displayed a mild phenotype w hich  
m anifested as ruffled, greying fur as the mice grew older. T hese  
mice were less dynamic than negative animals with re d u c e d
fertility (fewer, smaller litters). The order of phenotypic in te n s i ty  
w a s : -
Line 3 3 » >  44 > 48 > 49 > 39 
( le th a l)
Expression was found not to be restricted to B-lymphocytes in  
line33 mice, but detectable in a broad array of tisues. E xpress ion  
in line 39 was also analysed by northern blotting. On a long 
exposure LMP-1 transcript expression could be detected in sp leen  
and thymus, with none or below detectable levels in other t issues, 
perhaps accounting for the viability of line 39. Subsequently, on ly  
line 39 was maintained and it's further characterisation and long
latency phenotype is the subject of this chapter.
In the consideration of animal house space and in 
accordance with Home Office preferences, most m o u se  
experiments (including transgenic mouse lifespan) are limited to 1 
year of study. However there are several reports indicating t h a t  
transgene induced tumour onset can have a long latency. It w a s  
decided to investigate any long latency phenotype in line 39 (u p  
to 24 months) and simultaneously to investigate any synergy w ith  
EBNA-1 predisposition to lymphoma (Wilson and Levine, 1992; 
Wilson et al., 1996).
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EpEBNA-1 transgenic mice have been described p re v io u s ly  
in section IB.3. Two lines of mice, lines 26 and 59, expressing th e  
EpEBNA-1 transgene, succumbed to monoclonal B cell ly m p h o m a s  
with latencies of 4-12 months and 18-24 months re sp ec t iv e ly .  
The tumour phenotype is a dramatic enlargem ent of the sp leen  
along with enlargements of the liver and/or lymph nodes. For th e  
purpose of this study EjiEBNA-1 line 59 was crossed with EpLMP- 
1 line 39 because of the long latency to lymphom a of line 59. Co­
operation may be easier to follow in this cross because a change in  
tumour latency might be more obvious than in a line 26 cross 
where the mice are overcome with EBNA-1 induced lymphoma as 
early as 4 months of age.
Evidence that two oncogenes can co-operate to in d uce  
lym phom agenesis is provided by other transgenic cross b re e d in g  
studies. For example, E [ i-p im  -1 transgenic mice demonstrate v e ry  
low incidence of tumour developm ent which can be e n h a n c e d  
with transgene optimisation (Lohuizen et al., 1989). E p-c-m yc 
transgenic mice are predisposed to monoclonal lymphomas of p r e -  
B or B-cell type (Adams et al., 1985). However, when these tw o  
lines of mice are crossed, the Ep-c-m yc / Ep-/?/m -1 b i - t ra n sg e n ic s  
develop B-cell lymphomas in u tero  dem onstrating dramatic c o ­
operation (Verbeek et al., 1991).
5B RESULTS
SB .  1 C ross -breed ing  EpLMP-1 with EpE BN A -1:-
Low level LMP-1 express ion  is su f f ic ien t  alone 
to induce l y m p h o m a g e n e s i s .
Homozygous E|iLMP-l (line 39) transgenic mice were c ro s s -b re d  
with hemizygous EpEBNA-1 mice of line 59. All the offspring f ro m  
the crosses should be EpLMP-1 positive (hemizygous), w h e re a s  
50% of the mice should be EpEBNA-1 positive. Thus there w e re  
two groups under observation, one with mice harbouring E p L M P -1  
alone (line 39), and another with mice bi-transgenic for b o th  
EpLMP-1 and EpEBNA-1 (line 39/59.)
37 mice of E |iLMP-l line 39 were born (See appendix 2). 
Unfortunately, during this extended period of study sp a n n in g  
more than 4 years, there have been several moves of the a n im als  
(between different animal houses) and several changes in an im a l 
house staff. As a consequence the time of death of 9 mice was n o t  
accurately recorded. These have been indicated as ? (for age a t  
death). Except for mouse 39/59.1 , it was not possible to a sce r ta in
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cause of death. In addition, for 3 mice, although the age at death is 
known, it was not possible to ascertain cause of death from th e  
carcasses. For 25 mice, age at death/sacrifice  due to ill health a n d  
cause of death are i known.
15/20 (75%) mice succumbed to lymphoid neoplasia (fig 5.1) 
with the gross appearance of lymphoma between the ages of 16.5 
and 24 months (with the end point of the experim ent at 2 4 
months of age). The average latency to lym phom a was 20.1 
months. 5 mice were sacrificed at the experim ent end point (2 2 -  
24 months old) without obvious pathological abnormality. Mice 
sacrificed before the age of 22 months due to ill health o r  
otherwise (e.g. wounds from fighting) which was not a t t r ib u ta b le  
to lymphoma were not included in the final totals. For this re a so n  
5 mice were withdrawn from the study (at months 11,12,14,20 & 
21), hence the final total of 20 EpLMP-1 line 39 mice (Summarised 
in appendix 2). As many of the 12 mice which d ied /w ent m iss ing  
without record are likely to have also succumbed to ly m p h o m a  
(e.g. mouse 39/59.1), the total of 75% is probably an  
u n d e re s t im a te .
The mice were generally healthy up to the age of 16 months, 
after which point signs of illness became evident. The mice h a d  
either a massive swelling of the abdomen or were hunched a n d  
slow moving. When examined, the mice displayed a m a ss iv e  
enlargem ent of the mesenteric lymph nodes (MLN) and sp leen , 
with variable involvem ent of the liver and peripheral ly m p h  
nodes. The enlargement of the spleen consistently correlated w ith  
the swollen abdominal appearance, whereas the mice that looked  
sickly and were hunched/ slow moving generally had a MLN 
lymphoma which was probably constricting the gut and causing  
d iscom fort.
Of the mice diagnosed with lymphoma 12/15 (80%) m ice
displayed MLN involvement, 12/15 (80%) showed sp le en
enlargements, with 9/15 (60%) showing enlargem ents of both th e  
MLN and the spleen (See appendix 2). No single mouse h a d  
lymphoma which did not involve either the MLN or the spleen. I n 
addition, occasional involvem ent of other organs was noted ( l iv e r  
27%, peripheral lymph nodes 27%, peyer's patches 20%).
Pathological diagnosis on a section of tissues from a ffec ted  
mice consistently indicated lymphoblastic lymphoma, often w ith  
m ulti-organ involvement. However, there were also t h r e e  
examples of Histiocytic sarcoma (mice 39/59.57, 59/39.13, a n d
59/39.23- see appendix 2).
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Figure 5.1
Incidence of lymphoma in line 39 mice. From 16 months onwards 
mice began to develop lymphoma of the mesenteric lymph node 
and/or spleen characterised by a massive enlargement of those 
organs. There was also variable involvement of other tissues such 
as peripheral lymph nodes, liver or thymus.
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5 B .2  IgH and TcR r ea r ra n gem en ts  of Line 39
tu m o u r  s
In order to investigate the cell lineage and clonality of th e  
lymphoid tumours, rearrangem ents of the e n d o g e n o u s  
immunoglobulin and T-cell receptor loci were analysed. DNA f ro m  
line 39 tumour tissues was extracted as described in the m e th o d s
section 7B.3.1. Where possible, DNA was extracted from th r e e
different tissues with tumour involvem ent per mouse, g e n e ra l ly
including MLN, spleen and one other tissue. This a llow s
comparison of tissues from the same mouse and comparison o f  
tissues between mice. The DNA was digested with Eco R1 a n d
electrophoresed  for southern blotting. Two different probes w e re
used in order to investigate the cell lineage and clonality of th e s e  
line 39 tumours. The murine immunoglobulin heavy chain and T- 
cell receptor loci were analysed for rearrangem ents by using a 
heavy chain joining region (Jh ) DNA fragment and a T-cell (3 
receptor joining region (TcR Jp2) DNA fragment respectively as 
p ro b e s .
Of the 8 mice tested which were diagnosed as h a v in g
lymphoblastic lymphoma, 5/8 (63%) showed clonal
rearrangem ents  of the IgH locus (figure 5.2a,b,c). The germ line  
6.5kb Eco R1 IgH-J fragment was present in all of the samples as 
expected whether neoplastic or not because the tumour t is su e s  
still contain normal cells within them. However, many tu m o u r  
samples revealed one or two other bands indicating an IgH 
rearrangem ent(s) . The rearranged fragments detected w e re  
identical in the neoplastic tissues from a single mouse and o n ly  
ever 1 or 2 bands per tumour were detected. This d e m o n s t r a te d  
that the tumours were monoclonal. For those tissues which w e re  
initially observed as being enlarged but for which no IgH 
rearrangem ents  were detected, it may be that the neo p las t ic  
com ponent in the sample was too minor for detection of th e  
rearranged band, or, that they do not harbour IgH  
re a r r a n g e m e n ts .
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F i g u r e  5 , 2 a : -  C l o n a l  i m m u n o g l o b u l i n  h e a v y  c h a i n  r e - a r r a n g e m e n t s
D N A  ext racted  f rom tumour  t issue was Eco  R1 d iges ted  and e i ec t rophore sed  for southe rn  blot t ing.
A heavy  chain jo in ing region ( Jh )  D N A  f ragment  was used as a probe to analyse the mur ine 
im m u n o g lo b u l i n  he a v y  cha in locus .  The ge rm  line 6 .5kb  Eco  R1 IgH-J f ragment  is present  in all of tl 
s amples  because  of  the p resence of  normal  cells within the tumour  mass.  However ,  many  of  the tumour  
sa mp le s  also con ta in  addi t iona l  bands  r ep resen t ive  of  IgH rea r r ang em ent s .
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F ig u re  5 .2b :-  C lonal im m u n o g lo b u lin  heavy chain  r e - a r r a n g e m e n ts  
DNA extracted from tumour tissue was E co  R1 digested and electrophoresed 
for southern blotting. A heavy chain jo ining region (Jh) D N A  fragment was 
used as a probe to analyse the m urine immunoglobulin heavy chain locus. The 
germ line 6.5kb E co  R1 IgH-J fragm ent is present in all of the samples because 
of the presence of normal cells within the tumour mass. However, many of the 
tum our sam ples also contain additional bands representive of IgH 
r e a r r a n g e m e n t s .
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DNA ext racted f rom tumour  tissue was Eco  R1 d iges ted  and e lec t rophoresed  for  sou the rn  blott ing.
1 heavy chain jo in ing region (Jh)  D N A  f ragment  was used as a probe to analyse the murine immunoglobu lin  
kavy chain locus.  The ge rm  line 6.5kb Eco  R1 IgH-J f ragment  is present  in all of  the samples  because of the 
presence o f  n o r m al  cel ls  with in  the tu mo ur  mass .  H o w e v e r ,  many  of  the tu m o u r  samples  also con ta in  
additional ba n ds  r ep rese n t ive  of  IgH rea r rangem ents .
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Three of the mice which developed tumours were diagnosed 
as having histiocytic sarcoma’s although their gross appearance 
matched that of mice diagnosed as suffering from lymphoblastic 
lymphoma. The mice, 39/59.57, 59/39.13, and 59/39.23, all had 
slightly enlarged and highly discoloured spleens with a "lumpy 
texture" or obvious tumour in one area, and all had MLN 
involvement. The tumours from these mice were investigated 
further. IgH rearrangements were not detected in the tumours of 
mice 39/59.57 or 59/39.23, but were for mouse 59/39.13 (MLN 
tissue) (figure 5.2b) When tumours from these mice were 
analysed for TcR rearrangements, one set of samples from the 
mouse 59/39.13 revealed two additional bands along with the 
expected 2.0kb germline band indicating that rearrangements had 
occurred at both TcR alleles (figure 5.3). Although the upper band 
could potentially be a product of partial digestion, the lower band 
cannot. Both neoplastic tissues analysed had the same banding 
pattern. However, since IgH rearrangements were also noted for 
this tumour, it is not clear if both IgH and TcR rearrangements 
reside within the same neoplastic cells or if there are two cellular 
components to the tumour. No TcRP rearrangements were seen in 
tumour tissues from the other two mice with histiosarcoma or
from the 5 mice with lymphoblastic lymphoma. These three mice
may therefore represent a subgroup of tumours from line 39. No
other tumour samples revealed detectable alterations in the TcRp 
locus (figure 5.4)
Thus, in this line, low level LMP-1 expression in the 
lymphoid compartment of transgenic mice results in the 
neoplastic conversion to lymphoma which are predominantly B
cell in origin and monoclonal.
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F i g u r e  5 .3: -  T c R  r e - a r a n g e m e n t s
A T  cell  Receptor  J(32 probe was used to analyse the murine TcR  locus for r e ­
a r rangements .  The germ line 2.0kb E co  R1 TcR-JP2 fragment  is present in all of 
the samp les  because of  the presence of normal  cells within the tumour  mass.  
H ow eve r ,  sample  59/39.13 contains  ext ra bands  r epresentat ive  of IgH 
r e a r r a n g e m e n t s .
K EY-
* >  ^ > =  Extra bands from con tam ina ted  loading dyt
T cR  re -a r rangements
*= u n d e r lo a d e d  
o = poss ible part ial  digest ion pat t er r
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F ig u re  5-4
A T  cell Receptor  JP2 probe was used to analyse the murine TcR locus tor 
r ea r rangements .  The  ge rm line 2 .0kb EcoR1 TcR-jp2 f ragment  is the only band present
indicat ing  that  nor  r ea r rangements  of this locus have taken place in these tumours.
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5B .3  LMP-1 and EBNA-1 do not co-operate in
Ivm phom agenesis.
52% of the cross 39/59 FI mice were transgenically positive 
for both LMP-1 and EBNA-1 as determined by southern blotting 
of DNA extracted from tail and other tissues (See appendix 3). 
Both line 39 and 59 independently induce monoclonal B cell 
lymphoma of notably different gross presentation. Line 3 9 
present with lymphomas of the MLN plus spleen (60%) with no 
single case where either the MLN or spleen was not involved. Line 
59 on the other hand present with lymphomas of the spleen in 
100% of cases accompanied by liver and/or peripheral lymph 
node involvement. The MLN is very rarely a target for neoplastic 
involvement in line 59 (Wilson et al., 1996).
16/19 (84%) of bi-transgenic mice succumbed to lymphoid 
neoplasia between the ages of 16.5 months to 24 months, with an 
average latency to lymphoma of 20.2 months (figure 5.5). The 
pathological diagnosis was that of lymphoblastic lymphoma, 
generally with multi-organ involvement. 40 bi-transgenic mice 
were born in total, but due to the problems referred to in section 
5.2, 11 mice were found dead/missing and are denoted by ? in 
appendix 3. A further 10 mice were sacrificed before 22 months 
of the study period due to ill health not lymphoma related. These 
21 mice were not included in the final totals.
The general symptoms noted for the bi-transgenic mice 
were similar to those previously described for line 39. The mice 
had either an obviously distended abdomen or a hunched sickly 
appearance. 13/16 (81%) bi-transgenic mice had MLN
involvement, with 12/16 (75%) having spleen involvement. 100% 
of mice had lymphoma involving either MLN or spleen as was the 
case for line 39. Therefore MLN and spleen are again the two 
major tissues targeted for neoplastic alterations. This therefore 
differs from the line 59 situation where there is not usually a 
major involvement of the MLN (Wilson et al., 1996). In addition, 
liver (31%) and peripheral lymph nodes (44%) were also involved 
in some lymphoma cases in these bi-transgenic mice. The only 
differences between the tumour incidence in line 39 and the bi- 
transgenic mice were seen in the thymus and peyer's patches. 
25% of the bi-transgenics had enlargement of the thymus (as seen 
in line 59), whereas no mice from line 39 showed this phenotype. 
However, 20% of line 39 mice displayed involvement of the 
peyer's patches, a symptom not observed in either the bi- 
transgenics or line 59 mice. The gross phenotype therefore seems 
to reflect a combination of line 59 and line 39
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Figure 5.5:-
The incidence of lymphoma in line 39 mice compared to the 
bi-transgenic line 39/59 mice. There is no acceleration of 
tumorigenesis when both transgenes are expressed.
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DNA from bi-transgenic tumour tissue was extracted as 
described in the materials and methods in order to investigate cell 
lineage and clonality of the tumours. The same probes as 
described in section 5B.2 were utilised. Of the DNA from 12 b i-  
transgenic tumour samples tested, 8/12 (67%) d e m o n s t r a te d
clonal rearrangem ents of their IgH locus (figure 5.2). T he 
rearranged fragments detected were identical in the neop las tic  
tissues from a single mouse, demonstrating that the tumours w e re  
monoclonal. No rearrangem ents of the TcRp locus were d e te c te d  
indicating that the tumours are B cell in origin (figure 5.4).
Therefore, bi-transgenic mice expressing LMP-1 and EBNA-1 
in the lymphoid com partm ent succumb to ly m p h o b la s t ic  
lymphom a with phenotypes similar to the transgenic mice of 
EpLMP-1 line 39.
5C  D iscussion  o f  c h a p te r  5.
Expression of EpLMP-1 in line 39 is so low as to be a lm o s t  
undetectable by Northern blot on an extremely long len g th  
exposure. Despite this low level of expression, 75% of line 39 m ice  
succumbed to lymphoid neoplasia by 24 months of age. The f i r s t  
observation of neoplastic alterations was at 16.5 m o n ths . 
Thereafter mice steadily developed lymphoid tumours at a r a t e  
which gave an average latency to neoplasia of 20.1 months for th e  
75% of mice affected. Pathological diagnosis revealed that th e s e  
neoplasia’s were consistently lymphoblastic lymphoma, and in 
many cases encompassed many different organs. 3 cases o f 
histiocytic sarcoma were also noted although their g ross 
appearance did not differ from the lymphoma’s.
The tissues affected by these tumours were p r e d o m in a n t ly  
mesenteric lymph node and spleen with occasional involvement of 
other organs. Examination of the murine IgH and TcR loci in th e s e  
tumours to investigate the cell lineage and clonality of th e s e  
tumours, indicated that 63% showed clonal rearrangem ents  o f 
their IgH locus. The rearranged fragments were identical in th e  
different tumour tissues from a single mouse and only showed 1 
(or occassionally 2) rearranged bands indicating that the tu m o u rs  
were monoclonal (as several bands, even if the same in all th e  
tissues would mean that the tumour was at least oligoclonal in 
origin). One of the mice which was diagnosed as carrying a 
histiocytic sarcoma showed rearrangem ent of the TcR locus a n d  
IgH locus. Im m unohistochem ical analysis of the tumour w ith  
reagents which distinguish between B and T cells would reveal if
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this tumour was monoclonal or 2 cell types. Apart from this single  
example, the TcR locus was intact in every other case examined.
Therefore, it would appear that extremely low leve l
expression of LMP-1 in the lymphoid com partm ent is sufficient to  
induce a neoplastic conversion to lymphoma. These ly m p h o m a s  
are predom inantly  B-cell in origin and monoclonal. It is poss ib le  
that a subset of tumours exists which are histiocytic sarcomas a n d  
may show T-cell involvement. Certainly the only r e a r r a n g e m e n t  
of the TcR locus noted came from this group of 3 mice. 
Nonetheless, this is the first example of an in vivo role in 
lymphomagenesis for LMP-1.
Direct comparison can be made with another EBV la te n t ly  
expressed gene which induces lymphoma in transgenic mice. Two 
lines of EpEBNA-1 mice, lines 26 and 59, also succumb to
lymphoma (Wilson and Levine, 1992; Wilson et al., 1996). 100% of 
line 26 mice develop monoclonal B-cell lymphomas between 4 to  
12 months of age. Line 59 mice also develop lymphoma but with a 
much longer latency with approxim ately 50% of the m ice  
succumbing between 18 to 24 months. In both cases the t is su es
involved always include spleen with liver or lymph n o d e  
involvement. Thus EpLMP-1 line 39 mice succumb to ly m p h o m a  
at a slightly faster rate than EpEBNA-1 line 59 but with a
different bias in organ involvement.
Indeed this B-cell specific oncogenicity by LMP-1 may b e  
highly significant in understanding Hodgkin’s Disease. T he 
pathogenesis of HD is poorly understood but it is believed that th e  
m ultinucleated RS cells of the tumour mass are B-cell in orig in  
(Kieff, 1996). As LMP-1 has been shown to be present in RS cells 
of EBV positive HD tumours it is conceivable that it is the p re s e n c e  
of LMP-1 which drives the B-cell to assume the morphology of an  
RS cell. This premise is supported by the observation that LM P-1 
transfected into HD negative cells gives rise to cells with a n  
appearance very similar to that of RS cells (Knecht et al., 1996). 
Therefore, EpLMP-1 may be of significant value as a mouse m o d e l  
for EBV positive HD, however cells in those mice do not have an RS 
cell morphology. High level expression in many tissues of LM P-1 
in other EpLMP-1 lines appeared to be toxic. If this problem could  
be overcome it would be interesting to observe whether 100% of 
the mice would then succumb to lymphoma and if the latency to  
lymphoma would reduce.
Two other EBV latently expressed proteins, EBNA-1 a n d  
EBNA-2, are consistently detected in HD. EBNA-1 is n e ce ssa r i ly  
present because of it’s role of maintaining the viral episome. T he 
recent report from Wilson et al., 1996, have shown that EBNA-1 is 
oncogenic in vivo and therefore might also be involved in th e
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pathogenesis of HD. Whilst this may indeed be true, EpLMP-1 line  
39/EpEBNA-l line 59 bi-transgenic mice did not show c o ­
operation between EBNA-1 and LMP-1 in lymphom agenesis. This 
suggests that their functions may overlap using this assay of 
tumour latency. Crossbreeding with line 26 should be u n d e r t a k e n  
to confirm this theory.
84% of the bi-transgenic mice developed lymphoid n e o p la s ia  
with an average latency to lymphoma of 20.2 months. All 
lymphoid neoplasia’s which were pathologically examined p ro v e d  
to be lymphoblastic lymphomas. Similar percentages to line 39 fo r  
the individual organ involvement were also observed a lth o u g h  
slightly more liver and peripheral lymph node involvem ent w a s  
diagnosed in the bi-transgenic group. Almost identical numbers o f 
tumours showed monoclonal rearrangem ents of the IgH locus as 
was noted for line 39. Thus LMP-1 and EBNA-1 do not c o -o p e ra te  
to accelerate lymphomagenesis, and the tumours arising a ffec t  
very similar tissues to those seen previously in EpLMP-1 line 39.
Records for several mice were not kept (as detailed) so it is 
entirely possible and indeed likely that the percentage of mice in  
both line 39 and the bi-transgenic group which succumb to  
lymphoma is underestim ated. Furthermore, tumours which fa i led  
to highlight IgH rearrangem ents may simply have had a 
neoplastic component of the tissue too small to detect.
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CHAPTER 6:- Discussion and future work.
6 A
In the transgenic epidermis LMP-1 acts to increase ce llu la r  
proliferation. It is likely that it is through this action that i t  
functions as a tumour prom oter in chemical carcinogen s tud ies . 
T reatm ent of mouse dorsal skin with tumour prom oters such as 
TPA results in a variety of events. It is unknown w hether one of 
these occurrences is vital in promoting carcinogenesis, or w h e th e r  
the collection of events as a whole is essential. One such ou tcom e  
of repeated TPA trea tm ent is persistent general h y p e rp la s ia  
similar to that observed in PyLMP-1 lines 5 and 53. A n o th e r  
event influenced by TPA is the induction and activation of EGFR, a 
characteristic  observed in LMP-1 positive NPC biopsies. T hus 
LMP-1 may mimic some of the actions of the strong tu m o u r  
prom oter TPA.
A recent report adds support to the findings presented in 
this thesis. Anti-sense oligonucleotides to LMP-1 sequence , 
designed to suppress LMP-1 gene expression, resulted in an  
inhibition of proliferation of EBV transform ed B ly m p h o c y te s  
(Mattia et al., 1997). This suggests that LMP-1 functions to  
increase proliferation of LCL’s as well as the tran sg en ic  
e p ith e l iu m .
In these studies, no im pairm ent of the d if fe re n t ia t io n  
process was evident, in contrast to an earlier report using th e  
assay of in vitro transfection of LMP-1 into an imm ortalised n o n -  
tumorigenic squamous cell carcinoma line SCC12F (Dawson, et a l,
1990). These cells showed an im pairm ent in response to  
differentiation signals. However, this study was conducted in v i tro  
on one sub-clone of a cell line which was derived from a 
carcinoma. Therefore SCC12F may differ in many respects to th e  
situation in a living model such as the PyLMP-1 mice. In th e  
epidermis of transgenic mice, LMP-1 is the only a b n o rm a li ty  
within these cells, whereas when transfected into SCC12F cells, 
LMP-1 is arriving at an advanced stage of tum origenesis and m a y  
therefore act in a different manner, or in combination with o th e r
abnormal factors. The work described by Dawson and later b y  
Fahraeus et al., 1990, and Zheng et al., 1994a, may well r e f le c t
that the cell lines are already immortal, it is difficult to c o m p a re
the results with the in vivo situation in primary epithelium.
It should also be remembered that work with cell lines often 
gives confusing or contradictory results as evidenced by th e  
different effects induced by LMP-1 when transfected in to
different epithelial or B-cell lines (section ID .3). This adds f u r th e r  
difficulties to interpreting cell culture experiments. In d e e d ,
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Nicholson et a l ., 1997, reported that LMP-1 was not in h ib it in g
differentiation in the human epithelial cell line SCC12F in v i t ro  
and in vivo providing contradicting results to Dawson. Certain ly , 
differing levels of LMP-1 expression may contribute to th e
conflicting results since very high, non-physiological levels can b e  
achieved in some cell lines in culture.
One avenue not explored in chapter 2 was that LMP-1 cou ld  
be acting to block apoptosis thus causing a build up of cells a n d  
the observed PyLMP-1 phenotype, in addition to the increase in  
proliferation. LMP-1 has been shown to induce apoptosis in a 
human epithelial cell line (Rhek-1) although high levels of LM P-1 
expression were noted (Lu, et a l,  1996) and this is only a single  
report. Furtherm ore Wilson et al noted that expression of th e  
EpLMP-1 transgene was possibly toxic. With the increase o r  
induction of expression of Bcl-2 (Rowe et a l,  1994) and M cl-2  
(Wang et al., 1996) in B-cells, and the induced expression of CD40 
(Wang et al., 1988; and Dawson et al., 1990) and A20 (Miller et al., 
1995; and Laherty et a l,  1992) in both B-cells and epithelial cells 
following LMP-1 expression, it is possible that LMP-1 con fe rs  
protection from apoptosis to these cells. Investigating the level of
apoptosis in the epidermis of the PyLMP-1 mice might a n s w e r
such a question.
Taking all of the results into consideration, it appears t h a t  
LMP-1 operates in v ivo  to increase the rate of c e l lu la r  
proliferation in the epidermis (chapter 2). The results f ro m  
chapter 3 clearly support this. Papillomas arise as a result o f 
expansion (proliferation) of a single initiated cell. The o b se rv a t io n  
that LMP-1 expression transgenics developed more p ap il lo m as  
than the negative control mice suggests that the PyLM P-1 
epidermis displays increased cellular proliferation. That LM P-1 
has weak tumour promoting activity and more importantly acts as 
an effective second stage promoter is further indirect e v id e n c e  
that LMP-1 increases cellular proliferation. This has im p o r ta n t  
implications for the EBV associated malignancy NPC. A 
proliferating pool of cells might be more at risk of an oncogenic 
m utation leading to carcinoma than would non proliferating (o r  
slowly proliferating) epithelium. Indeed, Ki67 has also b e e n  
shown to be increased in NPC (Zheng et al., 1994b) indicating t h a t  
there is increased proliferation involved in NPC. Furthermore, it is 
known that proliferative activity and EGFR expression, e v e n ts  
induced by LMP-1, are linked to the size and stage of v a r io u s  
neoplasm ’s. Therefore LMP-1 expression in NPC may e n h a n c e  
proliferation and EGFR expression. Although an antibody to EGFR 
was available for use in im m unohistochem ical analysis of line 5 3 
dorsal skin, it was a murine monoclonal and problems w ith  
background levels of staining proved inhibitory to the analysis of
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the staining pattern. Determining the level of expression of EGFR 
in the PyLMP-1 mice therefore remains to be addressed.
In chapter 3 LMP-1 expression was shown not to b e  
sufficient to initiate carcinogenesis, nor was it able to in f lu e n ce  
the m alignant conversion rate or type of tumours arising. 
However, one cannot rule out a continued role for LMP-1 in d u c e d  
proliferation at this stage of carcinogenesis. Lymphoid in f i l t ra t io n  
has been observed in many NPC’s (giving rise to the t e r m  
lym phoepitheliom a) and it is possible that LMP-1 is in f lu en c in g  
this by activating the lymphocytes. It is also possible that LM P-1 
is acting to upregulate other potential oncogenes during m o u se  
skin carcinogenesis to act in concert with LMP-1 or to continue the 
carcinogenic process.
To investigate this possibility further, the PyL M P-1  
transgenic mice were bred with K5-Hara.v (provided by K.Brown) 
transgenic mice (chapter 4). While LMP-1 action has b e e n  
compared to activated ras in tissue culture experiments (D aw son 
et al., 1990) and has been proposed to upregulate EGFR (w h ich  
impacts the ras pathway) several studies here indicate that th e  
action of LMP-1 and ras are separate. For example, LM P-1 
increases cellular proliferation 2 to 3-fold whereas ras did n o t
induce a significant increase in proliferation. Chapter 3 sh o w e d  
that LMP-1 acts as a tumour promoter, not an initiator w h e r e a s  
ras is a tumour initiator not a promoter (although it is m u ta t e d  
further as a result of promotion). Finally, LMP-1 inhibited the K5- 
H aras phenotype of sebaceous adenomas (possibly as a result o f  
the hyperplastic  phenotype which the K5-Hara.v mice do n o t
display). Both the PyLMP-1 and K5-Har«.y mice were bred in a 
C57B1/6 background, a strain known to be resistant to the e ffec ts
of chemical carcinogens (DiGiovanni, 1991). Although not fu lly  
investigated, there appear to be susceptible ethnic groups to NPC. 
There may therefore be some correlation between th e  
susceptibility  genes involved in man and the suceptibility  to  
chemical carcinogenesis in mouse. Crossing both lines to th e
susceptible FVB background was initiated but not completed d u e  
to time constraints. The results from this cross might p ro v id e  
further information if the C57B1/6 background masked any c o ­
operative action between the proteins. The prom oter used in  
generating the ras mice was a truncated K5 promoter giving r is e  
to hair follicle expression. It is unclear whether LMP-1 is 
expressed in the hair follicles or not. If the expression p a t t e r n s  
are very different any potential co-operation would not be p ic k e d  
up in this particular crossbreed.
p53 is frequently mutated during chemical ca rc in o g en  
induced mouse skin carcinomas. This tumour suppresser protein is 
m utated at late stages in the pathway to carcinoma. LMP-1 m a y
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still play a role at this stage (providing proliferation) but in th e s e  
mice no increase in progression was noted. LMP-1 e x p re s s in g  
NPC’s grew faster than LMP-1 negative NPC’s (Hu et al., 1995) b u t  
expression was absent at later stages of NPC, suggesting that LM P-
1 acts early on during the disease process but may not b e  
required at later stages. The PyLMP-1 transgenic mice bred w ith  
p53 knockout mice showed identical latency and patterns o f 
tum our incidence as seen in p53 knockout mice alone where no  
skin carcinomas were observed. This suggests that the absence of 
p53 does not co-operate with LMP-1 in carcinogenesis. Lack of c o ­
operation between LMP-1 and P53 may be because further co- 
o p e ra to rs )  acting early are required before p53 loss takes effect. 
Bi-transgenic LM P Iras mice bred with p53 knockouts m ig h t  
provide answers to this point. Furthermore, other v ira l  
components are present in the disease state of NPC. EBNA-1, LM P-
2 and BARFO might be required in conjunction with LMP-1 b e fo re  
loss of a tumour suppresser might have an effect, p i 6 is known to  
be m utated in NPC and loss of this or other tumour s u p p r e s s e r  
genes in conjunction with LMP-1 (and other viral proteins) m ig h t  
be required for NPC to develop. The LMP-1 variant used to c re a te  
the transgenic lines involved in this work came from the B 95-8
strain of EBV. Using the NPC LMP-1 variant and d irec tin g  
expression to the nasopharynx, then crossing these mice w ith
transgenics where LMP-2 and EBNA-1 are also directed to th is  
region, might provide a more accurate model for NPC. This
programme of work is ongoing in the laboratory.
Correlating these results with the disease state of NPC a ro le  
for LMP-1 can be hypothesised. LMP-1 has no apparent in it ia t in g  
ability therefore requires this event to occur before it can e x e r t  
it’s effects. However, by increasing proliferation as a p r im a r y  
event, LMP-1 might increase the chances that an initiating e v e n t  
occurs. Once the nasopharynx is initiated, the in c re a s e d
proliferation induced by LMP-1 acts to promote ca rc inogenes is . 
When this event has proceeded, other factors come into play to  
convert the promoted cells to carcinoma. It is interesting to n o te  
that the diet of those Southern Chinese prone to NPC in c lu d es  
salted fish. The volatile nitrosam ines produced during th e  
preparation  of the fish have been shown to have tu m o u r  
promoting activity (Zou et al., 1994; Zou and Landolph, 1991; Yu e t  
al., 1989). In conjunction with the second stage promotion of LMP- 
1, this might be sufficient to either induce, or strongly p ro m o te  
carcinogenesis. Alternatively, with other factors present (EBNA-1, 
LMP-2 etc) including the promotion from the vo la ti le  
nitrosamines, LMP-1 might act as a strong (1st stage) prom oter in  
the nasopharynx. The epithelial cell type in the n a s o p h a ry n x  
might be different to the epithelial cells studied during m o u se
155
skin carcinogenesis allowing LMP-1 to act as a stronger p ro m o te r .  
Creating tri-transgenic (LM P-1/LM P-2/EBNA-1) mice w ith  
nasopharyngeal expression and feeding them salted fish or th e  
equivalent nitrosamines might recreate the situation in man in S.E. 
Asia. If this proves too difficult, treating PyLMP-1 t ra n sg e n ic  
epidermis with volatile nitrosamines would also provide results to  
support or contradict the hypothesis that this combination is 
oncogenic. With the creation of carcinoma cell lines from LM P-1 
positive and negative mice, and the creation of B-cell lines f ro m  
line 39 mice, this project could be taken in vitro. Analysis o f 
these cell lines for p l6 ,  p53, H a -ras  mutations etc. would be an  
interesting undertaking. These cell lines could also be used to  
investigate the LMP-1 signalling pathway. If it was intact in th e s e  
cell lines then it is likely that it is intact in vivo. A20, EGFR, NF-kB, 
CD40 etc. levels could all be analysed both in vitro and in vivo.
The results from the cross-breeding of PyLMP-1 and th e  
K lO -TG Fpl mice in chapter 4 are more difficult to interpret. Here, 
almost all of the FI mice born were LMP-1 negative sugges ting  
that the combination of the two transgenes is lethal in utero. Early  
analysis of em bryo’s taken from e l 6 onwards suggests that th is  
lethal effect takes; place earlier than e l 6. TGFpi expression is 
“switched on” at ertibryonic day l5  of mouse developm ent (B yrne  
et cil., 1994). If the bi-transgenics are dying earlier than this t im e  
point it may be due to this expression date being brought forward. 
Indeed LMP-1 has been shown in our laboratory to u p re g u la te  
expression of K10 3-4 fold at post natal d8. If this u p re g u la t io n  
occurs during em bryogenesis it is possible that LMP-1 is 
upregulating the K10 prom oter of the TGFpi transgenic mice th u s  
indirectly upregulating TGFpi. Early over-expression of TGFpi is 
known to be lethal to developing em bryo’s and might explain th e  
death in utero of the potential bi-transgenic mice. That 4/192 F I  
mice born from one litter were LMP-1 positive and only 2 
survived to adulthood suggests some genetic influence a llow ing  
these particular mice to escape the lethal effects of T G F p i.
The results from chapter 5 may have im portant s ign ificance  
to the study of other EBV associated malignancies, such as HD, a n d  
lymphom a in im m unosuppressed  patients. In chapter 5 I sh o w e d  
that transgenic mice expressing LMP-1 in the B-cell c o m p a r tm e n t  
succumbed to long latency monoclonal B-cell lymphomas. In th e  
subset of HD cases where EBV is associated, LMP-1 is e x p re s s e d  
and may therefore play a causal role. Indeed, LMP-1 t ra n s fe c t io n  
into an EBV negative HD cell line resulted in the appearance of RS 
morphology cells (Knecht et al, 1996). The results presented h e r e  
dem onstrate  that LMP-1 can predispose B-cells to ly m p h o m a . 
However, cells within the tumour do not adopt the RS m orpho logy .
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This might be because other factors, such as EBNA-1 and L M P-2  
(both expressed in HD) are not present. However, the b i-  
transgenic tumours also failed to adopt an RS morphology. F u r th e r  
crossbreeding experim ents to generate tri-transgenic LM P- 
1/LMP-2/EBNA-1 mice are required to generate a closer m o d e l  
for HD. The lack of HD morphology observed in the EpLMP-1 m ice  
may also reflect a difference between mouse and man. In th is  
chapter I also showed that LMP-1 and EBNA-1 do not c o -o p e ra te  
in inducing lymphom agenesis. This suggests that the functions o f 
the two proteins overlap in lym phom agenesis, or that a c o ­
operative action does not effect latency to tumour onset (the assay 
used here) but some other aspect of tumour progression n o t  
s tu d ied .
This thesis has therefore shown that LMP-1 acts to in c re a se  
the rate of cellular proliferation in PyLMP-1 transgenic e p id e rm is .  
LMP-1 has also been shown to be a mild or second stage tu m o u r  
promoter. Furthermore, LMP-1 has been shown to p re d is p o s e  
EpLMP-1 transgenic mice to B-cell lym phom a’s. Expression of th e  
LMP-1 transgenes in both lines of mice is low. It is interesting to  
speculate what might happen with regards to oncogenicity, if  
LMP-1 was expressed at higher levels or in a different e p ith e l ia l  
cell e.g. mucosal or basal cells. Obviously generation of n e w  
transgenic lines where LMP-1 is expressed at higher levels w o u ld  
be interesting.
The work presented in this thesis indicates that LMP-1 is 
likely to play a causal role in NPC and certain other EBV associated 
ly m p h o m as .
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CHAPTER 7:- Materials and methods .
i
7 A MATERIALS.
7 A . 1  Cells .
EBV negative cell lines:-
Ramos- Derived from an American BL - cat no. 85030802 
BJAB- Derived from an African BL - cat no. DSM ACC72
EBV positive cell lines:-
B95-8 - Marmoset peripheral blood lymphocyte cell line d e r iv e d  
following infection with B95-8 virus. Cell morphology b o th  
lymphocyte and fibroblast - cat no. 85011419 
Raji- Derived from an African BL - 85011429
Ramos-EHRB- The Ramos cell line infected in v itro  with EBV - c a t  
no. 85030804
All cell lines were provided by the European Collection of A n im al 
Cell Cultures(ECACC) except BJAB which was obtained from th e  
German Collection of micro-organisms and cell cultures (DSM).
Carcinoma cell lines were derived from mice treated w ith  
carcinogens where the carcinoma was explanted into medium (see  
methods section 7B.2.1).
7 A . 2 Ant i sera .
CD45R/B220
CD 90(Thy.l)
CRA Fl(M -20)
Desmocollin
D esm oplak in
EBNA-1 (AZA-2E8)
PharMingen, FITC conjugated Rabbit 
polyclonal anti-mouse CD45R, cat no.
0 1 1 2 4 A
PharMingen, Rabbit polyclonal anti-mouse 
CD90, cat no. 01021D
Santa Cruz Biotechnology, rabbit po lyclonal 
anti-mouse CRAF1, cat no. sc-947 
A kind gift from Prof.D.Garrod, Manchester 
Univ., rabbit polyclonal anti-bovine 
d e sm o c o l l in l
Mouse monoclonal anti-Desmoplakins 1+2 
(clone 11-5F), a kind gift from 
Prof.D.Garrod, Manchester Univ 
Monoclonal anti-EBNAl secreted from a 
hybridoma cell line (Hearing et a l , 1985)
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EGFR
Keratin 14
Ki67
LM P(C Sl-4)
LMP
LM P(S12)
MB1.2
TNFRII
Sigma, Mouse monoclonal anti-human 
EGFR, cat no. E2520 
A kind gift from Christina Cheng, NIH, 
Bethesda, affinity purified Rabbit 
polyclonal anti-mouse K14, designated 
K14-AF no.64
Dako, Rabbit polyclonal anti-human Ki67, 
cat no. A0047
Dako, Mouse monoclonal anti-LMP, cat no. 
M 0 8 9 7
Rabbit polyclonal anti-LMP peptide 
(Baichwal and Sugden, 1987)
Mouse monoclonal anti-LMP(C-terminus) 
secreted from a hybridoma cell line,
(Mann et al , 1985).
A kind gift from Dr.B.Chan, Univ. of 
Western Ontario, Rat polyclonal a n t i -m o u s e  
V L A -p i in tegrin
Santa Cruz Biotechnology, Goat polyclonal 
anti-mouse TNFR2, cat no. sc-1074
7 A .3 Reagents and solut ions .
A crv lam ide :-
A 30% solution of acrylamide/bis 29:1 (Bio-rad) was used w h ich  
was de-ionised by stirring with Amberlite beads (Sigma) and 
filtered through Nalgene 0.45fim filters. Ammonium p e rs u lp h a te  
(Sigma) was used to initiate polymerisation, catalysed by TEMED 
(Bio-rad).
A garose:- SeaKem LE agarose - Flowgen
Low Melting Point (LMP) - Gibco
A u to rad io g ra p h y :  -
Kodak XAR was used for most autoradiograms, or alternatively the 
more sensitive Kodak Biomax MS film.
Film development- X-ograph compactX2
Intensifying screens - Genetic Research Instrumentation(GRI) Ltd. 
Cassettes - GRI
Bag sea le r:-  Vacuum bag sealer - Salton
Buffered ph en o l:-  Buffer-saturated phenol pH7.5 - Gibco
Buffers:- MOPS-E - Boehringer
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Tris-base - Boehringer
Cam era+film :-
UVP image processor, Mitsubishi video copyprocessor a n d  
Mitsubishi thermal paper K65HM.
C e n t r i f u g e s Eppendor f  centrifuge 5415C
Beckman centrifuge model J2-21 
Heraeus labofuge 400
Chem icals:- Acetone- Fischer scientific
BrdU- Sigma 
BSA- Sigma
Chloroform- Fischer scientific
DAB- Sigma
DEPC- BDH
DePeX- Gurr’s
DMBA- Sigma
Ethanol- Fischer scientific
Ethidium bromide- Boehringer
Formaldehyde- BDH
Formamide- Sigma
Gelatin- Sigma
Haematoxylin- Sigma
Histoclear- National diagnostics
Hydrogen peroxide- Sigma
Isopropanol- Fischer scientific
Methanol- Fischer scientific
M ercaptoethanol- B io-rad
PMSF- Sigma
Tespa- Sigma
TPA- Sigma
D e te rg en ts :-  NP-40 - Sigma
SDS- Fisons/Sigma 
Triton-X-100 - Bio-rad 
Tween 20- Bio-rad
E lec trop ho res is :-
Power pack- 0-250v; 0.25A, Kikusui electronics 
Electrophoresis tank(DNA/RNA)- Kodak international
biotechnologies inc. 
Electrophoresis SDS-PAGE tank- Bio-rad Protean Ilxi cell and
mini-protean II cell 
Electroblotter(DNA/RNA)- TE series TransphorElectroblotter,
Hoefer
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El ec t r ob l o t t e r ( pr o t e i n) -  Hoefer
lkb  L a d d e r :-  
E nzvm es:-
Heating b locks:- 
H om ogen iser:-  
M e m b ra n e s : -  
M icroscopv:-
Microscopes used were the Olympus CK2 for tissue culture and cell 
counts, and the Leitz orthoplan for Fluorescence and high p o w e r  
magnification (i.e. x25-xl00).
Slides- Superfrost, Menzel-Glazer
Mouse su p p lie s :-  Anaesthetic- Fluothane liquid, Zeneca Ltd
Anaesthetising chamber- Fluotec 
Cauterising iron- International Market
Supply
Ear punch- ORME scientific 
Shaver- W elonda
PCR:- PCR machine- Appligene oncor crocodile3
Oligonucleotides- In-house or Cruachem 
Taq polymerase- Promega 
B uffer+M gC l 2 - Promega 
dNTP’s - Boehringer
Plasmids and P ro b e s : -
EBNA-1 - To detect the EBNA-1 transgene in blotting analysis, a 
1Kb Bst X I -Eco R1 3’ EBNA-1 DNA fragm ent derived from th e  
plasmid pEpEBNA-1 (lab no. 114) was used (Wilson and Levine, 
1992). See section 7B.3.5 for methods used to generate and iso la te  
all probe fragments used.
L M P - 1 - A Hind  III- Eco  R1 3kb fragm ent from plasmid pP yL M P - 
1 (lab no. 139) was used to detect the LMP-1 transcript (Wilson e t  
al,  1990).
Gibco
Aprotinin- Sigma 
DNA restriction enzymes- Gibco 
Exo(-) Klenow- Stratagene 
Lysozyme- Sigma 
Proteinase K- Boehringer 
Trypsin- Sigma
Eppendorf therm om ixer 5436
Kinematica polytron
Biodyne A+B, Pall biosupport membranes
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IgH J Region- X ba  1- X h o  1 900bp fragment from plasmid pEp(py) 
Bspt (lab no. 79).
p 5 3 - Kindly provided by Ken Brown at the CRC Beatson Labs.
Eco  R l-  N co  1 250bp fragment from plasmid pMt T (lab no. 287).
R as- Kindly provided by Ken Brown at the Beatson CRC Labs.
Sac  1 digest of plasmid Bklllrr/.v (lab no. 233) yielding a 2 .4 k b  
f ra g m e n t.
TCR Jfti+ 2  - Kindly provided by Jim Neil, Vet School, Glasgow, 
j p i -  Eco R l-  B am  HI 3.3kb fragment (Palacios and F am arid is ,
1991). Lab no. 463.
Jp2- Eco R l-  Hind  III 750bp fragment from the pJ locus (Palacios 
and Famaridis, 1991). Lab no. 464.
TGFp - Kindly provided by Rosemary Akhurst, Medical genetics, 
Glasgow. Sac  1- Xho  1 850bp fragment from plasmid pPoly A ( lab  
no. 453).
Radio-isotopes and associated e q u ip m e n t : -
All isotopes were obtained from ICN or Dupont in 0-4°C storage
liquid Easytide form respectively. Isotopes used were a 32P dCTP,
3 0 0 0 c i /m m o l .
Hybridisation- Hybaid midi oven and hybaid hybridisation tubes 
Isotope separation- Nuctrap probe purification columns and push
column beta shield device, Stratagene 
Pipette Tips- Aerosol Resistant Tips(ART), Gibco 
Random  prim ers/buffers/klenow - Stratagene Prime-it II kit. 
Scintillation counter- Beckman L S I 801 liquid scintillation systems 
Scintillation fluid- Ecoscint scintillation solution, National
Diagnostics
RNA w o rk :-
RNAzol B, Biogenesis, was used for all RNA extractions. 6 + 12ml 
Falcon tubes (2063 and 2059 respectively) were used to  
homogenise tissues and isolate RNA.
Rolling p la t fo rm s :-  Rolling, rocking and shaking platforms
were all from Hoefer.
Slot-blot a p p a ra tu s :-  Schleicher and Schuell minifold 2
S p e c tro p h o to m e te r : -  Spectronic 601, Milton Roy
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S t i r re r s /H o tp la te s : -  Fisons
Tissue c u ltu re :-
DMEM and RPMI 1640 medium were obtained from Gibco as w e re  
the supplements FCS, L-Glutamine, Penicillin, Streptomycin, a n d  
Fungizone.
DMSO- Sigma
Freezing container- Nalgene 
Incubator-  Heraeus 
P lasticware- Corning
UV e q u ip m e n t : -
Stratalinker- UV stratalinker 1800, Stratagene 
Transilluminator- UVP ultraviolet transilluminator, GRI
W a te rb a th s : -  G ran t
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7B METHODS.
7 B . 1 Animal procedures.
All mouse procedures were conducted in accordance w i th  
Home Office regulations and as detailed in the covering p ro jec t  
licence. Unless otherwise stated, the procedures were co n d u c ted  
by me as covered by my Home Office personal licence. Where th e  
use of brief anaesthesia was required a halothane/oxygen m ix tu re  
was used in an anaesthesia chamber.
7 B .  1.1 Breeding and numbering of  transgenic  mice.
All food, water and bedding requirem ents were handled b y  
the animal technicians. Mouse pups born to breeding pairs w e re  
observed at d a y 3 -d a y l0  for appearance of the LMP-1 line 5 3 
phenotype and due notes recorded. The phenotype of h y p e rp la s ia  
is most obvious between 3 and 10 days old as a s c u r fy /s c a ly  
appearance of the skin (Wilson et al ., 1990). This provides an  
additional m echanism  for assessing transgenic status, along w ith  
subsequent genomic DNA analysis.
At day 21 the mice were weaned and males and fem ales  
separated. The mice were given a number in consecutive sequence 
and identified by ear punching. A small biopsy was taken (T ail- tip  
0 .5-1.0cm) under halothane anaesthesia, which was transferred to  
an eppendorf containing 700pl of tail solution for subsequent DNA 
extraction. The mouse tail was cauterised with a hot iron to s top  
bleeding and sterilise the wound.
7 B .  1 .2  Moni tor ing  health status.
In accordance with procedures as described in the Hom e 
Office project licence, all animals subject to the developm ent of 
neoplasia, were monitored twice weekly for signs of ill health a n d  
discomfort. Any animal suffering or deviating from a n o rm a l  
health status was euthenased without delay.
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7 B . 1 . 3 Mouse  l i n e s .
Line  Id en t i f i c a t io n T r a n s g e n e E x p r e s s i o n R e f e r e n c e
5 3 P y L M P - 1 P r e d o m i n a n t l y  
ep id e r m is  and 
tongue  ep i t h e l iu m
Wilson et a l ,  1 9 9 0
H K 1 0 -T G F (J lact Act ivated T G F p i  in 
the supr aba sa l  
ke ra t inocytes  of  the 
e p i d e r m i s
Cui et a l ,  1 9 95
M5 K 6 - s T G F ( J lact Low level 
express ion in the 
ep id e r m is .  Ful l  
activation of  T G F p i  
apon induct ion of  
h y p e r p l  a s i a
Fowlis  et al., 1 9 9 6
7 6 9 K5-Har«.v E p i d e r m i s Bai l l eul  et a l ,  1990
9 2 3.7Kb of p53 gene 
inter rupted  in exon 
5 by a Pol U-neo  
ex pr e ss io n  casse t t e
p53 fully knocked 
out-  no express ion
Do n eh ow er  et a l ,  
1 9 9 2
3 9 EjiLMP-1 W e ak  express ion  in 
thymus  and B-cell  
c o m p a r t m e n t
Wi lson et a l ,  1990
5 9 EgEBN A-1 B - c e l l s Wi l son  and Levine,  
1 9 9 2
7 B . 1 .4  Chemical  carc inogenes i s  t reatment  of  
t ransgenic  m i c e .
All preparations and applications using chemical ca rc inogens 
were conducted in a fume hood and the utmost care was e x e r te d  
at all times. Two pairs of gloves were worn when in contact w ith  
the carcinogens and the outer pair was discarded into a specia lly  
designated cin-bin for incineration. Aerosol resistant tips (ART) 
were used to avoid contamination of pipettes and l ik ew ise  
discarded into the specially designated cin-bin. The pipettes u s e d  
were for carcinogen use only and were never removed from th e  
trea tm ent hood. After treatm ent the mice remained in the fu m e  
hood for lh r  minimum to ensure the chemicals had c o m p le te ly  
dried. Mice treated with carcinogens were kept in a d e s ig n a te d  
room away from contact with other mice. Gloves were w o rn  
w henever treated mice were to be handled, whether they h a d  
been recently treated or not.
The two chemicals used in the procedures were 7 ,1 2 -  
d im ethy l-benz[a ]an th racene  (DMBA) and 1 2 -0 -
te tradecanoy lpho rb o l-  13-acetate  (TPA). Stock solutions w e re  
made from anhydrous chemicals using acetone as solvent, a n d
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stored at -20°C. From these, working solutions of 5 x lO _<iM w e re  
made and also stored at -20°C.
Four d ifferent treatm ent regimes were employed, but in 
each case the dose and timing of carcinogen applied, the length of 
experiment, and the observation and scoring techniques w e re  
identical. Mice to be treated had their dorsal skin shaved 2 4 h r s  
before treatment. The chemical carcinogens diluted in ace to n e  
were then applied directly onto the dorsal skin. The acetone h e lp s  
to spread the carcinogens over the whole dorsal region and also 
facilitates drying.
Mice were shaved on a Monday and treatm ent began on th e  
following day. The standard chemical carcinogen t r e a tm e n t  
protocol involves a single treatment with 200pl DMBA followed b y  
twice weekly treatm ents with 2 0 0 p l TPA for 20wks. Thus DMBA 
was applied on a Tuesday followed one week later by the f i r s t  
TPA application, from then on applied on Tuesdays and F r id ay s  
for 20 weeks (Brown and Balmain, 1995)
Records were taken on developing lesions on a weekly b asis  
during the 20wk TPA treatment, and for a further 4 0 w k s  
thereafter. The hair was shaved frequently, carefully avo id ing  
damage to any lesions that had arisen. Papilloma’s a n d  
carcinom a’s were assessed on a measuring scale designed for th is  
experim ent and based on the size of the lesion. Thus p a p il lo m a ’s 
or carcinom a’s were designated number 1, 2, 3 or 4 depending on 
their diam eter where l=<0.2cm; 2 = 0 .2 -0 .5cm; 3=0.5-1.0cm; a n d  
4=> 1.0cm. Weekly counts were taken using this measuring scale.
Mice were euthenased when papilloma’s or carcinom a’s h a d  
reached a size of 2 c m 2 or when the overall papilloma load h a d  
reached a maximum Home Office approved limit (as advised b y 
animal house technicians). Tissue samples were removed as 
described in 1 . 6  and 2 . 1  of the methods section.
7 B . 1 .5  Transgenic  mice c r o s s - b r e e d i n g .
Transgenic mice from the LMP-1 expressing line 53 or 3 9 
were bred with other lines of transgenic mice expressing the Ha- 
Rcis , TGFp, and EBNA-1 genes respectively (see methods section  
7B.1.3), and also with mice lacking both functional copies of th e  
p53 gene. Offspring from these crosses were observed fo r  
alterations in the standard LMP-1 phenotype or any p h e n o ty p e  
associated with the line being crossed to, and each crossbred line  
given a unique identification number system. The mice w e re  
treated as previously described in sections 7B.1.1 and 7B.1.2. A n y  
lesions or abnormalities were noted and relevant tissues co llec ted  
according to the procedure outlined in section 7B.1.6.
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7 B .  1 .6  Collection of t issues from transgenic  m i c e .
Animals were euthenased by cervical dislocation o r  
increasing concentrations of CO2 . External lesions were r e m o v e d  
by shaving the skin to remove hair and rinsing with e th a n o l  
before careful excision with fine scissors and forceps. Part of th e  
lesion was then put into 1 0 % buffered neutral formalin f ix a tiv e  
and the rest snap frozen in liquid N 2 for -70°C storage. Mice w i th  
obvious internal abnormalities, or mice that were simply s ick ly  
looking were always dissected in the same manner. The fur w a s  
wetted with ethanol to exclude loose hair from the samples a n d  
then the animal was opened up from throat to stomach leav ing  
the peritoneum  intact. The skin was pulled back and th e  
peripheral lymph nodes examined. The peritoneum  was then c u t
to reveal the stomach area and the liver, spleen, in te s t in e ,  
m esenteric lymph node and kidneys examined. The chest c a v i ty  
was then exposed by cutting through the rib cage and the lungs, 
heart and thymus examined. Any abnorm alities in any of th e s e
tissues, or indeed ,in connective tissue etc., were noted and th e
lesion removed with scissors and forceps. Again part of th e  
sample was put in fixative and the rest snap frozen. In every case  
a piece of tail was also frozen for further genomic analysis a n d  
confirmation of transgene status if required. In cases where th e  
animal was found dead, a routine examination was undertaken to  
try to establish the cause of death and due notes recorded. No 
samples were taken in these cases. Where required the samples in  
fixative were sent for diagnosis to a pathologist contracted to th e  
Glasgow Vet. School histopathology service.
7 B . 1 .7  Analys is  of  epidermal  prol i ferat ion using
Br om o de ox vu r id in e  i n c o r p o r a t i o n .
Because Bromodeoxyuridine(BrdU) is a potent carcinogen, all 
procedures were carried out in the fume hood. C o n tam in a ted  
plastics, needles and mice were kept separate from general w a s te  
and later incinerated. Gloves were worn at all times and m a s k s  
were used when the BrdU powder was weighed out by difference. 
Once in solution masks were not necessary.
BrdU was dissolved at a concentration of 125mg/ml in water 
in a glass bijoux by heating the solution to 60°C. The bijoux w a s  
then wrapped in tin foil and stored at 4°C as the stock solution. 
From this a working solution of 25mg/ml in sterile saline (0.85% 
NaCl) was also made and stored wrapped in tin foil at 4°C. E v ery
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time the working solution was used it was first heated to 60°C to  
dissolve any crystals that had formed. Mice to be injected w i th  
BrdU had their dorsal skin shaved 24hrs prior to injection. T he
mice were weighed on an electronic scale and then each m o u se
was injected in traperitoneally  (i.p.) with the equivalent of 2 pl
BrdU solution per gram of mouse. For 7 day old mouse pups th e  
working solution was further diluted with sterile saline to  
2 .5 mg/ml so that the pups were injected with the equivalent o f
20 |i l  BrdU solution per gram of mouse.
When each mouse had reached lh r post-injection it w a s
euthenased and the appropriate tissues taken into 1 0 % b u f fe re d  
neutral formalin fixative. In most cases these tissues were d o rsa l  
skin, tongue and tail (Cui et aL, 1995).
7B .2 Cell culture techniques.
7 B . 2 . 1 E x p la n ta t io n  o f  c a rc in o m a s .
All stages of the explantation protocol were p e r fo r m e d  
under sterile conditions using 100% EtOH to clean surfaces a n d  
equipm ent and to swab mice. The mouse was sacrificed a n d  
swabbed in 100% EtOH. The carcinoma was excised and t r im m e d  
of skin and necrotic tissue. The carcinoma was rinsed briefly b u t  
thoroughly in EtOH and cut in half. One half of the carcinoma w a s  
placed in explant medium Dulbecco’s modified Eagle 
medium(DMEM) containing 8  7ug/ml Penicillin. 1 1 7 u g /m l  
Streptomycin, and 2.9pg/ml Fungizone on ice, and the other h a lf
was further split into two, one piece placed in fixative, and th e
other snap frozen and stored at -70°C. The carcinoma w a s  
transported  between animal house and laboratory in the e x p la n t  
medium  on ice, where it was transferred to warmed g row ing  
medium  DMEM containing 20%(v/v) FCS. 2%(v/v) L -G lu tam ine .
1 2pg/ml Penicillin. 9 7pg/ml Streptomycin. and 1 .2 p g /m l 
Fung izone  in a petri dish in the tissue culture hood. The ca rc in o m a  
was cut into small pieces using a sterile scalpel and then placed in  
an F25cm 3 culture flask. The carcinoma pieces were left to a d h e r e  
to the plastic for 2-5min then 2.5ml of warm growing m e d iu m  
was layered over the lumps of carcinoma carefully avo id in g  
dislodging the carcinoma pieces. The flask was incubated at 37°C 
and 5% CO2  for 7 days, then a further 2.5ml of 20% grow ing  
medium was carefully added and the tissue pieces incubated for a 
further 7 days. By this time outgrowth of adherent cells from th e
carcinoma was visible. The carcinoma pieces and medium w e r e
removed by aspiration and the remaining adherent cells w a s h e d
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with PBS.A/EDTA. The cells were then trypsinised as described in  
methods section 7B.2.3, and cultured in 20% growth medium u n t i l  
the cells were confluent. At this point the growth m edium  w a s  
reduced in FCS content to 10%. Cells were expanded to con fluence  
for 4 further passages in F 7 5 c m 2  flasks and then stored as frozen  
stocks as described in methods section 7B.2.4
7 B . 2 . 2  Growth of  suspens ion c e l l s .
B-cell lines were grown to be used as controls fo r  
various experiments. These were either EBV positive or EBV 
negative Burkitt’s Lymphoma cell lines OR LCL’s and were all
grown in supplemented RPMI medium.
7 B . 2 .3  Sub-cul tur ing  of  mammal ian c e l l s .
When cells reached 90% confluence they were s u b ­
cultured to allow m aintenance of the cell line. In the case of 
carcinoma cells, the medium was aspirated and the cells w e re  
washed in PBS.A/EDTA. Trypsin solution (0.25% trypsin and 0.02% 
EDTA in dulbeccos buffered saline) was gently layered over th e  
m onolayer and incubated at 37°C for 5 minutes to dislodge th e  
cells. Cells were resuspended in fresh medium, pelleted in a
Heraeus 400 centrifuge at 1000 rpm /194x g/ rotor no .8172 fo r  
5min, and resuspended in the appropriate  medium at th e  
required density. In the case of suspension cells, the cells w e re  
pelleted in exactly the same manner and then resuspended in th e
appropriate  fresh medium at the required density (method as
suggested by ECACC).
7 B . 2 . 4  Storage of  frozen s t o c k s .
Epithelial cells grown to 90% confluence w e re  
trypsinised and pelleted as before then resuspended in 20% FCS 
media containing 10% dimethyl sulphoxide (DMSO). 1 ml a liquo ts  
were placed in 1.5ml cryovials and placed in Nalgene cryo 1°C 
freezing container which was placed in a -70°C freezer for 2 4
hours to ensure gradual chilling of the cells ( a p p ro x im a te ly  
l°C /m inute). These vials were then transferred to a l iq u id  
nitrogen container for long term storage.
7 B . 2 . 5  Revival  of  frozen s t o c k s .
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Cells were removed for use when required and quickly 
thawed by placing in a 37°C water bath. The cells were washed in 
serum free medium by centrifugation in a Heraeus 400 c en tr ifu g e  
(1000rpm /194x  g/rotor no.8172/5m in) to remove DMSO, a n d  
transferred  to a small F 2 5 cm 2 flask containing a p p ro p r ia te  
medium. Suspension cells were pelleted as before, resuspended in  
the DMSO free media and thereafter treated as for epithelial cells 
(method as suggested by ECACC).
7 B .3 DNA extraction and manipulat ion .
7 B . 3 . 1  Genomic DNA e x t r a c t i o n .
35p l of proteinase K was added to the tail segment or t is su e  
segment in 7 0 0 p l  of tail solution, and incubated at 55°C w ith  
shaking in an eppendorf therm omixer overnight (o/n). Sam ples 
can then be stored at 4°C indefinitely. DNA was extracted from the 
sample by adding an equal volume of b u ffe r-sa tu ra ted  p h en o l  
pH7.5 and thoroughly mixing by inverting the tube 15-20 tim es. 
The samples were centrifuged in an eppendorf b e n c h to p  
centrifuge at 12 ,000rpm /12,000x g/rotor 5415c for 15 min. This 
creates two liquid layers with an interface. The upper a q u eo u s  
layer containing DNA/RNA was carefully transferred  into a f r e s h  
eppendorf tube without disturbing the interface, and mixed w ith  
an equal volume of 2FC (see materials section 7B.5) by in v e r t in g  
the tube 15-20 times. Again the samples were centrifuged in th e  
eppendorf benchtop centrifuge at 1 2 ,0 0 0 r p m / 1 2 ,0 0 0 x g / r o to r  
5415c for 15 min. The upper layer was carefully transferred in to  
a fresh eppendorf tube and mixed with lOOpl of 10M NH 4 0 AC a n d  
750 jil  of cold absolute EtOH by shaking vigorously by hand fo r  
several seconds. The samples were then centrifuged a t  
10 ,000rpm /8385x  g/rotor 5414c for 2 min to pellet the h igh  
molecular weight (HMW) DNA. The supernatan t was removed a n d  
the pellet washed with 1ml of 70% EtOH. After another 2 m in  
centrifugation at 10 ,000rpm /8385x g/rotor 5415c, th e  
supernatant was removed and the pellet allowed to air dry. T he  
pellet was then resuspended in 2 1 5 pi 1 of TE pH 7.6-8.0 by h e a t in g  
to 65°C for 30min, with occasional agitation to help th e  
resuspension process. The samples were then stored at 4°C 
(Wilson et aL, 1990).
7 B . 3 . 2  Quanti tat ion,  restrict ion and e l ec t rophores i s  of  
DNA.
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15pil of the DNA sample was used for OD 2 6 0  m e a s u re m e n t .  
This allows the DNA concentration to be ascertained, and th e  
samples were then adjusted to 0 .3 3 p g /p l  where possible to sp e e d  
subsequent analysis. Samples were then stored at 4°C indefinitely.
10}ig of genomic DNA was routinely digested with re s t r ic t io n  
enzyme o/n at 37°C using the recom m ended buffer. Typically 4pl 
of enzyme at a concentration of 1 5 u n i ts /p l  was used in th e  
reactions. The reaction was stopped by heating the mix to 65°C fo r  
lOmin. 10% of the volume of loading buffer was added to each  
reaction and the samples were loaded onto a 0.8-1.0% agarose gel 
made up in lxTAE and containing 2pl of lOmg/ml EtBr. 1Kb 
ladder was also added to one of the wells for subsequent b a n d  
size evaluation. The DNA samples were electrophoresed in a 
horizontal electrophoresis chamber at lOOv for 5 hrs in lxTAE 
buffer and then the DNA was visualised on a short wave UV 
(280nm) transillum inator to ensure the DNA was intact and h a d  
been equally loaded. A photograph was taken for records (W ilson 
et al ., 1990).
7 B . 3 . 3  Southern blott ing of  DNA and specif ic f r a g m e n t  
d e t e c t i o n .
The gel slab was then treated with DNA denaturan t (see  
materials section 7B.5) for 45min and then washed 3x l5m in  in 
0.5x TAE. The DNA was then transferred onto nylon (Biodyne B) 
m em brane by electroblotting for 4hrs at 75v/1.5A in 0.5xTAE. 
The nitro-cellulose filter was then UV crosslinked using a 
stratalinker, and baked at 80°C for lhr. The filter was stored at RT 
or probed directly.
To probe the nylon m embranes, the filters were placed in  
hybridisation tubes with 10ml of Church buffer and the tu b e s  
were placed in a hybridisation oven and rotated for 3hrs to o/n a t  
68°C to allow full prehybridisation. The 32P labelled DNA 
fragm ents used as probes were then denatured by heating to  
100°C for lOmin before addition and hybridised o/n at 68°C. T he 
filters were then stringently washed 4x l0m in  in 2xSSC. 0.1 % /w /v l 
SDS at RT, and then 2x30min in O.lxSSC. 0.1%/w/v) SDS at 68°C in  
a shaking waterbath. The filters were then sealed in p o ly th e n e  
bagging, taped into autoradiography cassettes with in te n s ify in g  
screens, and exposed to kodak XAR film at -70°C. Exposed film s 
were processed in a kodak x-omat (Wilson et al., 1990).
7 B . 3 . 4  Slot blot analysis  of  genomic DNA.
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Another technique which was occasionally used to assess the 
transgene status of DNA extracted from tails was the slot b lo t  
technique. This involves identification of a specific gene b y 
hybridisation of a; DNA probe fragment to undigested, genom ic 
DNA, and is particularly useful when large numbers of sa m p le s  
need to be tested at once. The technique is also less t im e  
consuming than Southern blotting as there are no re s t r ic t io n  
enzyme digests or gel electrophoresis steps.
lOjig of DNA was transferred into an eppendorf tube and the 
volume made up to 120pl with H2 O. 40jil of 1M NaOH was th e n  
added and the tubes vortexed vigorously. The samples were le f t  
at RT for lOmin and then 160|il of lOxTAE was added. T he 
samples were vortexed once again and then left on ice. The slo t 
blot apparatus was assembled with two pieces of pre-w et 3 m m  
filter paper underlying the nitro-cellulose membrane which h a d  
been pre-soaked in lxTAE for 30min. The samples were lo aded  
without vacuum, one sample per slot, and then the v a c u u m  
applied. When the samples had been sucked through, one d ro p  
from a Pasteur pipette of 5xTAE was added to each slot. T he 
membrane was then baked, DNA cross-linked, and the blot p ro b e d  
and washed exactly as a Southern blot membrane (Wilson et al., 
1990).
7 B .3 .5  P r e p a r a t io n  of 3 2P lab e lled  DNA p r o b e s .
Hybridisation probes for all nylon blotting were made using  
digested fragments from plasmid DNA. 10pg of the p la sm id  
containing the DNA to be used as a probe was digested w ith  
restriction enzymes to generate a suitable DNA fragment. T he 
digested DNA was electrophoresed slowly at 50V for 4hrs in low  
melting point agarose (LMP-agarose) containing 2pl of lO m g /m l  
EtBr and made up in lxTAE. The DNA was visualised on a long 
wave transilluminator to estimate the DNA content of the d e s i re d  
fragm ent which w is then collected. The fragment was heated to  
70°C to melt the agarose and an estimation of the volume m ade . 
From this the fragment concentration was then adjusted to  
approxim ately  5ng/pl and stored at -20°C.
5|il of the DNA fragment (~25ng) was used for each p ro b e  
reaction. The stratagene Prime-It II kit was used to prepare th e  
probe. 10pl of random 9-mer primers (27 OD units/pl) and 29pl o f 
H2 O was added to the DNA and heated to 100°C to denature th e  
dsDNA. Then lOpl of 5xdCTP buffer, 5pl of cx32p 
dCTP(3000ci/m mol) and lp l  of Exo(-) klenow were added to th e  
reaction mix and incubated at 37°C for at least lO m ins.
i
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Unincorporated nucleotides were removed over S tra ta g e n e  
Nuctrap probe purification columns in the stratagene push co lum n 
beta shield device using STE according to the Stratagene P r im e - i t2  
random primer labelling kit instruction manual, l p l  of the purified 
probe DNA was then used to count the specific activity of th e  
probe with counts of >5x10 8 routinely available. The probe could 
then be store at -20°C or used directly in which case the p ro b e  
was heated to 100°C for 5-10mins to denature the DNA, and th e n  
added directly to the hybridisation buffer and nylon filter.
7B .4 Protein manipulat ion.
7 B . 4 . 1  Protein extract ion and p r e p a r a t i o n .
Protein was extracted from snap frozen tissues (from -70°C) 
storage as follows. Pieces of tissue were cut on dry ice using a 
sterile dissection blade, and the tissues were never allowed to  
thaw before preparation. The tissue was then homogenised in a 
12ml (Falcon 2059) tube using a polytron blade with 2ml of NET:N 
and the proteinase inhibitors 2% Aprotinin and ImM PMSF (m ad e  
up in EtOH) freshly added. Once homogenised, tr iton-x-100 w as  
added to 0.5% per ml and the samples vortexed hard to  
thoroughly lyse the cells. The samples were transferred to  
eppendorf tubes and centrifuged at full sp e e d  
(14 ,000rpm /16 ,000x  g/rotor 5415c) in an eppendorf b e n c h to p  
centrifuge for lOmin at 4°C to pellet the cell debris. T he 
supernatant was removed to a fresh tube on ice. The pellet can b e  
stored at -70°C if required or further extracted. Since the m a jo r i ty  
of protein extraction's were designed to isolate LMP-1 it w as  
necessary to further extract the pellet where much of the LMP-1 
will be retained after the first extraction with non-ionic d e te rg e n t .  
The pellets were vortexed vigorously in 200jil of RIPA b u f fe r  
containing the ionic detergent SDS to 0.5%. The samples w e re  
centrifuged as before to pellet the debris and the s u p e r n a ta n ts  
combined with the first non-ionic extract. NET:N was added to  
each tube to bring the volume to 1ml and to dilute the SDS 
concentration to approxim ately 0.1% (Wilson et al ., 1990). P ro te in  
concentration was measured using the Bio-rad protein assay kit.
7 B . 4 . 2  Protein i m m u n o p r e c i p i t a t i o n .
Based on the’ protein concentration an aliquot was r e m o v e d  
to a fresh tube on ice, such that each tube had the same amount o f 
starting protein. All steps were carried out on ice or at 4°C. T he
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samples were made up to lml with NET:N and lOOpl of 50% 
protein-A-sepharose (Sigma) made up in NET:N pH 8 .8 , was a d d e d  
to each tube and the tubes rotated for 2hrs at 4°C. This p re -c le a r  
step removes non-specific proteins which may stick to th e  
sepharose beads. The isolation proceeds by adding a v o lu m e  
antibody directed against the protein of in terest and rotating th e  
tubes o/n at 4°C. When LMP-1 was to be im m unoprecip ita ted  fo r  
example, 30|il of Rabbit aLMP-1 (See m aterials section 7A.2) w as  
used. The precipitation step involves adding 30jil of 50% p ro te in -  
A-sepharose to each tube and rotating for 40min maximum at 4°C . 
The antibody already bound to the protein of interest now also 
binds to the sepharose beads. The samples were then c e n tr ifu g e d  
for 1 - 2  min in an eppendorf benchtop c en tr ifu g e  
(14,000rpm/16,000x g/rotor 5415c) in the cold room to pellet th e  
sepharose and the pellets washed x2 in lm l NET:N, and lx  in TBS 
by vigorous vortexing and centrifugation again a t  
14 ,000rpm /16 ,000x  g/rotor 5 4 1 5 c /2 m in /4 °C . The pellets w e re  
then stored at -70°C or used directly for SDS-PAGE (Wilson et al.y 
1990).
7 B . 4 . 3  SDS-PAGE separat ion of  proteins  and Western  
b l o t t i n g .
SDS-PAGE separation of im m unoprecip ita ted  protein w as  
earned out using a 10% running gel at pH 8 . 8  and 5% stacking gel 
at pH 6 . 8  (See frequently used solutions, materials section 7B.5). 
The sepharose pellets were heated to 95°C in 30pl of red u c in g  
sample buffer for 5min. The samples were briefly pulsed in th e  
benchtop centrifuge to collect the liquid and the samples stored on 
ice until the supernatant was loaded onto the gel along with a 
protein marker standard to allow size determ ination of th e  
desired protein. The samples were electrophoresed in ru n n in g  
buffer at 50V until the samples had “stacked” at the stacking gel 
and running gel interface, and then electrophoresed at 150V u n ti l  
the dye marker had run off the end of the gel. The proteins w e re  
then transferred in transfer buffer onto nylon ( Im m o b ilo n )  
m em brane (pre-w et with methanol) for 2hrs at 100V/1.5A. T he  
membrane was then submerged in PBS containing 5% non-fat Milk 
(NFM) o/n at 4°C on a rocking platform. This “blocking” step he lp s  
to reduce background signal at the later detection step.
The m em branes were probed as follows. The p r im a ry  
antibody was diluted in PBS containing 2.5%NFM to a 
concentration of 1/100 to 1/250 depending on the specificity o f 
the antibody, and added to the membrane for lhr. All a n t ib o d y  
binding and wash steps were carried out on a rocking p la tfo rm .
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The membrane was then washed 3x in Blotto HD and then b r ie f ly  
rinsed in PBS. The secondary antibody, which is HRP co n ju g a te d  
was again diluted in PBS containing 2.5%NFM to a concentration of 
1/100, and added to the membrane for lhr. The wash step w a s  
repeated with a further 2x5min PBS wash at the end. The p ro te in s  
were detected using the Amersham ECL kit reagents where th e  
HRP catalysed oxidation of luminol results in emission of light. 
Membranes were wrapped in cling film and exposed to kodak XAR 
film for between 5sec to lOmin. The film was developed in a 
kodak X-omat. The membranes were then stored at -20°C (W ilson 
et al ., 1990). The m em branes could be stripped of the ECL 
reagents and antibodies using stripping solution (See f r e q u e n t ly  
used solutions, materials section 7B.5), and re-probed.
7 B . 4 . 4  S ec tio n in g  of p a ra f f in  e m b e d d e d  t i s s u e s .
Tissues from the BrdU injected mice were left on a ro lling  
platform o/n in fixative, and then washed as follows:- lx30m in in 
PBS, lx30m in in saline (0.85%NaCl), 2x l5m in  in sa line  
(0.85%NaCl)/100% EtOH, and finally 2x l5m in  in 70% EtOH. All 
steps were carried out on the rolling platform at 4°C using s te r i le  
solutions. The 70% EtOH was replaced after the last wash w i th  
fresh 70% EtOH and the samples sent to the D erm ato logy  
departm ent for paraffin embedding.
7pm  sections were used for subsequent BrdU sta in ing . 
Frosted microscope slides were prepared to mount the sections b y 
coating them in 3-am inopropyl triethoxysilane (TESPA). Slides 
were incubated at RT for 50sec in 2% TESPA (in acetone) fo llow ed  
by 2x50sec washes in acetone and 2x50sec washes in d e - io n ise d  
water. All steps were carried out in the fume hood. The s lides  
were then baked dry at 42°C and stored in a slide box at RT u n t i l  
use .
The paraffin embedded tissues were kept in the f r id g e  
immediately prior to sectioning as this helps give more cleanly c u t  
sections. The 7pm sections were cut on a microtome and c a re fu l ly  
picked up and placed onto a TESPA coated slide using tw eeze rs .  
30% EtOH was dribbled over one edge of the section to “fla tten” 
out the paraffin creases. The microscope slide was then g e n tly  
immersed in a small 37°C water bath filled with millipore f i l te re d  
water so that the section floats off. The microscope slide was th e n  
carefully positioned under the section and the slide lifted up so 
that the section adheres t a  the slide. This procedure results in f la t  
sections which are now adherent to the slide. Slides with sec tions 
on them were dried o/n on a 42°C drying rack and kept thereafter 
at RT in a slidebox.
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7 B . 4 . 5  Detect ion of BrdU incorporated n u c l e i .
Sections were placed in a slide rack and immersed fo r  
2x7min in Histoclear to remove the paraffin. The sections w e re  
then hydrated by immersing them through 2x100%, 90%, 80%, and 
70% ethanol's respectively for 2min each. The sections were th e n  
washed by immersing 3x30min in TBS with a stir-bar to c ircu la te  
the solution. The eventual detection of BrdU is facilitated by th e  
Vectastain e li te  ABC kit (Vector laboratories) which is based u p o n  
an im m unoperoxidase detection system. For this reason it w as  
necessary to block endogenous peroxidase activity by im m e rs in g  
the sections in 0.5% H 2 O 2 for 30min. The sections were w a sh e d  
again 3x5min in TBS with circulation. The sections were th e n  
imm ersed in warmed (37°C) trypsin solution of 0.1% trvpsin a n d  
0.1% CaCh made in 50mM Tris pH 8.0  for 3min to permeabilise th e  
cell membrane. The sections were washed 3x5min in TBS as 
before. To minimise background antibody signal, the sections were 
then blocked with 1 % normal horse serum (because the se c o n d a ry  
antibody was raised in horse) from the Vectastain kit for 30m in . 
Excess serum was shaken off and 10|il of the undiluted p r im a r y  
anti-BrdU antibody(Sigma) applied to each section. To avo id  
evaporation of the antibody, each section was covered with a g lass 
coverslip. The anti-BrdU antibody was left for lh r  and th e n  
washed off with 3x5min TBS washes (the coverslips fall off d u r in g  
the washing). The secondary antibody, an anti-mouse b io t in y la te d
IgG antibody, was prepared as directed in the Vectastain kit a n d
applied for 30min. A much larger volume (200p l)  is applied to  
each section so there is no need for coverslips in this case. Once 
again the sections were washed 3x5min in TBS. 15min into th e  
secondary antibody step, the ABC complex was p r e p a r e d  
according to the Vectastain kit instructions and left at RT fo r  
30min. The two components of the ABC complex are Avidin a n d  
biotinylated horseradish peroxidase. Avidin has four binding s i tes  
for biotin and because of the dilution's used, at least one of th e s e
sites remains unbound and thus able to bind to biotin on th e
secondary antibody. After the washes the sections were t r e a te d  
with the ABC complex for lhr, where the avidin:biotinylated  HRP 
complex now binds to the biotinylated secondary a n t ib o d y  
through the biotin:avidin high affinity binding sites, and th e n  
washed 3x5min in TBS. To visualise individual BrdU stained cells 
the sections were “developed” with 3 ,3 ’-d iam ino benz id in e  
te trahydrochloride  (DAB) tablets(Sigma) which is a p e ro x id a se  
substrate. One lOmg tablet was dissolved in 15ml of TBS and 12|il
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of H 2 O 2 . Slides were placed in the fume hood with sections face u p  
and the DAB stain t applied to each section individually for l m i n  
before being washed off with TBS. The slides were th e n
imm ersed in freshly filtered undiluted H arr is ’s 
Haematoxylin(Sigma) for lOsec to counterstain the section, a n d  
then washed with tap water. BrdU staining nuclei now appear as 
brown, with non-staining nuclei blue. The slides were th e n
immersed in Scott’s tap water for lmin and rinsed with n o rm a l  
tap water for lmin. The slides were then dehydrated b y  
imm ersing them through a series of ethanol's from 30% to 50%, 
70%, 90% and 100% for 2min each. A further 5min immersion in 
100% EtOH was followed by a 2min and then 7min immersion in  
Histoclear. Finally the slides were mounted with DePeX and a glass
coverslip and the edges of the coverslip sealed with clear n a il-
varnish. Slides were then stored at RT.
The BrdU count is achieved by counting the average n u m b e r  
of positively staining cells per field of vision under x312 .5  
magnification (x25liens and xl2.5 eyepiece). Cell counts ex c lu d ed  
areas of hair follicle as these areas are already high in 
proliferating cells. All counts were done blind i.e. without kn o w in g  
transgene status.
7 B . 4 . 6  I m m i i no f lu or es en ce  of  p r o t e i n s .
Some of the frozen tissues were sent to Dermatology w h e re
7 p m  thick sections were cut on a cryotome. The sections were p u t
on a gelatin coated slide and the slides stored in a slide box at -
20°C. The sections were circled with a wax pen to prevent th e
subsequent antibody solutions spreading over the slide and th u s  
minimise the volume of antibody required. The sections w e re  
“blocked” with wash containing serum from the animal in w hich  
the secondary antibody was raised. For example if the se c o n d a ry  
antibody was raised in goat, then the sections were blocked w ith  
goat wash. This reduces the background signal created by n o n ­
specific binding of the secondary antibodies. Following the 3 0 m in  
blocking step the sections are briefly rinsed in PBS and lOpl of th e  
diluted primary antibody added for lh r in a humidified c h a m b e r  
(Tupperware box with damp paper towel lining and lid closed). 
The sections were then washed x3 in PBS and the f lu o re sc e n t  
conjugated secondary antibody added for lh r  in the h u m id if ie d  
chamber. The sections were again washed x3 in PBS and th e n  
m ounted with vectashield (Vector laboratories), covered with a 
coverslip and sealed with clear nail varnish. The slides w e re  
analysed using a fluorescence microscope and stored at 4°C in th e  
dark (Wilson et al ., 1990).
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7 B . 5  Formulation of frequently used so lut ions .
Church buffer
Denaturing solution 
2FC
Fix itive
lOx Goat wash
lOx Loading buffer(DNA)
lOx Loading buffer(RNA)
lOx Loading dye(RNA)
7%(w/v) SDS 
l%(w/v) BSA 
ImM EDTA 
250mM Na2 H P 0 4  
pH 7.2
0.4M NaOH 
0.6M NaCl
49.45% (v/v) redistilled phenol 
49.45% (v/v) chloroform  
l% (v/v) isoamyl alcohol 
0 . 1 % (w/v) 8 -hydroxyqu ino line  
Saturated with 1M Tris pH8.0
1 0 % buffered neutral formalin:-
NaH2 P 0 4
Na2 H P 0 4
F o rm a ld e h y d e
1.3M NaCl
70mM Na2 H P 0 4 .2H20  
30mM NaH2 P 0 4 .H20  
0.5%(w/v) sodium azide 
10%(v/v) Goat serum 
2% (v/v) T riton-x-100 
0.5% (v/v)Tween 2 0
20%(v/v) Ficoll 
0.1M EDTA pH8.0 
0.25%(w/v) Bromophenol blue 
0.25%(w/v) XC
lx MOPS-E
50%(v/v) pure, deionized formamide 
17.8%(v/v) fo rm aldehyde
50% (v/v) g lycerol(autoclaved) 
0.1%(w/v) Bromophenol blue 
0 . 1 %(w/v) XC
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Lysis buffer 1 %(v/v) T riton-x-100
0.5%(w/v) sodium deoxycholate
0.1%(w/v) SDS
0.1M NaCl
0.05 Tris-HCl pH7.4
0.005M MgCl2
MOPS-E
NET:N
20mM MOPS 
ImM EDTA 
5mM NaOAc 
pH /N aO H /7 .0
150mM NaCl 
5mM EDTA-NaOH pH8.0 
50mM Tris-HCl pH8.0 
0.05%(v/v) NP-40
PBS
PBS. A
137mM NaCl 
2.7mM KC1 
4.3mM Na2 P 0 4  
1.4mM KH2 P 0 4  
pH /H C l/7 .3
l%(w/v) NaCl 
0.025%(w/v) KC1 
0.14%(w/v) Na2 H P 0 4 
0.025%(w/v) KH 2 P 0 4
PBS.A/ EDTA 
RIPA buffer
PBS.A/ 0.54mM EDTA
150mM NaCl 
50mM Tris-HCl pH7.5 
1 %(v/v) T riton-x-100 
l% (w /v) sodium deoxycholate 
0.1%(w/v) SDS
R unning buffer(protein)
Sample buffer
0.025M Tris 
0.2M Glycine 
0.1%(w/v) SDS 
pH8.3
80mM Tris-HCl pH 6 . 8  
2%(w/v) SDS 
1 0 %(v/v) glycerol 
0.01% Bromophenol blue
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F r e s h  5 %(v/v)  2 - mercap to - e thano l
Scott’s tap water 
STE
SSC
Stripping solution 
Tail solution
TAE(50x stock soln.(lL))
TBS
TE
T ransfer  buffer(pro tein)
Magnesium Sulphate 20g/L 
Sodium Bicarbonate 2g/L
lOmM Tris.Cl pH7.5 
lOmM NaCl 
ImM EDTA
150mM NaCl
150mM sodium citrate
pH /N aO H /7 .5
lOOmM 2-m ercap toethano l
2%(w/v) SDS
62.5mM Tris-HCl pH6.7
l%(w/v) SDS 
150mM NaCl 
lOmM Tris-HCl pH7.5 
lOOmM EDTA pH8.0
242g Tris base 
57.1ml Glacial acetic acid 
37.2g Na2E D TA .2H ,0  
pH -8.5
140mM NaCl 
20mM Tris 
pH /H C l/7 .6
lOmM Tris-Base 
ImM EDTA 
pH /H C l/7 .6
192mM Glycine 
25mM Tris 
0.05%(w/v) SDS 
2 0 %(v/v) m ethanol
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A p p e n d ix  1 : -  Table of PyLMP-1 (line 53) transgenic m ice  
crossed with p53-/- (line 92) knockout mice indicating the age o f  
each animal at death, the transgenic and knockout status, and th e  
cause of death.
M o u s e  
i . d .
D . O . B . A g e L M P /
p53
S y m p t o m s  a n d  a p p e a r a n c e  o f  t i s s u e s
9 2 . 5 0 1 9 / 5 / 9 5 1.5 -/ +/- Sacr i f iced due to bad cuts f rom f ight ing
9 2 . 5 1 1 9 / 5 / 9 5 ? +/- Missing,  cause o f  death unknown
9 2 . 5 2 1 9 / 5 / 9 5 1.5 -/ +/- Sacr if iced due to bad cuts f rom f ight ing
9 2 . 5 3 1 9 / 5 / 9 5 3 . 5 +/- Dragging  rear  legs as if paralysed.  
Probable os t eo sa r co ma  on spine a l though 
none  vis ible
9 2 . 5 4 1 9 / 5 / 9 5 ? +/- Missing,  cause  o f  death unknown
9 2 . 5 5 1 9 / 5 / 9 5 1.5 -/ +/- Sacr i f iced because  of  LMP-1 nega t ive status
9 2 . 5 6 1 9 / 5 / 9 5 1.5 -/ +/- Sacr i f iced because  of  LMP-1 negat ive status
9 2 . 5 7 5 / 6 / 9 5 6 -/ +/- Hind l imb paralys i s  causing rear  legs to 
drag.  Small  lump on spine nea r  the middle
9 2 . 5 8 5 / 6 / 9 5 1 0 -/ +/- Hind  l imb paralysis .  Os te osa rco ma  on 
spine nea r  shou lde r s
9 2 . 5 9 5 / 6 / 9 5 12 . 5 -/ +/- Hind l imb paralys is .  No th ing obvious  on 
spine but  p r ob ab l y  os teosa rc oma
9 2 . 6 0 5 / 6 / 9 5 1 1 +/- Found dead,  cause unknown
9 2 . 6 1 5 / 6 / 9 5 8 . 5 +/- Hind  l imb pa ra lys i s
9 2 . 6 2 1 4 / 7 / 9 5 -/ 7 Sacr i f iced because of LMP-1 nega tive  status
9 2 . 6 3 1 4 / 7 / 9 5 -/ 7 As above
9 2 . 6 4 1 4 / 7 / 9 5 -/ 7 As above
9 2 . 6 5 1 4 / 7 / 9 5 -/ 7 As above
9 2 . 6 6 1 4 / 7 / 9 5 -/ 7 As above
9 2 . 6 7 1 4 / 7 / 9 5 -/ 7 As above
9 2 . 6 8 1 4 / 7 / 9 5 -/ 7 As above
9 2 . 6 9 1 8 / 7 / 9 5 9 .5 - -/- Swol len  a b do m en ,  spleen en la rg ed / m ass iv e
9 2 . 7 0 1 8 / 7 / 9 5 10 + +/- Dragg ing  h ind  l imbs.  O s te osa rcoma?
9 2 . 7 1 1 8 / 7 / 9 5 14 - +/- Dragg ing  hind l imbs.  O s te osa rcoma?
9 2 . 7 2 1 8 / 7 / 9 5 4 -/- Cause o f  death unknown
9 2 . 7 3 1 8 / 7 / 9 5 8 + +/- Very sickly looking  with swoll en abdomen .  
Sp leen mass ive
9 2 . 7 4 1 8 / 7 / 9 5 7 - +/- Cause of  death unkown
9 2 . 7 5 1 8 / 7 / 9 5 7 - +/- Cause of  death unkown
2 0 6
A p p e n d ix  1 :-  Table of PyLMP-1 (line 53) transgenic m ice  
crossed with p53-/- (line 92) knockout mice indicating the age of 
each animal at death, the transgenic and knockout status, and th e  
cause of death.
M o u s e  
i . d .
D . O . B . A g e
( m o )
L M P /
p5 3
S y m p t o m s  a n d  a p p e a r a n c e  o f  t i s s u e s
9 2 . 7 6 1 8 / 7 / 9 5 8 +/  +/- Hind  l imb pa ra lys is .  O s te os a r co m a?
9 2 . 7 7 1 8 / 7 / 9 5 4 -/ -/- Found dead.  Spleen and l iver  massive
9 2 . 7 8 1 8 / 7 / 9 5 5 +/  -/- L ive r  g ross ly  enla rged
9 2 . 7 9 1 8 / 7 / 9 5 7 -/ -/- Swol len  abdomen .  Enlarged spleen and 
d i s c o lo u r e d  l ive r
9 2 . 8 0 1 8 / 7 / 9 5 5 +/  -/- Mouse looked very sickly but had  no 
obvious  tumours.  Liver  very pale,  rest 
n o r m a l
9 2 . 8 1 1 8 / 7 / 9 5 7 -/ +/- Cause of  death unknown
9 2 . 8 2 1 8 / 7 / 9 5 1 2 -/ +/- Ly mph oma .  Spleen and pe r iphe ra l  lymph 
node s  en l a rg ed
9 2 . 8 3 1 8 / 7 / 9 5 1 4 -/ -/- As above
9 2 . 8 4 1 0 / 9 / 9 5 8 -/ -/- Mouse v.sick.  All pe rLN enlarged.  MLN,  
spleen,  l iver  and thymus all massive
9 2 . 8 5 1 0 / 9 / 9 5 9 -/ +/- Poor  mobil i ty.  Spine rough to touch.  
O s t e o s a r c o m a ?
9 2 . 8 6 1 0 / 9 / 9 5 5 . 5 -/ -/- Mouse v.sick.  Spleen and M L N  lymphomas.  
Some enlargement  o f  p e r L N ’s
9 2 . 8 7 1 0 / 9 / 9 5 5 -/ -/- L y m p h o m a
9 2 . 8 8 1 0 / 9 / 9 5 9 . 5 +/- Hind  l imb para lys i s .  O s te os a r co m a?
9 2 . 8 9 1 0 / 9 / 9 5 ? +/- Cause o f  death unknown
9 2 . 9 0 1 0 / 9 / 9 5 7 - -/- Poor  mo bi l i ty -os teosa rcom a?  L y m p h o m a  of 
spleen also
9 2 . 9 1 1 0 / 9 / 9 5 14 - +/- Mouse looked sick but was ok
9 2 . 9 2 1 0 / 9 / 9 5 10 + +/- L y m p h o m a
9 2 . 9 3 1 0 / 9 / 9 5 5 - -/- V .swollen  abdomen .  Spleen mass ive ,  all 
pe r L N  en la rg ed
9 2 . 9 4 2 0 / 1 0 / 9 5 5 - -/- Hind  l imb pa ra lys is  with severe hunched 
ba c k-  o s t e o sa r c o m a ?
9 2 . 9 5 2 0 / 1 0 / 9 5 ? - -/- Sacr if iced because LMP1 nega t ive
9 2 . 9 6 2 0 / 1 0 / 9 5 - -/- As above
9 2 . 9 7 2 0 / 1 0 / 9 5 - -/- As above
9 2 . 9 8 2 0 / 1 0 / 9 5 - -/- As above
9 2 . 9 9 2 0 / 1 0 / 9 5 - -/- As above
9 2 . 1 0 0 2 0 / 1 0 / 9 5 8 + +/- Mouse very hunched up no paralysis .  M L N  
l y m p h o m a
9 2 . 1 0 1 2 0 / 1 0 / 9 5 7 - +/- Sacr if iced because LMP1 nega t ive
9 2 . 1 0 2 2 0 / 1 0 / 9 5 7 - -/- As above
2 0 7
A p p e n d ix  1 : -  Table of PyLMP-1 (line 53) transgenic m ice  
crossed with p53-/- (line 92) knockout mice indicating the age of 
each animal at death, the transgenic and knockout status, and th e  
cause of death.
M o u s e  
i . d .
D.O.B. A g e L M P /
p5 3
S y m p t o m s  a n d  a p p e a r a n c e  o f  t i s s u e s
9 2 . 1 0 3 2 0 / 1 0 / 9 5 ? -/ -/+ As above
9 2 . 1 0 4 2 6 / 1 1 / 9 5 5 -/ -/- Lump on right  hind leg. PLN lymphom a
9 2 . 1 0 5 2 6 / 1 1 / 9 5 5 -/ -/- T u m o u r  on back  be low right  shoulde r
9 2 . 1 0 6 2 6 / 1  1 / 9 5 3 -/ -/- Dif f i cu l ty  b rea thing and moving
9 2 . 1 0 7 2 6 / 1  1 / 9 5 7 . 5 -/ -/- Large lym p h om a
9 2 . 1 0 8 2 6 / 1 1 / 9 5 ? -/ -/- Cause  of  death unknown
9 2 . 1 0 9 2 6 / 1  1 / 9 5 4 . 5 -/ -/- Mouse  hunched  and slow moving.  Spleen x3, 
os t eo sa r co ma  on spine
9 2 . 1 1 0 2 6 / 1  1 / 9 5 7 Poor  mobi l i ty  in hind l imbs .Sp ine  feels 
“r ib be d” . LA LN  poss . en larged .  Ma ss i ve  
t h y m u s
9 2 . 1 1 1 2 6 / 1  1 / 9 5 ? -/ -/- Cause o f  death unknown
9 2 . 1 1 2 2 6 / 1 1 / 9 5 ? -/ -/- As above
9 2 . 1 1 3 2 6 / 1  1 / 9 5 7 -/ -/- As above
9 2 . 1 1 4 2 6 / 1  1 / 9 5 6 -/ -/- T u m o u r  above right  shoulder .  T u m o ur  v. red 
and bloodv.  Everything else ok
9 2 . 1 1 5 2 6 / 1  1 / 9 5 7 -/ -/- Severe  hind l imb paralys i s
9 2 . 1 1 6 2 0 / 1 2 / 9 5 7 7 Cause  of  death unknown
9 2 . 1 1 7 2 0 / 1 2 / 9 5 7 As above
9 2 . 1 1 8 2 0 / 1 2 / 9 5 6 . 5 S u r p l u s
9 2 . 1 1 9 2 0 / 1 2 / 9 5 6 . 5 S u r p l u s
9 2 . 1 2 0 2 0 / 1 2 / 9 5 7 Cause  of  death unknown
9 2 . 1 2 1 2 0 / 2 / 9 6 7 As above
9 2 . 1 2 2 2 0 / 2 / 9 6 4 Hind  l imb pa ra lys i s
9 2 . 1 2 3 2 0 / 2 / 9 6 7 Cause o f  death unknown
9 2 . 1 2 4 2 0 / 2 / 9 6 4 Large tumour  on neck
9 2 . 1 2 5 2 0 / 2 / 9 6 7 Cause  o f  death unknown
2 0 8
J  r  ^  a.. j -  m. ,  _ A. 4:. *  „ _  ^
A p p e n d ix  2s* 1 SbiC Oi EjlLM P-1  ^1 inc 3^) m ice crossed  w 1 tfi lijLtJU-UiN1  (lincs^,) snow ing trie iransgcnic status or each m ouse, it’s age at Ueatii, cause o f
death, pathological diagnosis, and IgH/TcR re-arrangements.
Mouse
i .d .
D.O.B. Age
(mo)
E/L Symptoms and appearance of tissues Tissues By Pathology diagnosis Re-ags
Ig H /T c R
M 39/59.1 6 /4 /9 3 7 - / + Spleen enlarged and discoloured with white spo ts. 
Other tissues normal
F:- S.L.MLN 7 Marked autolysis and bacterial overgrowth were present. 
Diagnosis inconclusive due to poor morphology
+ / -
M 39/59.2 6 /4 /9 3 1 1 - /  + Nothing detected F:- S.L UBB ND ND
M 39/59.4 6 /4 /9 3 23 - /  + Sacrificed due to 24 month time point. Nothing 
detected
F:- S.L 
P.- S.L
DIIC Marked autolysis and bacterial overgrowth were present. 
Diagnosis inconclusive due to poor morphology
ND
M 39/59.7 6 /4 /9 3 22.5 -/ + MLN lymphoma F:-
S.L.MLN,T,Th
? ND - / -
F 3 9 /5 9 .1 0 6 /4 /9 3 24 -/ + Liver enormous and discoloured. Spleen and MLN 
slightly enlarged
F:- S.L 
P:- S.L.MLN
JAC S:- Red pulp expanded due to marked EMII activity with 
participation of all cell lineages 
L:- Extensive EMII
M LN:- Congestion, oedema, reactive and inflammatory 
changes present
ND
M 39/59.13 1 7 /5 /9 3 18 -/ + Spleen, MLN, perLN’s and kidney all enlarged F:- ?
P:-
S.MLN.L.K
7 S:- Grossly enlarged and almost replaced by lymphoblasts. 
M L N :- Enlarged and replaced by large, pale staining tumour 
cells including numerous multinucleated giant cells 
suggesting a histiocytic origin.
L:- Foci of granulocytic EMII
K:- Several, large lymphoblastic infiltrates were seen in the 
cortex and pelvis
D iagnosis:- L y m p h o b lastic  lym phom a w ith m u lt i ­
organ  invo lvem ent and h istiocy tic  lym phom a.
ND
M 39/59.15 1 7 /5 /9 3 7 - /  + 7 F:- S,L,Th 
P:- S.L
DIIC S:- Autolytic 
L :-  Autolytic
ND
F 3 9 /5 9 .18 1 7 /5 /9 3 14.5 -/ + Found dead None 7 ND ND
F 3 9 /5 9 .2 0 1 7 /5 /9 3 17 -/ + Spleen and perLN massive F:-7
P:- S.perLN.L
? S:- Enlarged and replaced with lymphoblasts 
L N :- Enlarged and replaced with lymphoblasts 
L:- NAD
D iag n o sis :-  L y m p h o b la s tic  lym phom a
ND
F39/59 .21 1 7 /5 /9 3 18.5 -/ + MLN and perLN tumours F:- S.MLN
P:-
S,MLN,Th,L
7 S:- Almost replaced by lymphoblasts showing high mitotic 
rate and tumour cell necrosis.
M L N :- Replaced by tumour cells.
Th:- Replaced by lymphoblasts.
L :- Heavily infiltrated and some part replaced by tumour 
cells forming nodular masses.
Diagnosis:- Lymphoblatic lymphoma with multi- 
organ involvement
ND
M 39/59.26 2 6 /6 /9 3 24 -/ + Sacrificed due to hunched appearance and poor 
mobility. MLN red/bloody but normal size
F:- L,MLN,T 
P:- L.MLN
JAC L:- Small foci of histocyte/macrophage type cells which 
appeared to be benign
M L N :- Reactive hyperplasia and lymphadenitis
+ /-
M 39/59.27 2 6 /6 /9 3 21 -/ + MLN red/bloody but normal size F> 7 
P:-
S.L,MLN,Th
7 S ,L ,T h>  NAD
M LN :- Reactive changes present
ND
F 3 9 /5 9 .3 0 2 6 /6 /9 3 7 -/ + 7 None ? ND ND
F 39/59 .31 2 6 /6 /9 3 20.5 - / + MLN massive. Spleen enlarged x3 F:- S,L,MLN 
P:- S.L.MLN
DHC ND + / -
209
l
A p p e n d ix  2 ;- Table of EpLMlM (line 39) mice crossed with UpBBNA-l (line59) showing the transgenic status of each mouse, it’s age at death, cause of
death, pathological diagnosis, and IgH/TcR re-arrangements.
F39/59.34 26/6/93 17.5 -/ + MLN tumour F:- ?
P:-
S,L, Intestine
DIIC S:- Red pulp enlarged due to marked EMH
L:- Dilated and congested blood vessels and centrilobular
necrosis of hepatocytes
1:- Submucosa was markedly thickened due to infiltration by
lymphoblasts showing high mitotic activity
Diagnosis:* Alimentary lymphoblastic lymphoma
ND
F39/59.35 26/6/93 24 - /  + Spleen massive (x5). MLN lymphoma F:-
S.L,MLN(x3),
T
P:-
S.L,MLN(x3)
JAC S:- Replaced by pleomorphic lymphoid cells comprising of 
smaller cleaved cells and medium to large sized 
lymphoblasts showing high mitotic activity 
I.:- Marked EMH and some tumour cells
MLN:- Grossly enlarged and replaced by tumour cells with 
morphology seen in spleen
Diagnosis:- Mixed cell type of lymphoma w ith  
multi-organ involvement
+ /-
F39/59.38 19/7/94 23 - /+ Sacrificed because of bad cuts after fighting. One 
kidney was very red/bloody and abnormal in shape
F:- S.L.K.T 
P:- K
JAC K:- llaentorrhagic necrotic tissue infiltrated by neutrophils ND
F39/59.46 12/9/94 ? - /+ ? None 7 ND ND
F39/59.47 12/9/94 14 - /+ Found dead None ? ND ND
M39/59.49 20/10/9
4
18 - /  + Missing, presumed dead None ? ND ND
M39/59.50 20/10/9
4
24 - /  + Sacrificed because animal had reached 24months of 
age. No abnormalities
F:- T JAC ND ND
M39/59.52 20/10/9
4
16.5 - / + Sacrificed due to prolapse. Peyers Patches very 
large. Spleen, MLN and SILN enlarged
F:-
S.L.MLN.SILN
.PP.T
P:-
S.L.MLN.SILN
.PP
JAC S:- White pulp expanded and replaced by tumour cells. 
Small areas of red pulp with EMII 
L:- Foci of EMH
MLN:- Replaced by lymphoblasts
SILN:- Slight reactive changes but normal architecture 
PP:- Reactive hyperplasia with germinal centre formation 
Diagnosis:- Lymphoblastic lymphoma
- / -
F39/59.55 20/10/9
4
24 - / + Sacrificed because animal had reached 24 months of 
ace. No abnormalities
None JAC ND ND
F39/59.56 20/10/9
4
? - / + ? None 7 ND ND
F39/59.57 20/10/9
4
24 - / + Sacrificed because animal had reached 24 months of 
age. Massive tumour at one end of spleen. MLN 
lymphoma. Liver discoloured and 'lumpy'. PP 
enlarged
F:- S.L,MLN,T
P:-
S,L,MLN,PP
JAC S:- Large part of the spleen was replaced with proliferating 
histiocytes which appeared to be mainly mature type with 
irregular, indented, vesicular nuclei and abundant 
cytoplasm. There were numerous multinucleated forms of 
varying size showing a range of appearances including those 
of foreign body and Langhans type cells. In some of the 
histiocytes accumulation of lipid was present. This 
morphology is similar to the conditions described in humans 
as 'Histiocytosis X'
L:- Several foci of granulocytic EMH. Plasma cells and 
histiocytic type cells also present
MLN:- Marked plasma cell and plasmablast hyperplasia 
with many Russell bodies
PP:- Plasma cell hyperplasia with Russell bodies and 
increased blast cell activity 
Diagnosis:- Histiocytic sarcoma
- / -
M39/59.61 8/4 /95 21 - /+ Sacrificed because animal was slow and hunched. 
Spleen enlarged x3 with tumour
F:- L,T 
P:- S
DHC ND ND
j
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A p p e n d ix  2 :-  Table of E|iLMP-l (line 39) mice crossed with EpEBNA-1 (line59) showing the transgenic status of each mouse, it’s age at death, cause of
death, pathological diagnosis, and IgH/TcR re-arrangements.
M39/59.62 8 /4 /95 14 - / + Sacrificed due to bad ulceration under chin. Kidney 
poss. enlarged. Other tissues normal
F:-
S.L.K.T.Ulcer
ation
P:-
S.K.Ulceratio
n
JAC ND ND
F39/59.66 8/4 /95 20 - / + Spleen slightly enlarged with white spots on it F:- S.L 
P> S.L
DIIC ND ND
M39/59.67 10/6/95 ? - / + 7 / / / /
M39/59.68 10/6/95 12 - / + Sacrificed because of badly cut and infected tail. 
Everything normal
F:-S,L,T JAC ND ND
M39/59.69 10/6/95 ? - / + 7 / / / /
F39/59.70 10/6/95 ? • / + 7 / / / /
F39/59.71 10/6/95 ? - / + 7 / / / /
M59/39.13 30/10/9
4
20 - / + Sacrificed because of poor mobility. Spine hunched 
and rough to touch. Massive MLN lymphoma. SILN 
slightly enlarged. Spleen slightly enlarged and 
discoloured. Liver poss. enlarged
F:-
S.L.MLN.T.Gu
t
P:-
S.L.MLN.SILN
.Gut
JAC S:- Partially replaced by histiocytic/histioblastic type cells 
showing many multinucleated giant cells, phagocytic 
activity and high mitotic rate
L:- Large areas of EMH and other areas infiltrated by tumour 
cells of the morphology described for spleen 
MLN:* Replaced by histiocytic/histioblastic type cells 
S1LN:> Numerous neutrophils were present indicating a 
lymphadenitis
Diagnosis:* Histiosarcoma
* + / +
M59/39.14 30/10/9
4
19 - / + Sacrificed due to prolapse. Massive MLN lymphoma. 
PP slightly enlarged. Spleen normal size but 
discoloured
F:- S.L,MLN,T 
P:- S.MLN.PP
JAC S:- White pulp expanded and replaced by medium to large 
lymphoblasts
MLN:- Loss of architecture, replaced by lymphoblasts 
PP:- Grossly enlarged, neoplastic with large lymphoblasts 
Diagnosis:* Lymphoma
+  / -
M59/39.19 15/12/9
4
20 - / + Sacrificed due to poor mobility. Everything normal F:- S.L..T 
P:- S.L.
MED ND ND
M59/39.23 4/2/95 19 - / + Sacrificed because mouse looked v.sick. Spleen 
normal size but with ‘lumpy* areas. MLN enlarged 
x2. Thymus poss. enlarged
F:-
S.L,MLN(x2),
Th,T
P:- S.MLN
JAC S:- Loss of architecture due to replacement by pleomorphic 
large blast cells with indented, irregular, vesicular nuclei 
containing multiple nucleoli and fairly abundant 
eosinophilic cytoplasm.
MLN:- Enlargement due to loss of architecture caused by 
replacement by tumour cells with the morphology described 
for spleen. Many mitotic figures, giant and multinucleated 
cell forms and evidence of phagocytic activity 
Diagnosis:- Histiocytic sarcoma
?/-
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A p p e n d ix  3 :-  Table of EjiLM P-1 (line 39) mice crossed with E^EBNA-1 (line59) showing the transgenic status of each mouse, it’s age at death, cause of
death, pathological diagnosis, and IgH/TcR re-arrangements
M o u se  
i . d .
D .O .B . A g e
(m o )
E /L Symptoms and appearance of tissues T i s s u e s B y Pathology d iagnosis R e -a g s
IgH /T cR
M 39/59.3 6 /4 /9 3 ? + /+ 7 None 7 ND ND
M39/59.5 6 /4 /9 3 22.5 + /+ Huge MLN lymphoma. F:- S,L,MLN,T 
P:- S.L,MLN
7 Marked autolysis and bacterial overgrowth were present. 
Diagnosis inconclusive due to poor morphology.
+ / -
M 39/59.6 6 /4 /9 3 11 +/+ Nothing detected F:- S.L IJBB ND ND
M39/59.8 6 /4 /9 3 7 +/+ 7 None 7 ND ND
F 39/59 .9 6 /4 /9 3 23 +/+ Ovary(7), CLN and spleen enlarged. Other tissues  
normal
F:- S.O 
P:- S.O.CLN
DIIC Marked autolysis and bacterial overgrowth were present. 
Diagnosis inconclusive due to poor morphology
ND
F 3 9 /5 9 .11 6 /4 /9 3 ? +/+ 7 None ? ND ND
M 39/59.12 1 7 /5 /9 3 7 +/+ 7 None 7 ND ND
M39.59.14 1 7 /5 /9 3 23 + / + Sacrificed due to 24 month time point. Nothing 
detected
I-:- S.L.SILN 
P:- S.L
DIIC Marked autolysis and bacterial overgrowth were present. 
Diagnosis inconclusive due to poor morphology.
ND
M 39/59.16 1 7 /5 /9 3 22.5 + / + MLN enlarged, all other tissues normal F:- S.L.MLN.T 
P:- S.L.MLN
DIIC ND - / -
F 3 9 /5 9 .17 1 7 /5 /9 3 24 +/+ Swollen stomach which turned out to be full  
bladder- urinary tract blockage?
F:- S.L.T 
P:- S.L
JAC S:- NAD
L:- Small foci of EMH
ND
F 3 9 /5 9 .19 1 7 /5 /9 3 7 +/+ 7 F:- S.L DIIC ND ND
F 39/59 .22 1 7 /5 /9 3 22 +/+ Spleen massive and virtually white. Liver enlarged 
and pale. MLN enlarged
F:- S.L.MLN.T 
P:- S.L.MLN
DIIC ND - / -
F39/59 .23 1 7 /5 /9 3 7 +/ + 7 None ? ND ND
M 39/59.24 2 6 /6 /9 3 7 + /  + 7 F:- S 
P:- S.L
7 S,L:- NAD ND
M 39/59.25 2 6 /6 /9 3 ? + /  + ? None 7 ND ND
M 39/59.28 2 6 /6 /9 3 24 + /+ MLN massive and bloody. Two other gut assoc, 
tumours. White lump at one end of spleen but 
spleen normal size.
F:-
L,MLN(x3),T
P:-
S,MLN(x3)
JAC S:- White pulp expanded and replaced by lymphoblasts 
showing high mitotic rate
MLN:- Gross enlargement due to replacement by tumour 
cells
Diagnosis:- Lymphoblastic lymphoma with m u l t i -  
organ involvement
- / -
F39/59 .29 2 6 /6 /9 3 20 + /+ ? None 7 ND ND
F 39/59 .32 2 6 /6 /9 3 7 + / + 7 None ? ND ND
F 39/59 .33 2 6 /6 /9 3 20.5 + / + Liver enlarged x2 and pale cf. to normal. Spleen 
enlarged x3, pale with white spots. Tumour on one 
end of spleen. MLN and CLN enlarged also.
F:- S,L,MLN 
P:-
S.L,MLN,CLN
DHC ND - / -
M 39/59.36 1 9 /7 /9 4 24 + / + Sacrificed because animal was 24 months old. No 
abnormalities
F:- S,L,T 
P:- S.L
MED ND ND
F 39 /59 .37 1 9 /7 /9 4 24 + / + Sacrificed because animal was 24 months old. 
Stomach full of murky red fluid. MLN poss. 
enlarged and red/bloody. Spleen enlarged x2 and 
discoloured
F:- S,MLN,T 
P:- S,MLN
JAC S:- White pulp markedly expanded and replaced by large, 
pleomorphic lymphoblasts showing high mitotic activity and 
tumour cell necrosis.
MLN:- Infiltrated by pleomorphic lymphoblasts 
D ia g n o s is : -  L ym phoblastic  lym phom a
+  / -
2 1 2
;
Ap p en d ix  3 :- Table of EjaLMP-1 (line 39) mice crossed with E|iEBNA-l (line59) showing the transgenic status of each mouse, it’s age at death, cause of
death, pathological diagnosis, and IgH/TcR re-arrangements
M39/59.39 12 /9 /94 18 + /+ Sacrificed because of poor mobility. All organs 
normal
F:-
S,L,T,Spine 
P:- S.L,Spine
MED S:- Expanded white pulp showing reactive follicular 
hyperplasia
ND
M39/59.40 1 2 /9 /9 4 18 + /+ Sacrificed because of poor mobility. All tissues  
normal
F:- S.L,T 
P:- S.L
JAC S:- Reactive hyperplasia of the white pulp 
L:- NAD
ND
M39/59.48 2 0 /1 0 /9
4
18 + /+ Spleen massive and very pale. Thymus enlarged x2 F:-
S.L.CLN.SILN,
Th,T
P:- S.L.SILN
MED S:- Enlarged
SILN:- Loss of architecture. Replaced by medium sized 
ly m phobias Is 
Diagnosis:- Lymphoma
+ /-
M39/59.51 2 0 /1 0 /9
4
19 + /+ Animal sickly but nothing abnormal noted !•:- S,L,T 
P:- S.L
JAC ND ND
M39/59.53 2 0 /1 0 /9
4
20.5 + /+ Sacrificed due to lump oil muzzle which was red and 
soft to touch. Liver massive with lymphoma
F:-
L.T.Muzzle 
lump
P:- L.MuzzIc 
lump
JAC L:- Focal necrosis probably due lo 'Tyzzer's disease', which 
is commonly seen in mice, caused by an intracellularly 
growing bacteria
Ilacmaiigioma-type lesions also present 
Skin:- Capillary hacmaiigioma (benign lesion)
Diagnosis:- Ilacmangioma
ND
F39/59.54 20 /1 0 /9
4
20.5 + /+ Sacrificed due to swollen stomach. Spleen massive 
(xlO). MLN enlarged
F:-
S.MLN.T.Inte
stine
P:-
S.MLN.Intesti
ne
JAC S:- Enlarged and replaced by a pleomorphic population of 
atypical cells
MLN:- Enlarged and replaced with pleomorphic atypical 
cells
Diagnosis:- Lymphoma
ND
M39/59.60 8 /4 /9 5 21 + /+ Sacrificed because animal was slow and hunched. 
Heart pale but otherwise rest ok
F:- S.L.T 
P:- S.L.H
DIIC ND ND
M39/59.63 8 /4 /9 5 17 + /+ Paralysed rear legs. All tissues normal None JAC ND ND
M39/59.64 8 /4 /9 5 20 + /+ Mouse looked sickly but all tissues were normal F:- S.L 
P:- S.L
DIIC ND ND
F39/59.65 8 /4 /9 5 17 + /+ Sacrificed due to massively swollen stomach. All 
perLN's enlarged. MLN enlarged and red/bloody. 
Spleen massive (xlO) and discoloured. Liver 
massive (x5) and discoloured
F:-
S.L.MLN.perL
N’S.T
P;- S.L.MLN
JAC S:- Completely replaced by large pleomorphic lymphoblasts 
showing high mitotic rate
L:- Heavily infiltrated and partially replaced by tumour 
cells which were forming tumour masses 
MLN:- Replaced by lymphoblasts with morphology 
described for spleen
Diagnosis:- Lymphoblastic lymphoma
+ / -
M5 9/3 9.1 2 4 /9 /9 4 18/5- “~ + /+ Found dead — -None ? ND ■**».■■*— ND
M 59/39.12 3 0 /1 0 /9
4
18.5 + /+ Sacrificed because of poor mobility. All organs 
normal size although spleen had tumour on one end
F:-
S,L,T,Spleen
tumour
P:-
S,L, Spleen 
tumour
MED S:- Reactive white pulp showing follicular hyperplasia ND
F 5 9 /3 9 .15 3 0 /1 0 /9
4
10 + /+ Sacrificed because of carcinoma. Liver normal size  
but pale. Spleen enlarged x2
F>
S.L.T,Carcino 
ma
P:-
S.L.Carcinom
a
JAC S:- Red pulp expanded due to EMH 
L> Foci of EMH
Skin:- Squamous cell carcinoma
ND
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A p p e n d ix  3 :- Table of EpLMP-1 (line 39) mice crossed with linEBNA-1 (line59) showing the transgenic status of each mouse, it’s age at death, cause of
death, pathological diagnosis, and IgH/TcR re-arrangements
M59/39.16 1 5 /12 /9
4
16.5 +1+ Sacrificed due to hind limb paralysis. All perLN’s 
enlarged. Thymus enlarged. Spleen massive and 
white. MLN massive.
F:-
S,L.perLN’s,T 
h,Kidney 
tumour, Gut 
tumours. 
P:-As above 
plus spine
JAC S> Loss of architecture, replaced by lymphoblasts 
L:- Small foci of EMH
pcrLN's:- All enlarged and replaced by lymphoblasts 
Th:- Replaced by lymphoblasts 
Diagnosis:* Lymphoblastic lymphoma
+ /-
M59/39.20 15 /12 /9
4
20 + /+ Sacrificed due to poor mobility. Thymus massive F:- S,L,Th,T 
P:- S.L.Th
MFD ND + /-
M59/39.22 4 /2 /9 5 19 + /+ Spleen massive (x20), bi-lobcd and full of white 
pulp. MLN and CLN enlarged
F> S.L.CLN.T 
P> S.L.CLN
MI23 ND + /-
F59/39 .24 4 /2 /9 5 19 + /+ Found dead. MLN and liver lymphomas. PerLN 
slightly enlarged
None JAC ND ND
F59/39.25 4 /2 /9 5 18 + /+ Sacrificed because mouse looked v.sick. Massive 
MLN lymphoma. Spleen, liver and thymus enlarged
F:-
S.L,MLN,Th,T
P>
S,L,MLN,Th
JAC S> Almost entirely replaced by lymphoblasts and only 
small foci of EMH were recognisable
MLN:- Grossly enlarged and replaced by sheets of large 
lymphoblasts showing high mitotic rate and tumour cell 
necrosis.
Diagnosis:- Lymphoblastic lymphoma
ND
F59/39.27 4 /2 /9 5 16.5 + /+ Sacrificed because of ulceration on neck. MLN and 
spleen lymphomas
F:-
S.L.MLN.T.UI
ceration
P:-
S.MLN.UIcera
tion
JAC S+MLN:- White pulp of both was markedly enlarged with 
some loss of architecture. Both contained a variety of cel l  
types including plasma cells and atypical cells which 
possibly represented a grossly exaggerated reactive process 
turning into a neoplasia
+ /-
t
2 1 4
